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Elemental Iodine: Relief for the Painful
Breast?
John K. MacFarlane, MD, FACS, FRCSC
Chairman, Department o f Surgery, St. Paul’s Hospital, Vancouver, BC. Member, Editorial
Board, Canadian Journal of Surgery

I

n this issue of the journal (pages
453 to 460) the subject of cystic
mastopathy is featured in an article
by Ghent* and associates. They de
scribe three clinical studies of io
dine therapy in what has tradition
ally been called fibrocystic breast
disease.
The findings of these studies,
which involved almost 1400 wom
en, appear to support the concept
that elemental iodine (I2) rather
than iodine-containing compounds
such as Lugol’s solution produces a
significant regression of both the
symptoms and the signs of this
common condition in the menstru
ating woman.
The authors have produced their
evidence from a series of studies
with crossover from one compound

Dr. Ghent unfortunately died on July 29,
1993, after a distinguished career in surgery
at Queen’s University.

to another, based on the “demo
graphic association” between in
creased incidences of both benign
and malignant breast disease and
iodine deprivation in patients with
goitre. Unfortunately, this has not
been referenced in the article, so
the basis of the study is not entirely
clear. Nevertheless, the impressive
number of volunteers in the studies
indicates the significance of these
symptoms and signs in the general
population.
Dr. Ghent and his colleagues at
the Virginia Mason Clinic in Seattle
and at the Medical College of Penn
sylvania in Philadelphia are to be
congratulated on an excellent and
meaningful study.
The results have been evaluated
with both a subjective and an objec
tive measuring process and seem to
confirm the validity of the hypothe
sis that molecular iodine can be of
significant benefit to patients with
fibrocystic breasts.

It would be of interest to deter
mine the site of the iodine action
within the breast. Although the
mechanism is clear in the rat exper
iments of Eskin and associates1
techniques for tracking the effect of
the iodine on the epithelial cell of
the breast would be an important
follow-up.
This study is an important one;
however, the findings should be
confirmed by another centre before
elemental iodine is recommended as
standard therapy for symptomatic
benign breast disease.

Reference
1. E skin BA, K rouse TB, Modhera PR et al:
Etiology of mammary gland pathophysi
ology induced by iodine deficiency. In
M edeiros-N eto G, Gaitan E (eds): Fron
tiers in Thyroidology, Proceedings o f the
Ninth International Congress, 1985, Sao
Paolo, Brazil, vol 2, Plenum, New York,

1986: 1027-1031
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Medical Memories: an Aortoesophageal
Fistula
D. Michael Grace, MD, FRCSC
Professor, Department o f Surgery, University Hospital, The University o f Western Ontario,
London, Ont. Member, Editorial Board, Canadian Journal of Surgery

ortoesophageal fistulas are ex
tremely rare, “dramatic,” mem
orable and usually fatal. The most
common causes of such fistulas
have been thoracic aneurysms and,
more recently, malignant tumours
or foreign bodies. In this issue
(pages 480 to 482), Katyal, Jewell
and Yakimets report such a case. A
benign Barrett’s ulcer in an elderly
man caused a fatal gastrointestinal
hemorrhage; all appropriate mea
sures were taken. The case is well
described, and this particularly rare
problem is reviewed. Autopsy in
such a case of sudden death may be
of medicolegal importance but is
certainly critical in explaining
events and educating the medical
and nursing staff involved.
In every surgical practice there
are a few cases that stand out in
memory and that influence future
clinical decisions. These cases pro
vide excitement, even panic, in con
trast to routine procedures like her
nia repairs and appendectomies. As
surgeons we are present at signifi
cant times in people’s lives and have
the opportunity to influence not
just the life of the patient but also
the lives of the entire family, their
circle of friends and even future
generations. The dramatic and in
teresting case helps to maintain
enthusiasm for surgical practice.
The description of an aortoeso

A
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phageal fistula by Katyal, Jewell
and Yakimets led me to relive the
events involved in a case that is
etched clearly in my memory. The
date was Aug. 2, 1970, and I was a
resident on loan from the Royal
Victoria Hospital in Montreal,
spending 6 months at the General
Hospital in St. John’s. It was a
lovely summer weekend and I had a
chance to explore the rugged New
foundland coast with my girlfriend,
and future wife, who had just ar
rived from Montreal. I made what
was planned to be a short hospital
visit to check on a 17-year-old boy
who, 6 days earlier, had had a
foreign body that was eroding his
esophagus removed by thoracoto
my. The foreign body was a piece of
nonopaque dental plate broken dur
ing eating 7 weeks earlier that had
not been identified by chest radiog
raphy. His dysphagia had pro
gressed until an upper gastrointesti
nal series in a smaller centre had
revealed the problem. Endoscopic
removal was not possible so thora
cotomy was necessary. The foreign
body had been removed and a medi
astinal abscess drained. His course
had been smooth apart from a lowgrade spiking fever.
Just as I arrived to see him he
suddenly vomited and had a massive
projectile upper gastrointestinal he
morrhage with profound hypoten

sion and collapse. Multiple intrave
nous lines were inserted immediate
ly in femoral vessels, and 0 nega
tive blood was pumped in as he was
being taken to the operating room.
Blood pressure was still unobtain
able. We quickly carried out a lapa
rotomy and opened the stomach,
which was massively distended with
blood. When blood poured down
the esophagus the left chest was
reopened and an aortoesophageal
fistula identified. The aorta was
friable and difficult to suture, but
the aorta and esophagus were re
paired. A pleural flap was used to
separate the two. After many hours
of operation and resuscitation he
returned to the ICU in reasonable
condition. After prolonged discus
sions with a concerned family I was
able to resume my interrupted
weekend. Fortunately my visiting
friend was patient, understanding
and supportive, and our relation
ship was stronger for the experi
ence.
Unfortunately, the young patient
continued to have complications,
which were eventually fatal. Eight
days after the first “bleed,” he had
another, which required 20 units of
blood. The aorta was repaired
again, and esophagostomy and gas
trostomy were performed. His
course was marked by progressive
sepsis, pneumonia and recurrent

AORTOESOPHAGEAL FISTULA

bleeding, and he finally died 5
weeks after the first hemorrhage
and 6 weeks after the thoracotomy.
The memories of these tragic
events — the struggle of a young
man for life, the effect on his family
and the need for sympathetic sup
port, and the reality and responsibil
ity for major complications after
apparently successful surgery —
have never left me.
It was my good fortune to have
had the experience of working in
another part of Canada, where 1

learned to appreciate the hospitality
and determination of Newfound
landers and the rugged beauty of
the coast and adjacent ocean in all
its moods. Because early decisions
regarding specialization must be
made, it is rare that medical stu
dents or residents have a chance to
work under different cultural or
medical conditions in other parts of
Canada or elsewhere. In this respect
they are missing an important part
of personal and medical education.
I have related the story of one

case that affected my life and that
of a young man’s family. Unfortu
nately, treatment was unsuccessful,
as it usually is for an aortoesophageal fistula, but many of our
dramatic cases in surgery are suc
cessful and encourage us to carry
on. In these days of declining medi
cal income and prestige we can be
grateful for the challenge of clinical
medicine and surgery and be aware
of our responsibility to patients and
their families whether the problem
is routine or unusual.*

Then specific chapters relate to the
surgical technique and selection of
prostheses, emphasizing constrained
and nonconstrained prostheses. Special
chapters are devoted to the controver
sial questions of unicompartmental
knee replacement, custom total knee
replacement and cementless total knee
arthroplasty.
Complications specific to total knee
replacement are well covered. They in
clude chapters on bone defects, sepsis,
extensor mechanism complications and
deep vein thrombosis. A special chapter
is devoted to the rehabilitation of the
patient who undergoes total knee re
placement.
Despite the involvement of multiple
authors, the editors have managed to
maintain a uniform style in the text and
the illustrations. The references for
each chapter appear complete but not
excessive.
The book will be extremely useful for
surgeons who perform a moderate num
ber of total knee replacements. It will be
essential in the library of any hospital
involved in postgraduate education in
orthopedic surgery because it contains
an excellent description of the basic
science and design considerations as
well as the basic surgical technique of
total knee arthroplasty. Furthermore, it

acts as a valuable resource for surgical
technique for a variety of total knee
prostheses.

BOOK REVIEWS
CRITIQUES DES LIVRES

The following books are also re
viewed in this issue: Gastrointesti
nal Bleeding (page 416); Endovas
cular Surgery (2nd edition) (page
421); Introduction to Vascular Ul
trasonography (3rd edition), Elec
trical Trauma: the Pathophysiolo
gy, Manifestation and Clinical
Management, The Knee: Form,
Function, Pathology & Treatment
(page 492); Advances in Cardiovas
cular Engineering, Series A: Life
Sciences, Volume 235, Surgery of
the Ear and Temporal Bone (page
493).
TOTAL KNEE ARTHROPLASTY. Ed
ited by James A. Rand. 480 pp. Illust.
Raven Press Ltd., New York, 1992.
$130. (US). ISBN 0-88167-930-5
This multiauthored textbook is devoted
exclusively to total knee arthroplasty
and its role in the management of
degenerative, inflammatory and posttraumatic conditions of the knee.
The book is well organized into 29
chapters. The chapters flow logically,
starting with biomechanics of the knee,
patient selection and indications for
surgery and preoperative planning.

James P. Waddell, MD, FRCSC
St. Michael's Orthopedic Associates
Suite 800
55 Queen St. E
Toronto, ON
M5C 1R5

RADIOSURGERY: BASELINE AND
TRENDS. Edited by Ladislau Steiner.
320 pp. Illust. Raven Press, New
York. 1991. $105 (US). ISBN 0 88167-847-3
This book, one of the first on radi
osurgery, is valuable for neurosurgeons
and neuro-oncologists because both
need to know the capabilities and limi
tations of the technique now that it is
becoming an integral part of their prac
tice. The text is intended to show the
less common aspects of radiosurgery as
utilized in centres around the world and
to act as a baseline for the assessment
of future advances. Excerpts from Lekcontinued on page 416
CJS, VOL. 36, NO. 5, OCTOBER 1993
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Carotid Endarterectomy Without
Angiography. The Reliability of Doppler
Ultrasonography and Duplex Scanning
in Preoperative Assessment
Raymond Cartier, MD;* Paul Cartier, MD;t Andre Fontaine, MD$
Objective: To validate the use of Doppler ultrasonography and duplex scanning as the only means of
preoperative assessment in carotid disease.
Design: A retrospective study performed between January 1980 and December 1989.
Patients: Of 597 carotid endarterectomies carried out by one author, 130 procedures were performed
on 118 patients (47 women, 71 men, ranging in age from 49 to 85 years) without preoperative cerebral
angiography. Justifications for proceeding without angiography were risk of angiography (27
patients), iodine allergy (8 patients), renal insufficiency (5 patients), technical problems (4 patients)
and surgeon’s preference (74 patients).
Interventions: Doppler ultrasonography and duplex scanning were the only means of preoperative
assessment on 130 occasions. The studies were done by fully trained radiologists. Until 1982 carotid
stenosis was assessed with a continuous wave bidirectional Doppler flowmeter and gray-scale
ultrasonography in equivocal cases. Thereafter, a real-time spectrum analyser connected on-line to a
Doppler flowmeter was used. Duplex scanning was introduced in 1985.
Main Outcome Measures: Surgical observations confirmed the preoperative assessment on 124
occasions (96%).
Results: Six patients had occlusion of the internal carotid artery (ICA); five patients had recent
thrombosis that had occurred between the noninvasive assessment and the endarterectomy.
Revascularization was successful in all. In one patient, the ICA was chronically occluded. In 63
patients, the mean pressure in the ICA stump and the mean gradient across the stenosis, measured
intraoperatively, were 40 ± 3 mm Hg (95% confidence interval: 34 to 48 mm Hg) and 55 ± 3 mm Hg
(95% confidence interval: 46 to 58 mm Hg), respectively, which confirmed the severity of the stenosis.
Conclusion: The authors conclude that in their institution, carotid endarterectomy based on Doppler
ultrasonography and duplex scanning only is reliable and safe.

Objectif: Valider l’usage du Doppler et du duplex carotidien comme unique moyen d’investigation
preoperatoire d’une chirurgie carotidienne.
Conception : Etude retrospective effectuee au cours de la periode s’echelonnant de janvier 1980 a
decembre 1989.
Patients : Des 597 endarteriectomies carotidiennes partiquees par l’un des auteurs, 130 procedures ont
ete effectuees chez 118 patients (47 femmes et 71 hommes dont l’age a varie de 49 a 85 ans). Les
raisons qui ont motive cette pratique ont ete les suivants : le risque potentiel de l’angiographie (27
patients), l’allergie a l’iode (8 patients), l’insuffisance renale chronique (5 patients), problemes
techniques (4 patients) et la preference du chirurgien chez 74 patients.
Interventions : Le Doppler et le duplex carotidien ont ete les seuls moyens devaluation en 130
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occasions. Tous les examens ont ete faits par un radiologiste certifie. Jusqu’en 1982, revaluation
carotidienne etait faite a 1 aide d’un Doppler continu bidirectionnel et i’echographie avec echelle de gris
dans les cas douteux. Plus tard, un analyseur spectral en temps reel tut couple au Doppler. Enfin, le
duplex fut introduit en 1985.
Principaux effets mesures : L’exploration chirurgicale a continue le diagnostic preoperatoire en 124
occasions (96 %).
Resultats : Six patients ont presente une occlusion de la carotide interne (Cl). Cinq etaient des cas de
thrombose recente de la Cl survenue entre le moment de Fevaluation non invasive et
l’endarteriectomie. Ils furent tous revascularises avec succes. Un patient avait une occlusion chronique
de la Cl. Chez 63 patients, la pression carotidienne residuelle et le gradient transstenotique mesures en
periode peroperatoire, se situaient, respectivement, a 40 ± 3 mm Hg (intervalle de confiance de 95 %
[Cl] : 34 a 48 mm Hg) et 55 ± 3 mm Hg (Cl 95 % : 46 a 58 mm Hg) confirmant la severite de la stenose.
Conclusion : Les auteurs conduent que dans leur etablissement, la chirurgie carotidienne basee
uniquement sur 1 investigation au Doppler et au duplex s’est averee une pratique fiable et securitaire.

he modem era in carotid artery
assessment began in 1937
when Moniz, Lima and de Lacerda1
publicized the value of cerebral an
giography for the evaluation of ca
rotid artery disease. Since then an
giography has remained the stan
dard method of investigating extra
cranial carotid disease. In the
mid-1960s Doppler scanning gave
the vascular surgeon a broader
spectrum of methods for assessing
cerebral blood flow.2 Nevertheless,
it was only a decade ago that
surgeons started performing inter

T

nal carotid endarterectomy on pa
tients assessed solely by Doppler
scanning.3 Although the accuracy
of noninvasive evaluation of he
modynamics and tissue character
ization in carotid disease have been
documented in many reports,4-10
routine carotid endarterectomy
based only on Doppler ultrasonog
raphy or duplex scanning is still
seriously questioned.1112
The purpose of this study is to
present our initial experience with
patients who had carotid endar
terectomy based on the preoperative

findings of Doppler ultrasonogra
phy and duplex scanning without
the use of cerebral angiography.

Patients and Methods
Patients

Between January 1980 and De
cember 1990, 597 carotid endar
terectomies were performed by one
of us (P.C.) for internal carotid
artery (ICA) stenosis causing a re
duction of more than 75% of the
surface area of the artery. During
this period, 130 (22%) procedures
were performed on 118 patients
without the use of cerebral angiog
raphy. The majority were performed
after 1986 (Fig. 1). There were 47
women and 71 men, ranging in age
from 49 to 85 years (mean 66 ± 7
years). The preoperative risk factors
are documented in Table I. Before
endarterectomy, the contralateral
ICA was occluded in 14 (12%) pa
tients or had 50% or greater steno
sis in 41 (35%) patients. Six (5%)
Table I. Carotid Endarterectomy:
Preoperative Risk Factors (/V = 118)
Risk factor

FIG. 1. Number of patients who underwent carotid endarterectomy without cerebral
angiography (black portion of bars) compared with total number who underwent
carotid endarterectomy (white bars).
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Ischemic heart disease
Hypertension
Diabetes
Smoking habit
Hyperlipidemia
Peripheral vascular disease

Patients, no.
(%)
1 ( 1)
25 (19)
36 (28)
26 (20)
23 (18)
22(17)

DOPPLER AND DUPLEX FOR CAROTID ENDARTERECTOMY

patients had previously undergone
carotid surgery and were reoperated
on for symptomatic recurrence.
Hemispheric symptoms were
present in 65 (55%) patients and
nonhemispheric symptoms in 45
(38%) patients. Twenty-two (19%)
patients were asymptomatic and 1
patient presented with tinnitus re
lated to carotid stenosis.
Justifications for proceeding
without angiography were as fol
lows: angiographic technical failure
related to severe peripheral vascular
disease in 4 patients (3%), chronic
renal insufficiency in 5 patients
(4%), dye allergy in 8 patients (7%)
and potential neurologic complica
tion during angiography (especially
in patients with symptomatic criti
cal stenosis) in 27 patients (23%).
In 74 (63%) patients, the decision
to proceed without angiography
was related to the surgeon’s prefer
ence.
Doppler Ultrasonography and
Duplex Scanning
Doppler and duplex examinations
were performed by fully trained,
certified radiologists. Over 80% of
the procedures were performed by
one of us (A.F.). Our criteria for
Doppler evaluation of carotid ste
noses have evolved with the devel
opment of the Doppler and duplex
technologic advances that took
place between 1980 and 1990. Ac
quisition of more sophisticated
equipment has allowed the tech
niques to be refined and the results
improved. In the early 1980s only a
continuous-wave bidirectional Dop
pler flowmeter (D800; Delalande,
Tours, France) was available. It dis
played an analogue time-frequency
tracing that became distorted in
turbulent flow situations. During
those years, the severity of carotid
stenosis was assessed mainly on the
acoustic analysis of audio Doppler
signal frequencies, by listening to

the degree of acceleration and tur
bulence. Increased resistance index
and signs of collateralization
through the ophthalmic artery from
branches of the external carotid
artery (ECA) were also sought to
reinforce previous findings. Occa
sional gray-scale ultrasonography
was done in equivocal cases.
In 1982, the availability of a
real-time spectrum analyser (Vasculab D 10SP25; Medasonics,
Mountainview. Calif.) connected on
line to a Doppler flowmeter allowed
display of the full Doppler spec
trum. On the assumption of a
8-MHz frequency and 45° angle to
the skin, increased peak systolic
frequencies in the range of 10 to
14 kHz were considered tight ste
nosis (75% to 90% reduction of the
vessel’s surface area); frequencies
over 14 kHz were considered very
tight stenosis (more than 90% re
duction in vessel surface area). De
grees of spectral broadening, in
creased resistance index and ECA
collateral flow complemented the
overall Doppler picture. Duplex
technology (Ultramark-8; Advanced
Technology Laboratory, Bothell,
Wash.) was introduced in our insti
tution in 1985 and was used con
currently with continuous wave
Doppler ultrasonography preoperatively in 73 cases. Morphologic in
formation with Doppler data can be
acquired with duplex scanning. The
carotid artery wall can be imaged,
plaque can be characterized (surface
irregularities, intraplaque, hemorrh
age and ulceration) and, mostly,
absolute flow velocity instead of
relative frequencies can be ex
pressed. Since then, our estimation
of significant extracranial carotid
arterial stenosis (a reduction in ar
terial surface area greater than
75%) has been based on three crit
eria:
• The assessment of cross-sec
tional area reduction on transverse
scan

• A threefold or fourfold in
crease of peak systolic velocity into
or immediately beyond the stenotic
zone compared with the peak sys
tolic velocity in the areas of laminar
flow, either downstream or up
stream, within the same carotid
artery (ICA versus ICA and common
carotid artery versus common carot
id artery)
• An absolute peak systolic ve
locity of 250 c m /s or more.
Degrees of turbulence, elevated
resistance index and plaque charac
terization are also used to confirm
duplex findings.
Study Endpoints
Surgical findings and the accura
cy of the preoperative assessment
were noted in particular as were
surgery-related neurologic events
(transient and permanent) and the
operative death rate.

Results
Surgical Findings
Surgical exploration confirmed
the presence of a significant steno
sis in 124 occasions. The ICA was
occluded in six patients. A fresh
thrombus, which could have formed
between the time of investigation
and surgical exploration was found
in five patients. They all underwent
successful revascularization without
complication. One patient had
chronic ICA occlusion and severe
ECA disease. This patient initially
presented with an ipsilateral tran
sient ischemic accident (TIA). A
successful external carotid endar
terectomy was done, and the patient
remained asymptomatic. This was
our only case of misdiagnosis.
Anatomic Features
Surgical exploration revealed an
CJS, VOL. 36. NO. 5, OCTOBER 1993
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atherosclerotic plaque in all but
three patients who presented with
intimal hyperplasia. These three
were operated on for recurrent ca
rotid stenosis. The atherosclerotic
plaque was associated with loose
debris in 17%, subintimal hemorrh
age in 33% and ulcer in 55% of
patients.
In 63 procedures, pressure gradi
ents across the stenosis and the
stump pressure were measured. The
mean carotid stump pressure was
40 ± 3 mm Hg (95% confidence
interval [Cl]: 34 to 48 mm Hg) and
the mean pressure gradient was 55
± 3 mm Hg (95% Cl: 46 to 58
mm Hg).

charged 5 days later with no sign of
cardiac ischemia. Unfortunately 6
days later he was readmitted for
chest pain and died of a myocardial
infarction. Two patients sustained a
TIA in the recovery room but fully
recovered. The postoperative course
was complicated by reperfusion syn
drome in two other patients. Both
responded successfully to medical
management. Unfortunately two
(1.7%) patients, who had hemisphe
ric symptoms preoperatively, sus
tained perioperative strokes (mono
plegia) and recovered only partially.
None of the asymptomatic patients
sustained transient or permanent
deficit related to the operation.

M orbidity and M ortality (Table II)

Discussion
Two patients died during the
early postoperative period. Both
were over 80 years old and had
multiple risk factors. The first pa
tient presented with crescendo
hemispheric TIA. Investigation re
vealed an ipsilateral ICA stenosis
greater than 80% and a contralater
al ICA occlusion. At surgery, exten
sive atheromatous debris was
found. The patient sustained a mas
sive cerebrovascular accident (CVA)
postoperatively and died 48 hours
later. Either multiple embolism or
subarachnoid hemorrhage second
ary to a reperfusion syndrome was
incriminated as the cause of death.
The second patient had nonhemispheric symptoms. Significant, bi
lateral, carotid stenosis was found
(left side more than 80%, right side
more than 50%). An uncomplicated
left carotid endarterectomy was per
formed, and the patient was dis

Cerebral angiography is a wellestablished invasive diagnostic pro
cedure. Renal insufficiency has been
reported up to 10% in high-risk
populations, with a 2.5% incidence
of patients requiring permanent
renal dialysis.13 Contrast allergic
reaction is unusual and is asso
ciated with cerebral angiography in
about 2% of cases.14 A neurologic
event is the most feared complica
tion of the procedure. Overall, cere
bral angiography carries a 0.1%
risk of permanent neurologic defi
cit. However, in an atherosclerotic
population, the combined risk of
transient or fixed deficit has been
reported to range from 0.4% to
4%.13-18
Even though carotid angiography
has been considered the gold stan
dard in extracranial carotid disease,
it has been supplanted by duplex

Table II. Morbidity and Mortality of Carotid Endarterectomy According to Preoperative Indications
Preoperative indications
Hemispheric symptoms
Nonhemispheric symptoms
Asymptomatic

TIA, no.

CVA, no.

Operative
death, no.

2
0
0

3
0
0

1
1
0

TIA = transient ischemic attack, CVA = cerebrovascular accident
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scanning in the morphologic char
acterization of arteriosclerotic
plaque.19
Since Von Reuten, OrtegaSchkramp and Spiiner3 reported 15
cases of carotid endarterectomy di
agnosed on spectral analysis, many
authors have reported good results
with this practice.459 The conclu
sions of these authors were that
patients with hemispheric symp
toms, especially crescendo TIA or
preocclusive lesions, patients with
allergy or other medical contrain
dications and patients previously
investigated by angiography but
found to have progressive disease
on follow-up ultrasonography could
be operated upon safely without
angiography.
However, others have not been so
optimistic. Geuder and associates,11
in a study of 100 patients assessed
preoperatively by angiography and
duplex scanning, reported an 8%
incidence of wrong or missed diag
noses. Some wrong diagnoses were
linked to nonhemispheric symp
toms, and some of the missing
information was related to arch
vessel stenosis, which could have
been detected on physical examina
tion or continuous Doppler scan
ning. Furthermore, in their study,
two patients sustained permanent
neurologic damage during the angi
ographic procedure. This could
have been avoided by limiting the
assessment to duplex scanning
alone.
In our study, the only incorrect
diagnosis was made on a symptom
atic patient with ICA occlusion and
severe ECA stenosis. An external
carotid endarterectomy was carried
out successfully and the patient was
cured. This misinterpretation oc
curred before duplex scanning was
introduced to our institution and
when continuous spectral Doppler
scanning was the only alternative
technique available.
Asymptomatic patients in this se-

DOPPLER AND DUPLEX FOR CAROTID ENDARTERECTOMY

ries underwent surgery without
deaths or neurologic complications.
The First Phase Report of the Co
operative Veterans Administration
Asymptomatic Carotid Study has
reported a 0.4% incidence of neuro
logic deficit related to cerebral angi
ography.18 Since all the patients
were asymptomatic, these results
are troublesome. The necessity of
routinely performing angiography
on patients suffering asymptomatic
carotid disease is questionable. The
purpose of angiography becomes
that of detecting any associated
lesions that could compromise the
success of surgery. These lesions
are mainly tandem vascular lesions
(siphon stenosis or arch disease) or
intracerebral lesions like berry an
eurysms or brain tumours.
Carotid siphon disease has a
slower natural evolution than extra
cranial carotid disease but should
not preclude the correction of the
latter.20 The influence of carotid
siphon disease on carotid endar
terectomy is not clear, and, lately,
clinical series have denied any dele
terious effect on the procedure.21-22
The concomitant occurrence of
asymptomatic berry aneurysms has
not been found to jeopardize the
issue of carotid endarterectomy
when that procedure is justified.23
Proximal tandem lesions can be
detected by the use of continuous
Doppler scanning and can be con
firmed by arch angiography.
There is an unquestionable ad
vantage in managing asymptomatic
patients without the use of routine
angiography since the incidence of
neurologic complications must be
kept as low as possible. Concerns
may be expressed when the surgeon
has to deal with nonhemispheric
symptoms. In our study, patients
with nonhemispheric symptoms
were operated upon without any
further investigation. The outcome
has been successful for all but one
patient who died 11 days after

operation of a myocardial infarc
tion. Nevertheless, we agree with
the necessity of performing routine
cerebral computed tomography (CT)
in this subset of patients to exclude
other brain-related diseases that
could be responsible for nonhemis
pheric symptoms.10 Furthermore, in
patients presenting with unilateral
carotid stenosis, carotid angiogra
phy should be performed to visual
ize the intracerebral and posterior
circulation and to determine if the
vertebrobasilar circulation is defi
cient.
We do not believe that routine
use of cerebral CT is necessary in
patients with hemispheric symp
toms. Akers, Bell and Kerstein,23 in
a retrospective study of 1000 con
secutive cerebral angiograms, in
cluding 784 intracranial views ob
tained for evaluation of carotid ar
tery disease, found just one case of
brain tumour. They concluded that
intracranial studies did not alter the
management of their patients and
questioned the cost-effectiveness of
the procedure.23 Others have come
to the same conclusion in patients
presenting with focal symptoms.7-24
In this context, the place of routine
cerebral CT before the operative CT
is not clear. Nevertheless, a major
drawback to this practice is the
reliability of professionals carrying
out the duplex scanning. Their
technical skill must be appraised
and challenged with carotid angiog
raphy done in their own institution.
Their expertise will count on case
load and referral. Therefore, duplex
scanning should be limited to major
centres where professionals can
reach this level of expertise.
In conclusion, we believe that
carotid endarterectomy performed
with preoperative duplex imaging
only is an acceptable alternative to
standard cerebral angiography in
patients with carotid artery steno
sis. Patients presenting with non
hemispheric symptoms should un

dergo brain CT to rule out any
other cerebral disease. We strongly
recommend the use of carotid angi
ography when the findings on du
plex scanning are inconclusive,
when the stenosis is located distally
on the 1CA, in patients who have
vertebrobasilar symptoms with uni
lateral carotid stenosis, when there
is evidence of carotid high resist
ance index without carotid stenosis,
suggesting intracerebral disease,
and when arch vessels are involved.
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knife radiosurgery for acoustic neuro
mas and uveal melanomas, by heavycharged-particle radiosurgery for pitu
itary tumours and by LINAC radiosurg
ery for malignant intracranial tumours.
The series reported are small. Clearly
more experience with longer follow-up
is required before the place of radi
osurgery in the treatment of tumours is
established. In the editor’s comments,
other series are discussed, adding
weight to the use of radiosurgery in
acoustic neuromas, pituitary adenomas
and solitary brain metastases. Further
experience is needed in the treatment of
meningiomas and glial tumours.
The fifth section of the book de
scribes radiosurgery in the treatment of
arteriovenous malformations (AVMs).
The technique is already established for
the use of the gamma knife and heavycharged particles, so the chapters in
this section are more specific. They deal
with AVMs of the posterior fossa, com
bined embolization and radiosurgery,
the LINAC technique and results and
evaluation of sequelae of treatment.
There is also a chapter on heavycharged-particle radiosurgery for intra
cranial, angiographically occult AVMs,
containing the editor’s comments based
on a round-table discussion.
The final part of the book discusses

radiosurgery in functional diseases.
Overall, this text achieves its aim to
act as a baseline for radiosurgery and is
useful as an introduction to the subject
for those contemplating this modality of
treatment.

BOOK REVIEWS
continued from page 407

sell’s Brain Fragments are also included
as a tribute.
The first three parts of the book are
offered without editorial comment.
They cover radiobiology, radiosurgical
technique and experimental studies.
The radiobiologic basis for the response
of nervous tissue to large single frac
tions of radiation is described, and an
attempt is made to predict complica
tions and the biologic effect of the
radiation, depending on a number of
variable factors. The chapter on graph
ics and computer technology is complex
and hard to follow unless one is already
an expert in this field, although these
developments are fundamental to radi
osurgery. Subsequent chapters describe
the practical techniques of radiosurgery
with the gamma knife, linear accelera
tor (LINAC), stereotactic heavy-charged
particles and a method for stereotactic
fractionated radiotherapy for extracrani
al targets (although no data on
reproducibility in practice are offered).
The third part describes a number of
experimental radiosurgery studies in
sphenoid and animal models — these
experiments are among the first of their
kind, and much more work is needed
here.
The fourth part of the book describes
the treatment of patients by gamma416
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This comprehensive, multiauthored
book is intended as a reference text for
physicians who are interested in the
diagnosis and treatment of gastrointes-
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T h e Influence of Intermittent
Positive-Pressure Ventilation on the
Cardiorespiratory Dynamics
of Diaphragmatic Rupture With Gastric
Herniation
Jameel Ali, MD, FRCSC, FACS; Wan Qi, MSc
To determine the effect of intermittent positive-pressure ventilation (IPPV) on gastric herniation in
diaphragmatic rupture, 16 piglets underwent laceration of the left hemidiaphragm. Arterial blood gas
levels, pulmonary artery wedge pressure, cardiac output and arterial blood pressure were measured.
The stomach was then placed above the diaphragm. The initial measurements were repeated, and
displacement of the stomach above the diaphragm (S/D) was measured. The animals were divided into
two groups: group 1, eight animals breathing 80% oxygen spontaneously and group 2, eight animals
receiving IPPV. Initially in group 2 there was only a small decrease in mean (± SD) arterial oxygen
tension from 484 ± 34 mm Hg to 424 ± 20 mm Hg (other parameters were unchanged). In group 1,
gastric herniation produced a further fall in arterial oxygen tension to 308 ± 1 0 mm Hg at 1 hour, a
rise in arterial carbon dioxide tension to 49 ± 4 mm Hg and a decrease in pH to 7.32 ± 0.04. In group
2 similar changes in arterial blood gas levels occurred with gastric herniation, but there was a return
to baseline values of 490 ± 28 mm Hg for arterial oxygen tension, 37 ± 4 mm Hg for carbon dioxide
tension and 7.38 ± 0.05 for pH after IPPV. Similar changes were seen in blood pressure, cardiac
output and pulmonary artery wedge pressure. S /D remained at 6.3 ± 0.2 cm in group 1 but decreased
from 6.0 ± 0.2 cm to 1.1 ± 0.5 cm after 1 hour in group 2.
The authors conclude that diaphragmatic rupture produces cardiorespiratory changes, but these are
small in the absence of gastric herniation. IPPV effectively reduces gastric herniation and corrects the
cardiorespiratory abnormalities and is therefore a valuable temporary treatment until a definitive
operation can be done.

Dans le but de mesurer l’effet de la ventilation a pression positive intermittente (VPPI) sur l’hernie
gastrique dans les cas de rupture diaphragmatique, on a fait subir a 16 porcelets, une laceration de
l’hemidiaphragme gauche. Initialement, on a mesure les gaz arteriels, la pression capillaire
pulmonaire, le debit cardiaque et la tension arterielle. L’estomac fut ensuite place au dessus du
diaphragme. Les mesures initiales furent repetees et on mesura le deplacement de l’estomac au dessus
du diaphragme (E/D). Les animaux furent separes en deux groupes : le groupe 1, constitue de huit
animaux respirant de l’oxygene a 80 % de fa?on spontanee, et le groupe 2, forme de huit animaux qui
eurent une VPPI. Au debut, dans le groupe 2, on n’a enregistre qu’une petite diminution de la tension
d’oxygene arterielle moyenne (± ET), celle-ci passant de 484 ± 34 mm Hg a 424 ± 20 mm Hg (les
autres parametres demeurant inchanges). Dans le groupe 1, l’hernie gastrique a provoque une baisse
supplementaire de la tension d’oxygene arterielle a 308 ± 10 mm Hg apres une heure, une
augmentation de la tension de bioxyde de carbone arterielle a 49 ± 4 mm Hg et une diminution du pH a
7,32 ± 0,04. Dans le groupe 2, des modifications similaires des gaz arteriels ont suivi l’hernie
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gastrique mais, apres la VPPI, on a assiste a un retour aux valeurs de depart de 490 ± 28 mm Hg pour
la tension d’oxygene arterielle, de 37 ± 4 mm Hg pour la tension de bioxyde de carbone et de 7,38 ±
0,05 pour le pH. Des changements similaires furent observes pour la tension arterielle, le debit
cardiaque et la pression capillaire pulmonaire : une baisse initiale des valeurs mesurees et une chute
accrue apres l’hernie gastrique, suivies d’un retour aux valeurs de depart dans le groupe 2. Le E /D est
reste a 6,3 ± 0,2 cm dans le groupe 1 mais il a diminue de 6,0 ± 0,2 a 1,1 ± 0,5 cm apres 1 heure dans
le groupe 2.
Les auteurs concluent qu’une rupture diaphragmatique provoque des changements
cardiorespiratoires mais que ces changements sont minimes en l’absence d’une hernie gastrique. La
VPPI est efficace pour reduire l’hernie gastrique et corriger les anomalies cardiorespiratoires. Elle est
done utile comme traitement temporaire en attendant qu’on puisse proceder a une operation definitive.

iaphragmatic rupture may
occur after blunt or penetrat
ing injury to the torso. In the
absence of increased intra-abdomi
nal pressure, visceral herniation
does not uniformly occur during
spontaneous breathing when there
is diaphragmatic rupture.1 When it
does, it may be associated with only
mild cardiopulmonary dysfunction.2
We have shown previously that in
creased intra-abdominal pressure in
the presence of diaphragmatic rup
ture not only precipitates visceral
herniation but also is responsible
for severe cardiopulmonary compro
mise and death; we have further
shown that intermittent positivepressure ventilation (IPPV) partially
reverses the cardiopulmonary ef
fects and improves the chances of
survival.2
The present study was designed
to determine the cardiopulmonary
effects of IPPV on diaphragmatic
rupture with gastric herniation in
the absence of increased intra
abdominal pressure. We used pigs
because their anatomic chest struc
ture is similar to that in humans in
that the hemithoraces are separated
by an intact mediastinum.

D

Methods

Sixteen, healthy, New Hampshire
piglets, weighing between 30 and
32 kg, were anesthetized with sodi
um thiopental and ketamine hydro
chloride. The animals were intubat
ed and maintained on spontaneous
418
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ventilation with 1% halothane and
80% oxygen. A solution of normal
saline was administered intrave
nously and continuously at an
hourly rate of 2 mL/kg. Carotid
artery and pulmonary artery pres
sures were measured by a multi
channel recorder and by pressure
transducers connected to catheters
in the appropriate vessels. A SwanGanz thermodilution catheter was
introduced into the pulmonary ar
tery through an external jugular
vein. Cardiac output obtained from
thermodilution was measured in
triplicate and an average taken.3
An ABL2 blood gas analyser
(Radiometer, Copenhagen, Den
mark) was used for measuring tem
perature-corrected blood gas levels
from carotid artery blood. All mea
surements were made at the end of
expiration.
After the animal’s condition had
been stabilized, a surgical laceration
of the left hemidiaphragm, 12 cm
long, was made through a small left
lateral thoracotomy. Metallic mark
ers were then placed on the edge of
the diaphragm, and the stomach
was manually positioned exactly in
the centre of the diaphragmatic
laceration at the level of the dia
phragm. The position of the stom
ach was identified fluoroscopically
by means of a safety pin secured to
the uppermost surface of the stom
ach.12 A 16-French catheter was
placed in the pleural space, the
thoracotomy closed and the cathe
ter removed after all the residual
gas had been aspirated. Baseline

measurements were then made in
all animals. The thoracotomy was
reopened, and the stomach was
placed 6 cm above the lacerated
diaphragmatic edge, as determined
by the fluoroscopic markers. The
thoracotomy was again closed after
aspiration of residual gas from the
pleural space.
The position of the stomach rela
tive to the diaphragm was moni
tored by means of fluoroscopy at a
fixed magnification and distance
from the chest wall. The vertical
distance between the safety pin and
the diaphragmatic fluoroscopic
marker was measured on the fluoroscope screen (Fig. 1). The base
line cardiopulmonary measurements
made before displacement of the
stomach above the diaphragm were
repeated at 15 minutes, 30 minutes,
45 minutes and 1 hour after dis
placement. In group 1, eight ani-

FIG. 1: Fluoroscopic appearance of
diaphragmatic marker (bottom) and
gastric marker (safety-pin). Vertical
distance between diaphragmatic and
gastric markers was used as index of
gastric herniation.

IPPV IN DIAPHRAGMATIC RUPTURE

and it did not change after lacera
tion but before gastric herniation.
After displacement of the stomach
above the diaphragm, however,
there was a statistically significant
(p < 0.05) decrease in arterial blood
pressure to the same extent in both
groups. The animals in group 1
maintained this arterial blood pres
sure at 1 hour after gastric hernia
tion. The animals in group 2
showed a return to baseline arterial
blood pressure at 1 hour after
gastric herniation, once IPPV had
been instituted.

phragm showed a slight but statisti
cally significant decrease in arterial
oxygen tension (Pa02), with no sig
nificant changes in pH or arterial
carbon dioxide tension (PaC02).
There were no significant differ
ences in Pa02 between the groups.
At 15 minutes after gastric her
niation, both groups showed a simi
lar statistically significant (p <
0.05) decrease in Pa02, with a small
but statistically significant rise in
PaC02 and no change in pH. At 30
minutes after gastric herniation the
Pa02 in group 1 fell further, there
was another rise in PaC02 and a
slight but statistically significant
fall in pH. At 45 minutes and 1
hour after herniation there had
again been decreases in Pa02, in
creases in PaC02 and decreases in
pH in group 1. By 30 minutes after
gastric herniation and 15 minutes
after IPPV, group 2 showed a sta
tistically significant rise in Pa02,
and the increase was progressive
back to baseline levels of fti02 at 1
hour after herniation. Although
there was a trend for the PaC02 to
decrease this did not reach statisti
cal significance in group 2 after the
30-minute measurement. Similarly
the pH remained relatively constant
in this group.

mals remained intubated and spon
taneously breathed 80% oxygen; in
group 2, the other eight animals
were ventilated with IPPV of 20
cm H20 and 80% oxygen after the
15-minute measurement. The mea
surements were then repeated at
the same times as for the animals in
group 1. The animals maintained
their own respiratory rate.
At the end of the experiments the
animals were sacrificed by intracar
diac instillation of potassium chlo
ride solution.
Paired f-tests were used for com
parisons of the data within the
groups. Analysis of variance fol
lowed by Tukey’s multiple range
test was used for multiple compari
sons among the groups. A p value
of 0.05 was accepted as statistically
significant. The data are presented
as means plus or minus the stan
dard deviation.

Results
All the animals survived the
1-hour period of the study.
Arterial Blood Gas Levels (Table I)
Arterial blood gas levels were
similar in both groups before dia
phragmatic laceration and during
spontaneous breathing. Baseline
measurements taken after diaphrag
matic laceration with the stomach
located at the level of the dia

Cardiac Output (Table II)
Baseline cardiac output measure
ments in the two groups of animals
were similar both before diaphrag
matic laceration and after laceration
but without gastric herniation. At
15 minutes after gastric displace
ment, the cardiac output fell slight
ly and was 3.6 ± 0.2 L/m in at 1
hour in group 1. In group 2 there
was a similar decrease at 15 min
utes after herniation and a return to
baseline levels by 1 hour with the
institution of IPPV.
Pulmonary Artery Wedge Pressure
(Table II)
Baseline measurements of the
pulmonary artery wedge pressure
were similar in the two groups
before diaphragmatic laceration and
did not change significantly after

Blood Pressure (Table II)
The arterial blood pressure was
similar in the two groups of animals
before diaphragmatic laceration,

T a b le

1. A rte r ia l

B lo o d G a s L e v e ls

Group 2

Group 1
M e a su re m e n t

Pao2, mm Hg

tim e

Paco2, mm Hg

pH

flao2, mm Hg

Paco2, mm Hg

PH

38 ± 3

7 .3 8 ± 0 .0 5

P re -th o r a c o to m y

480 ± 36

39 ± 4

7 .3 9 ± 0 .0 5

484 ± 34

B a s e lin e

4 3 0 ± 19

39 ± 5

7 .3 9 ± 0 .0 5

424 ± 20

39 ± 5

7 .3 9 ± 0 .0 5

1 5 m in

4 0 0 ± 14*

41 ± 5*

7 .3 9 ± 0 .0 5

3 9 6 ± 12*

40 ± 4

7 .3 8 ± 0 .0 6

3 0 m in

356

46 ± 3 * t

7 .3 6

320

8*

48

±

2t

7 .3 4

6 0 m in

308

±
±
±

4*

4 5 m in

49 ± 4 +

7 .3 2

±
±
±

' p < 0 .0 5
p < 0 .0 5

t

10*

±
±
±

0 .0 2 *

420

0 .0 2 f

470

0 .0 4 t

490

14*

39 ± 2

7 .3 9

3 0*

38 ± 3

7 .3 8

28

37

±

4

7 .3 8

±
±
±

0 .0 5
0 .0 5
0 .0 5
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diaphragmatic laceration without
gastric herniation. There was a very
small but significant increase in
pressure after gastric herniation in
group 1 but no further statistically
significant change in this measure
ment throughout the experiment.
In group 2 the pulmonary artery
wedge pressure increased slightly at
15 minutes after herniation, and
there was a small but statistically
significant fall by 1 hour after
gastric herniation.

tion during spontaneous breathing
is associated with only minor he
modynamic and respiratory dys
function in the absence of visceral
herniation. Gastric herniation re
sults in moderate changes in blood
pressure, cardiac output, pulmo
nary artery wedge pressure and ar
terial blood gas levels. These
changes are, however, all compati
ble with short-term survival.
We have shown that the displace
ment of the stomach above the
diaphragm during spontaneous
breathing is maintained (for at least
1 hour) and that this displacement
can be decreased with the institu
tion of IPPV. We have also shown
that after gastric herniation the use
of IPPV improves arterial blood gas
levels, pulmonary artery wedge
pressure and blood pressure. This
improvement in cardiorespiratory
function occurs even before there is
any detectable decrease in the de
gree of gastric herniation. Our re
sults demonstrate that diaphrag
matic laceration during spontane
ous breathing without visceral her
niation is well tolerated and that
even with gastric herniation the

Displacement o f the Stomach Above
the Diaphragm (Table III)

By design, the distance of the
stomach above the diaphragm
(S/D) was similar in the two groups
before and after diaphragmatic lac
eration until the stomach was man
ually displaced above the dia
phragm. At 15 minutes after dis
placement, the S /D was similar in
the two groups. At 30 minutes
there was a trend for the S /D to
decrease in group 2, although this
was not significant. The S /D of
group 1 animals was unchanged at
45 minutes and 1 hour, but the
S /D of group 2 animals was
markedly decreased at these times.

hemodynamic changes are compati
ble with short-term survival. Our
study may explain the observation
that diaphragmatic rupture is a fre
quently missed or delayed diag
nosis,4-6 particularly in patients
with multiple injuries whose minor
hemodynamic changes (such as oc
curred in these animal studies) may
be easily explained by other, associ
ated injuries. Thus, it seems that
the monitoring of hemodynamic
and pulmonary parameters alone
may not lead to the diagnosis of
diaphragmatic rupture with or with
out visceral herniation and that
other investigative modalities may
be required.7
Our study also suggests that in
patients with cardiopulmonary dys
function after diaphragmatic rup
ture and visceral herniation, IPPV
is a useful therapeutic modality: it
not only improves hemodynamic
and respiratory function before re
ducing the visceral herniation, but
also effectively decreases the her
niation; thus, it can be used as a
temporizing measure, particularly
in cases of multiple trauma, until
definitive surgery is possible.

Table III. Stomach Displacement Above Diaphragm
Measurement time, min

Group 1

15
30
45
60

Discussion

6.0
6.0
6.0
6.3

Group 2

± 0.1
± 0.2
± 0 .1 *
± 0.2*

6.0
5.5
3.2
1.1

± 0.2
± 0.3
± 0.2t
± 0 .5 t

*p < 0.05 compared with group 2
t P < 0.05 compared with previous value

In this study we have demon
strated that diaphragmatic lacera

Table II. Hemodynamic Data
Group 1
Measurement
time

BP, mm Hg

CO, L/min

Pre-thoracotomy
Baseline
15 min
30 min
45 min
60 min

120 ±
118 ±
100 ±
98 ±
99 ±
99 ±

3.9 ± 0 .1
3.8 ± 0.1
3.6 ± 0 .1 *
3.5 ± 0.1t
3.5 ± 0 .2 f
3.6 ± 0 .2 t

8
10
6*
6*
4t
6t

Group 2
PAWP, mm Hg

7.9
8.0
8.4
8.6
8.4
8.4

±
±
±
±
±
±

'p < 0.05 compared with previous value
t P < 0.05 compared with group 2
BP = blood pressure, CO = cardiac output, PAWP = pulmonary artery wedge pressure
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0.1
0.1
0.2*
0 .2 t
0 .2 t
0 .3 t

BP, mm Hg

CO, L/min

118
119
99
114
116
118

4.0
3.9
3.5
4.0
4.1
4.0

±
±
±
±
±
±

8
10
8*
4*
4
9

± 0.1
± 0 .1
± 0.2*
± 0 .1 *
± 0 .1
± 0.2

PAWP, mm Hg

7.8
7.9
8.6
8.0
7.9
7.9

± 0.2
± 0.2
± 0.2*
± 0 .1 *
± 0.2
± 0.2
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tinal hemorrhage. Emergency room
physicians, internists, gastroenterolo
gists, family physicians and surgeons
will “find relevant guidance” from rec
ognized experts in the “day to day
encounters with bleeding from the gas
trointestinal tract.”
The book is organized into six sec
tions. The first section deals with the
general aspects of upper and lower
gastrointestinal bleeding: the magni
tude of the clinical problem; the pathol
ogy of bleeding lesions; liver disease in
gastrointestinal bleeding; drug-induced
gastrointestinal bleeding; hematologic
problems in gastrointestinal bleeding;
and gastrointestinal bleeding in the crit
ical care unit. A separate chapter focus
es on gastrointestinal bleeding in in
fants and children. Another chapter is
devoted to the problem of chronic gas
trointestinal bleeding. The second sec
tion, comprising five chapters, discuss
es, separately, bleeding from the esoph
agus, stomach, duodenum, small intes
tine and large intestine. The third sec
tion covers diagnosis, including diag
nostic imaging, upper gastrointestinal
endoscopy and colonoscopy. A separate
chapter deals with intraoperative endos
copy. The fourth section is a short one.
Its two chapters are on acute manage
ment and identification of risk factors
and on the treatment of shock. The
fifth section deals with the treatment of
nonvariceal bleeding, and the last sec
tion covers the treatment of variceal
bleeding.
The text is clear and readable. It is
comprehensive. It brings together data
that have been generated in the last 20

years in a number of specialties involved
in the diagnosis and treatment of gas
trointestinal bleeding. The general stan
dards of the chapters are high; some
are excellent. I particularly liked the
chapters on intraoperative endoscopy
and the two chapters by Dr. Ernest
Ring on angiographic management and
radiologic therapy for esophageal vari
ces. Both are excellently written and
superbly illustrated with radiographs.
The chapters on endoscopic treatment
of nonvariceal bleeding are also well
written, summarizing most of the re
cent data on the efficacy of newer
modalities of endoscopic intervention,
including heater probe, bipolar and mul
tipolar electrocoagulation, laser therapy
and injection therapy. Most of the re
cent randomized controlled trials in this
area are included in the discussion, so
readers can judge for themselves the
scientific data underlying the claims of
efficacy of these endoscopic treatment
modalities. The final section, on the
treatment of variceal bleeding is well
balanced, clear, succinct and inclusive.
First, emergency treatment, balloon
tamponade and pharmacologic control
are discussed, and supporting data are
presented. Next, endoscopic scleroth
erapy of varices is neatly summarized,
followed by a chapter that compares
injection sclerotherapy with other ther
apies, particularly shunt surgery. The
chapter on surgical shunts for bleeding
esophageal varices by Dr. Jeremiah Turcotte is expertly written; the surgical
procedures are clearly illustrated with
diagrams for nonsurgeons, and the sur
gical results are neatly summarized.

The final chapter on stapler esophageal
transection by Dr. Yasuo Idezuki is
mainly ■a discussion of the Sugiura
procedure — it is a superb summary.
Overall, this is an excellent book on
the current management of gastrointes
tinal bleeding and should be useful to
all physicians who have to treat patients
with this condition. I would highly
recommend this book to any hospital
library and particularly to gastroen
terologists and general surgeons who
are experts in their own fields and who
want to familiarize themselves with ad
vances in other specialties in this chal
lenging area.

Jarley Koo, MB, ChB, FRCSC, FACS

Division of General Surgery
St. Michael's Hospital
University of Toronto
30 Bond St.
Toronto, ON
M5B 1W8

ENDOVASCULAR SURGERY. 2nd
edition. Edited by S.S. Ahn and W.S.
Moore. 612 pp. Illust. W.B. Saunders
Co., Philadelphia. 1992. $182. ISBN
0-7216-4370-1

This is a large and impressive second
edition, edited by two vascular surgeons
from the UCLA Centre for Health Sci
ences. The editors are part of a mul
tidisciplinary team of cardiac and vascucontinued on page 430
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One Toradol 30 mg IM injection has been
proven as effective as morphine 12 mg IM and
meperidine 100 mg IM.10
Toradol IM offers an improved side effect
profile compared to narcotics.5,16 Patients
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Effect of Cardiac Stabbing on Ventricular
Function: Evaluation by Radionuclide
Angiography
Erik D. Skarsgard, MD, MSc(Surg), FRCSC;* P. Terry Phang, MD;*§ Allan S. Belzberg, MD, FRCPC;t
James A. Russell, MD, FCCP, FRCPC$
Objective: To determine whether cardiac stab wounds cause early ventricular dysfunction.
Design: Retrospective case series over 7 years.
Setting: University-affiliated teaching hospital.
Patients: Nine consecutive survivors of cardiac stab wounds.
Interventions: Postoperative radionuclide angiography performed in all patients between 1 and 13 days
after injury and repeated in two patients 2 months and 7 months respectively after injury.
Main Outcome Measures: Information on the patient’ s clinical presentation and hospital course was
obtained from the patient’s charts and correlated with ventricular function as measured by the right
and left ventricular ejection fractions (RVEF and LVEF).
Results: Cardiac injuries consisted of isolated right (five) and left (three) ventricular lacerations, and
one biventricular laceration. Three patients had perioperative dysrhythmias (two ventricular, one
atrial), and nonspecific electrocardiographic changes occurred in seven patients. Six patients had
postoperative complications: pericarditis in three and pneumonia, pulmonary thromboembolism and
abdominal wound dehiscence in one each. The LVEF was normal in all patients. Although none had
clinically apparent cardiac dysfunction at the time of radionuclide angiography, six patients had a
reduced RVEF (less than 0.45). All patients remained asymptomatic at the time of discharge from
hospital (median 12 days postoperatively). In two of the six patients who had a reduced RVEF, one had
a normal RVEF 2 months later; the other had a near-normal RVEF (0.43) but had persistent right
ventricular enlargement 7 months later. Both were asymptomatic.
Conclusions: Although a reduced RVEF is common in survivors of cardiac stab wounds, the reduction
is small and is not associated with clinically apparent cardiac dysfunction.

Objectif: Determiner si les blessures cardiaques par couteau causent un dysfonctionnement
ventriculaire immediat.
Conception : L’examen retrospectif des cas vus pendant une periode de 7 ans.
Contexte : Un hopital universitaire.
Patients : Neuf survivants consecutifs a des blessures cardiaques par couteau.
Interventions : Une angiographie isotopique postoperatoire pratiquee chez tous les patients, de 1 a 13
jours apres la blessure, et repetee chez deux patients, respectivement, 2 et 7 mois apres la blessure.
Principaux effets mesures : Le tableau clinique du patient a 1’arrivee et son evolution a l’hopital furent
extrait du dossier d’hopital et mis en parallele avec le fonctionnement ventriculaire mesure par les
fractions d’ejection ventriculaire droite et gauche (FEVD et FEVG).
Resultats : Les lesions cardiaques etaient constitutes de cinq lacerations ventriculaires droites isolees,

From the *Department of Surgery, fDepartment of Nuclear Medicine and f Program o f Critical Care Medicine, St. Paul’s Hospital, University of
British Columbia, Vancouver, BC
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Accepted for publication Feb. 1, 1993
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de trois laceration ventriculaires gauches et d’une laceration des deux ventricules. Trois patients ont
developpe des dysrythmies peroperatoires (deux ventriculaires, une auriculaire) et des changements
non specifiques du trace electrocardiographique sont survenus chez sept patients. Six patients ont
souffert de complications postoperatoires : trois pericardites et, un cas chacun de pneumonie, d’embolie
pulmonaire et de desunion des sutures d’une plaie abdominale. La FEVG etait normale chez tous les
patients. Bien qu’aucun n'ait manifesto de dysfonctionnement cardiaque cliniquement apparent au
moment de l’angiographie isotopique, six patients montraient une reduction de la FEVD (moins de
0,45). Tous les patients etaient asymptomatiques au moment de recevoir leur conge de I’hopital
(mediane de 12 jours postoperatoires). De deux des six patients qui avaient montre une diminution de
la FEVD, un s’etait normalise 2 mois plus tard; l’autre avait une FEVD presque normale (0,43) apres 7
mois mais conservait une hypertrophie ventriculaire droite. Les deux etaient asymptomatiques.
Conclusions : Meme si une diminution de la FEVD est frequente chez les survivants d’une blessure
cardiaque par couteau, cette diminution est petite et n’est pas reliee a un dysfonctionnement cardiaque
cliniquement apparent.

enetrating injuries of the heart
represent one of the most ur
gent conditions facing those in
volved in trauma care. The pro
found physiologic derangement im
posed by penetrating injury compli
cated by pericardial tamponade
mandates immediate intervention to
restore cardiac function. Although
prompt thoracotomy and cardiorrhaphy can restore a physiologic
hemodynamic state in the short
term, there have been no studies of
early postoperative right and left
ventricular function in survivors of
cardiac stab wounds. Therefore, we
carried out this study first to deter
mine whether severe penetrating
cardiac injury decreases the right
and left ventricular ejection frac
tions (RVEF and LVEF) as mea
sured by radionuclide angiography
and second to correlate ventricular
ejection fractions with clinical pre
sentation and outcome.

P

Patients and Methods
Over a 7-year period ending in
July 1990, nine survivors of cardiac
stab wounds were treated at St
Paul’s Hospital, Vancouver, and un
derwent radionuclide angiography
at least once before discharge. In
formation on the nature of the
weapon and injury, clinical cardio
vascular status on admission, treat
ment, response to treatment and
426
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complications were obtained from
the hospital charts.
Radionuclide Data Acquisition and
Processing

All radionuclide angiograms were
obtained with a portable gamma
scintillation camera (Picker Dyna
mo, Northford, Conn.), positioned
so that there was maximal separa
tion between the right and left
ventricular images (40° to 50° left
anterior oblique). Electrodes were
placed on the chest, and a gating
device was connected to a mobile
minicomputer (DPS 2800; ADAC
Laboratories, Sunnyvale, Calif.).
The patient’s red blood cells were
labelled by injecting stannous chlo
ride (0.03 m g/kg) 10 to 30 min
utes before the injection of 20 to
25 mCi of technetium 99m ( 99mTc)
through a central venous catheter.1
Multigated scintigraphy was done
using 16-frame images obtained
over 80% of the cardiac cycle. Each
frame contained 2 000 000 counts.
All data were acquired with hard
ware zooming to expand the data
1.5 times and were recorded in a
byte mode 64 X 64 matrix.
After nine-point smoothing, com
puter-generated (DPS 2800; ADAC
Laboratories) regions of interest
were assigned around the right and
left ventricle. All frames were re
viewed manually, and changes were
made when necessary to ensure

correct placement of the region of
interest. A left paraventricular back
ground region was assigned on the
end-systolic frame. Backgroundsubtracted time-activity curves were
generated, and the computer select
ed the end-diastolic and end-systolic
points on the basis of maximal and
minimal counts, respectively. Ejec
tion fraction (EF) was calculated
by means of the formula EF =
(EDC-ESC) -r EDC, where EDC =
end-diastolic counts and ESC =
end-systolic counts. In our depart
ment, the lower limits of normal
RVEF and LVEF are 0.45 and 0.50
respectively.
Reproducibility o f L V E F and R V E F

We have previously determined
the reproducibility of equilibrium
LVEF and thermodilution cardiac
output in seven ventilated, critically
ill patients.2 LVEF was measured by
three observers who were blind as
to the study. LVEF and cardiac
output were measured three times
at 15-minute intervals for 30 min
utes without change of any sup
port. When the three measurements
over 30 minutes were compared,
the correlation coefficient and stan
dard deviation of LVEF were calcu
lated to be 0.94 and 0.02 respec
tively.
Measurement of RVEF requires
separation of right atrial activity
from right ventricular activity. We

VENTRICULAR FUNCTION AFTER CARDIAC STAB WOUNDS

performed two manoeuvres to maxi
mize this separation. First, the
gamma camera was carefully posi
tioned in the left anterior oblique
position with cranial angulation as
necessary to minimize right atrial
and right ventricular overlap. Sec
ond, end-systolic and end-diastolic
regions of interest were defined sep
arately by computer and independ
ent observers. Maddahi and col
leagues3 have shown that measure
ment of the RVEF by this technique
correlates well with first-pass ra
dionuclide cineangiography (r =
0.95). In our hands the correlation
coefficient between two observers
(interobserver variation) for equilib
rium RVEF was 0.91 and for repeat
equilibrium studies (intraobserver
variation) it was 0.98.
For a qualitative description of
regional abnormalities in ventricular
wall motion, the blood-pool ra
dionuclide cineangiograms were
routinely supplemented by regional
EF images and were defined as
abnormal if localized areas of hypo
kinesia, akinesia or dyskinesia were
observed.

moperitoneum. None of the patients
had a history of significant premorbid cardiopulmonary disease.
Four patients underwent urgent
thoracotomy and pericardiotomy in
the emergency department for re
lease of severely compromising peri
cardial tamponade a median of 10
minutes after admission (range from
6 to 23 minutes). Of the patients
who underwent thoracotomy in the
emergency department, two pre
sented with absent vital signs, and
three remained in profound shock
from tamponade despite aggressive
cardiopulmonary resuscitation (en
dotracheal intubation, intravenous
volume loading). The other four
patients maintained a systolic blood
pressure of at least 80 mm Hg after
aggressive volume resuscitation and
underwent either median sternoto
my or left lateral thoracotomy in
the operating room, a median of 55
minutes (range from 35 to 67 min
utes) after admission. One patient
underwent pericardiocentesis for re
suscitation before thoracotomy.
All patients had hemopericardium. Five patients had isolated right
ventricular lacerations, three had

isolated left ventricular lacerations
and one had biventricular lacera
tions with injury to the acute mar
ginal branch of the right coronary
artery, requiring ligation. Cardiac
lacerations were repaired with inter
rupted sutures, with or without
Teflon pledgets. One patient with
hemoperitoneum also underwent
exploratory laparotomy, which re
vealed a lacerated left hemidiaphragm without injury to an intra
abdominal viscus.
Three of the patients experienced
nonrecurrent perioperative dys
rhythmias (Table II). Ventricular
dysrhythmias occurred in two pa
tients (intraoperative ventricular fi
brillation and postoperative ventric
ular tachycardia), and one patient
experienced postoperative paroxys
mal atrial tachycardia. Nonspecific
ST segment changes developed in
seven patients postoperatively.
These changes returned to normal
in four patients during hospitaliza
tion (8 to 19 days).
Postoperative complications de
veloped in six patients. Three pa
tients suffered from pericarditis as
determined by chest pain, pericardi-

Statistical Analysis
T a b le 1. C lin ic a l F e a tu re s o f N in e S u r v iv o rs o f C a rd ia c S ta b W o u n d s

Associations between abnormal
radionuclide angiograms and clini
cal variables were assessed using
Fisher’s exact test.

P a t ie n t
n o.

A ge.
Sex

yr

Eight of nine patients were men,
with a median age of 30 years
(range from 19 to 51 years). A
single anterior thoracic stab wound
was the source of injury in seven
patients; the other two had multiple
thoracic stab wounds (Table I). As
sociated injuries were confined to
the thorax in four patients, (hemopneumothorax or open chest
wound), and one patient had a stab
wound in the left flank with he-

w ound

1

M

32

R, L p a ra s te rn a l
ICS 6

2

M

19

3

M

29

4

M

30

5

F

38

6
7

M
M

21
22

8

M

51

9

M

26

L p a ra s te rn a l
ICS 7
L m id c la v ic u la r
ICS 6
L m id c la v ic u la r
ICS 2, 5
L m id c la v ic u la r
ICS 6
S u b x ip h o id
L m id c la v ic u la r
ICS 5
L m id c la v ic u la r
ICS 5
L a n te rio r a x illa ry lin e
ICS 6

Findings

S it e o f
c a r d ia c
in ju r y

T im e to
S y s to lic B P
on a d m is s io n , th o r a c o to m y ,
m in
m m Hg

E x te r n a l

R V, L V a c u te
m a rg in a l
a rte ry
RV

50

3 5 , OR

0

6 , ER

60

1 0 , ER

LV

80

6 5 , ER

LV

80

6 7 , OR*

RV

60
0

6 5 , OR
8 , ER

RV
RV

50

4 5 , OR

RV

130

2 3 , ER

LV

‘ P re ce d e d b y p e ric a rd io c e n te s is
ICS = in te rc o s ta l s p a c e , BP = b lo o d p re s s u re , OR = o p e ra tin g ro o m , ER = e m e rg e n c y r o o m , K V
= rig h t v e n tric le , LV = le ft ve n tricle
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al friction rub and ST elevation on
the electrocardiogram. One patient
had postanoxic encephalopathy and
paraplegia as a result of prolonged
prehospital hemodynamic compro
mise from pericardial tamponade,
despite undergoing thoracotomy
within minutes of arrival in the
emergency department. Other com
plications included pneumonia (one
patient), pulmonary thromboembo
lism (one patient) and dehisence of
the abdominal incision (one pa
tient).
Periods of hospitalization ranged
from 4 days in one patient who left
against medical advice, to 105 days
in the patient with anoxic encepha
lopathy (Table II). The median hos
pitalization was 12 days.
At the time of discharge, none of

the patients had evidence of cardi
opulmonary dysfunction detectable
by either clinical examination or
chest radiography.
Radionuclide Angiography
Radionuclide angiography was
performed in all patients a median
of 4 days after injury (range from 1
to 13 days). At the time of the
examination none of the patients
had clinical evidence of left or right
ventricular failure or dysrhythmia.
Decreased RVEF (< 0.45) was
present at initial study in six pa
tients (Table III), including two who
had an isolated left ventricular (LV)
laceration. One patient had right
ventricular (RV) enlargement and
hypokinesis in association with re

Table II. D y s rh y th m ia s , C o m p lic a tio n s and D u ra tio n o f H o s p ita liz a tio n
Patient
no.
1

Dysrhythmia

ST-T segment
change

Peri
carditis

E le v a tio n

Y es

None

12

E le v a tio n
E le va tio n
F la tte n in g
None
E le v a tio n

No
No
No
No
Y es

P n e u m o n ia
N one
N one
N one
N one

12
10
8
4*
9

Complication

Hospital
stay, d

E le va tio n

Y es

C e re b ra l a n o xia

105

8

V e n tric u la r
ta c h y c a rd ia
N one
None
None
None
P a ro x y s m a l
a tria l
ta c h y c a rd ia
V e n tric u la r
fib r illa tio n
None

N one

No

17

9

None

E le va tio n

No

A b d o m in a l w o u n d
d e h is c e n c e
P u lm o n a ry
e m b o lis m

2
3

4
5
6

7

19

'P a tie n t disch a rg e d h im s e lf a g a in s t m e d ic a l advice.

Table III. F in d in g s o f P o s to p e ra tiv e R a d io n u clid e A n g io g ra p h y *
Patient
no.

Postop day of
study

LVEF

RVEF

Ventricular wall
motion

1

4
4
6
1
60
1
13
2
7
225
2

0 .6 5
0 .7 6
0 .6 9
0 .7 5
0 .6 7
0 .5 7
0 .5 5
0 .6 2
0 .5 3
0 .4 7
0 .5 9

0 .3 5
0.51
0.3 7
0 .3 8
0 .4 5
0.4 2
0.3 3
0.4 5
0.3 7
0.4 3
0 .4 5

N o rm a l
N o rm a l
N o rm a l
N o rm a l
N o rm a l
N o rm a l
N o rm a l
N o rm a l
RV e n la rg e d , h y p o k in e tic
RV e n la rg e d
N o rm a l

2
3
4
5
6
7
8
9

'P a tie n ts 4 and 8 had fo llo w - u p ra d io n u c lid e a n g io g ra p h y at 6 0 and 2 2 5 d a y s re s p e c tiv e ly .
LVtr = le ft v e n tric u la r e je c tio n fra c tio n , RVEF = rig h t v e n tric u la r e je c tio n fra c tio n , RV = rig h t
v e n tric le
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duced RVEF. Two patients who had
reduced RVEF underwent follow-up
radionuclide angiography, one at 2
months and one at 7 months after
injury. Both patients were asymp
tomatic with unremarkable findings
on physical examination, a normal
chest radiograph and a normal elec
trocardiogram at the time of the
follow-up radionuclide angiography.
Follow-up radionuclide angiography
showed normal RVEF in one patient
and near normal RVEF (= 0.43) in
the other patient associated with
persistent enlargement of the right
ventricle. Initial studies showed that
the LVEF was normal (> 0.50) in
all patients.
Associations Between Radionuclide
Angiography and Clinical Variables
Reduced RVEF occurred in iso
lated LV lacerations as well as in
RV lacerations. There was no asso
ciation between reduced RVEF and
age. There was a trend in the
association between reduced RVEF
after injury and time from admis
sion to thoracotomy: only two of
five patients who underwent thora
cotomy within a median of 10 min
utes of arrival in the emergency
department had reduced RVEF, but
all four patients who had thoracoto
my or sternotomy in the operating
room a median of 55 minutes after
arrival had reduced RVEF (p <
0.17). Dysrhythmias and pericardi
tis occurred in the same patients,
and occurred only in patients who
had reduced RVEF. Dysrhythmias
and pericarditis did not occur in
patients who had a normal RVEF.
LVEF was normal and independent
of anatomic site of injury.

Discussion
The major finding of our study is
that severe penetrating cardiac inju
ry decreased the RVEF in the ma-
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jority of patients, but all patients
had a normal LVEF. Second, de
spite the decreased RVEF the clini
cal outcome was excellent in that
no patient had clinical symptoms of
right heart failure or any other
persistent complication of the cardi
ac stab wound.
To our knowledge this is the first
report of reduced RVEF after cardi
ac stab wounds. In addition to de
creased RVEF we report early se
quelae of penetrating cardiac injury,
including pericarditis and atrial and
ventricular dysrhythmias similar to
the findings of others.4-9 These
complications were readily treated
and did not cause major acute mor
bidity. Others4-9 have reported more
serious complications of penetrating
cardiac injury, including valvular
insufficiency, ventricular septal de
fect, ventricular aneurysm and myo
cardial infarction. None of these
occurred in our small group of
patients. We suggest that heart
failure did not develop in our pa
tients because there was no major
structural injury to the heart.
Although reduced RVEF from
penetrating cardiac wounds has not
been documented previously, re
duced RVEF from blunt cardiac
injury is well documented and has a
prevalence of 36% to 55%.10-15 As in
our study of penetrating cardiac
injury, the commonest abnormality
on radionuclide angiography after
blunt cardiac injury is reduced
RVEF, with or without focal or
global wall-motion abnormalities.
Also similar to our study, there
appears to be little correlation be
tween reduced RVEF and clinical
cardiopulmonary dysfunction in the
majority of blunt cardiac trauma.
Abnormalities in radionuclide angi
ography resolved in the majority of
patients who had blunt trauma
within their period of hospitaliza
tion so that at 1 year after injury
there was little significant cardiac
dysfunction after blunt traumatic

myocardial contusion.14 Therefore,
although reduced RVEF is a com
mon finding after cardiac injury,
reduced RVEF is rarely associated
with clinical evidence of cardiac
failure in survivors of either pene
trating or blunt traumatic cardiac
injury.
The mechanism of decreased
RVEF after penetrating cardiac in
jury is not known and was not
investigated in our study. There are
at least three potential mechanisms
of RV dysfunction. First, direct
myocardial injury alone could re
duce RVEF after penetrating cardi
ac trauma. Second, RVEF could
decrease because of increased RV
afterload (increased RV afterload
and increased pulmonary vascular
resistance may occur after penetrat
ing trauma because of concomitant
pulmonary injury, hypoxia, acido
sis, sepsis and pulmonary embo
lism). Third, RV ischemia may
occur first because of reduced coro
nary perfusion pressure during
shock and second because of in
creased RV wall tension caused by
increased RV afterload and volume
following rapid intravenous fluid re
suscitation. In our study only one
patient had pulmonary arterial
pressure monitoring at the time
of radionuclide angiography.
This patient had an increase in
the pulmonary artery pressure
(40/18 mm Hg) with a reduced
RVEF. Patient no. 1 had a lacera
tion of the right coronary artery,
which was ligated at surgery. Oc
clusion of the right coronary artery
could have resulted in RV ischemia
and decreased RVEF. We have no
other direct evidence that increased
RV afterload or RV ischemia con
tributed to reduced RVEF in the
other patients. Increased RV after
load and RV ischemia have been
postulated as mechanisms of re
duced RVEF in other critically ill
patients who had multiple traumatic
injuries or sepsis.1516 In those

studies, nonsurvivors of trauma and
sepsis had more marked decreases
of RVEF (mean RVEF 0.18) than
did the survivors of severe penetrat
ing cardiac injury in our study
(initial mean RVEF 0.40).
We did not routinely assess pa
tients after hospital discharge. Two
patients who had decreased RVEFs
were selected for later assessment,
one patient at 2 months and one
patient at 7 months after injury.
Both patients had normal clinical
cardiac findings at that time, and
both had recovery of the decreased
RVEF.
In summary, survivors of cardiac
stab wounds had reduced RVEFs,
but LVEFs remained normal. How
ever, the magnitude of reduction in
the RVEF was small and was not
associated with clinically apparent
cardiac dysfunction. We suggest
that isolated cardiac stabbings with
out major cardiac structural injury
do not cause right or left heart
failure or clinically significant ven
tricular dysfunction.
We thank the nuclear medicine tech
nologists at St Paul’s Hospital, Vancou
ver, for their assistance and cooperation
in performing the nuclear angiography
in these patients.
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BOOK REVIEWS
continued from page 421

lar surgeons, cardiologists and interven
tional radiologists who dedicate them
selves to endovascular therapy. Such a
unit, to the best of my knowledge, has
no counterpart in any academic centre
in Canada.
The editors state that their book is
designed as an “integrated, comprehen
sive, up-to-date textbook covering all
aspects of this rapidly developing, everexpanding and exciting new field of
endovascular surgery.” Indeed, it pro
vides a detailed overview of the scope of
modern noncardiac vascular interven
tion as practised in a well-funded and
research-oriented academic centre in
the United States. This should certainly
be of interest to my surgery and radiol
ogy colleagues in our clinically over
loaded and woefully underfunded Cana
dian institutions.
The list of contributing authors is
extensive and includes staff and resi
dents from several departments of sur
gery, radiology, medicine and engineer
ing as well as nonmedical experts from
the private sector. In fact, this wide
range of contributors allows each chap
ter to stand on its own, but this results
in some loss of coherence in the text.
After a short introductory section
dealing with the organization, goals and
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standards of the endovascular team, a
long section dealing with angioscopy
and intravascular ultrasonography fol
lows. As neither of these techniques is
yet of established clinical value, and as
neither is routinely used in Canada, this
particular section is only of academic
interest and reference value.
The third section deals with balloon
angioplasty. After a historical review
and a basic consideration of equipment
required, there are chapters on aortoiliac, femoropopliteal, renal and mes
enteric angioplasty. Honest comparison
with surgical alternatives ensues. One
benefit of the multidisciplinary ap
proach may be a more honest and open
comparison of competing procedures.
The fourth and fifth sections deal
with mechanical atherectomy and laserassisted angioplasty and, again, are of
less practical import in the current
Canadian medical system, where it is
increasingly difficult to justify the use
of expensive, disposable, “high-tech”
gadgetry. Anyone contemplating the
purchase of a laser or in the initial
stages of an atherectomy program,
however, will find this a helpful review.
The sixth section is a grab-bag of
adjunctive procedures, including carbon
dioxide angiography, thrombolysis,

stents and venacaval filters. I would
have favoured a more extensive discus
sion of all of these topics.
A final section deals with the histo
logic, morphologic and physiologic re
sponses to many of the previously de
scribed interventions. It offers a refresh
ing and interesting perspective.
This is an attractive tome, full of
useful radiographs and diagrams as well
as photographs of equipment and speci
mens. The layout is appealing and al
lows for easy reading. I have no hesita
tion in recommending it as a reference
text to my academic surgery colleagues.
It provides a timely overview of the
wide range of endovascular therapies,
many unproven, available today in large
US centres.

Andrew A. Common, MD, CM, FRCPC
Head, Division of Vascular Radiology
University of Toronto.
Director, Angiography
and Interventional Radiology
St. Michael's Hospital
30 Bond St.
Toronto, ON
M5B 1W8
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Recycling of Cardiopulmonary Bypass
Cannulae: a Risk-Benefit Analysis
Richard J. Novick, MD, MSc, FRCSC, FACS
Objective: To determine whether recycling of arterial and venous cannulae for cardiopulmonary bypass
is associated with an increased risk of infectious complications after open heart surgery.
Design: A prospective, risk-benefit analysis.
Setting: A university teaching hospital.
Patients: Five hundred and forty patients underwent a variety of non-transplant cardiac operations,
which were performed by one surgeon between October 1988 and July 1993.
Interventions: Standard techniques of open heart surgery were used. Ascending aortic and vena caval
cannulae and the multiple perfusion device for administering cardioplegia down saphenous vein bypass
grafts were reused an average of 10 to 15 times after sterilization with ethylene oxide after each use.
Main Outcome Measures: The postoperative morbidity and mortality and the estimated savings
achieved by recycling the cannulae.
Results: The operative mortality (total in hospital plus within 30 days of operation) was 2.8% (15
patients). There were no cases of endocarditis; there was only one case of superficial presternal
infection and one case of mediastinitis. Gram-negative organisms were cultured from the blood of two
patients and gram-positive organisms from the blood of one patient. Only one patient died of an
infectious complication. The estimated cost saving during the study period was more than $50 000.
Conclusions: The risk of wound and hematogenous infection after open heart surgery in which recycled
cannulae are used is less than 1%. This rate is lower than that quoted in most recent reports. Reuse of
heart-lung bypass cannulae may realize substantial cost savings without detriment to the patient.

Objectif: Determiner si le recyclage des canules arterielles et veineuses utilisees pour la circulation
extracorporelle est relie a une augmentation du risque infectieux lors d’une operation a coeur ouvert.
Conception : Une analyse couts-benefices prospective.
Contexte : Un hopital universitaire.
Patients : Cinq cent quarante patients qui ont subi diverses operations cardiaques (autres que des
greffes) pratiquees par un chirurgien entre octobre 1988 et juillet 1993.
Interventions : Les techniques standards de chirurgie a coeur ouvert on ete utilisees. Les canules de
l’aorte ascendante et de la veine cave, ainsi que les multiples instruments de perfusion utilises pour
administrer la solution de la cardioplegie dans les greffons de saphene ont ete reutilises, de 10 a 15
fois en moyenne, apres sterilisation a l’oxyde d’ethylene entre chaque usage.
Principaux effets mesures : La morbidity postoperatoire et la mortality, de meme que l’estimation des
economies resultant du recyclage des canules.
Resultats : La mortalite operatoire (totale hospitaliere plus dans les 30 jours suivant l’intervention) fut
de 2,8 % (15 patients). II n’y a eu aucun cas d’endocardite et seulement un cas d’infection presternale
superficielle, et un cas de mediastinite. Des bacteries Gram negatif ont ete cultivees a partir du sang de
deux patients et des organismes gram-positif a partir du sang d’un patient. Un seul patient est decede
d’une complication infectieuse. Les economies realisees pendant la periode de l’etude sont estimees a
plus de 50 000 $.
Conclusions : Le risque d’infection de plaie ou d’infection hematogene apres une chirurgie a coeur
ouvert oil on utilise des canules recyclees est de moins de 1%. Ce taux est inferieur a ceux qui ont ete
signales dans les publications les plus recentes. La reutilisation des canules de circulation
extracorporelle peut permettre des economies substantielles, sans nuire au bien-etre des patients.
From the Division o f Cardiovascular-Thoracic Surgery, University Hospital, London, Ont.
Accepted fo r publication Feb. 16, 1993
Reprint requests to: Dr. Richard J. Novick, Division o f Cardiovascular-Thoracic Surgery, University Hospital, PO Box 5339, London, O N N 6A 5 A 5
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assurance and cost effec
Q uality
tiveness have become increas
ingly important concepts in health
care practice and research.1' 4 In
Canada, the recent failure of hospi
tal budgets to increase beyond the
rate of inflation has made cost
reductions in many surgical sub
specialities, including cardiac sur
gery, mandatory. At University Hos
pital, in London, Ont., recycling of
cardiopulmonary bypass (CPB) cannulae has been used as a method of
cost saving for many years. A pro
spective cost-benefit analysis of this
practice was therefore undertaken
to determine the risk of infection
and the cost reduction that may be
achieved by recycling these cannulae.

Patients and Methods
From October 1988 to July
1993, 599 patients underwent oper
ations that required median ster
notomy and CPB. All procedures
were performed by a single surgeon
at University Hospital. Fifty-nine of
the operations were heart or heartlung transplant procedures; these
patients were excluded from the
study because recycled cannulae
were not used. Of the remaining
540 patients, 446 underwent first
time or repeat coronary artery by
pass procedures, 51 underwent iso
lated valve repair or replacement
operations, 24 underwent combined
coronary artery bypass grafting and
valve replacement and 19 had mis
cellaneous procedures (resection of
cardiac tumours and repair of ven
tricular septal defect, atrial septal
defect, ascending aortic aneurysms
and dissections). All patients were
included regardless of their preoper
ative clinical and hemodynamic sta
tus.
Most patients received cefazolin,
1 g intravenously, before the induc
tion of anesthesia. If they were
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allergic to penicillin, vancomycin,
1 g intravenously, was given. The
skin was prepared with povidoneiodine solution, and disposable
drapes and a Vi-drape (3M Corp.,
St. Paul, Minn.) were used. Median
sternotomy was performed, and the
patients were placed on CPB, with a
no. 21 French Argyle THI aortic
perfusion cannula (Argyle Inc., St.
Louis, Mo.) in the ascending aorta
and no. 30 and no. 32 French Bard
vena caval cannulae (Bard Corp.,
Tewksbury, Mass.) inserted through
two separate right atriotomies. Cardioplegic arrest was achieved with
cold blood cardioplegic solution ad
ministered into the aortic root and
then sequentially into the vein
grafts by means of the DLP 14 000
multiple perfusion set (DLP Inc.,
Grand Rapids, Mich.). In most cases
of coronary artery bypass grafting,
a combination of left internal tho
racic artery and saphenous vein
grafts was used, although in pa
tients under 55 years of age, both
internal thoracic arteries were rou
tinely employed. At the conclusion
of the procedure, the wound was
irrigated with 1 litre of warm sterile
saline, and the sternal edges were
reapproximated with nine 22-gauge
no. 4 surgical wires. The fascia was
closed with running 0-Ticron su
tures, the subcutaneous tissues
with 2-0 Vicryl sutures and the skin
edges with running 4-0 Dexon su
tures. Postoperative antibiotic ther
apy consisted, in most cases, of
cefazolin 1 g intravenously every 8
hours for the first 48 hours. The
mediastinal and pleural tubes were
removed on the 2nd postoperative
day, and antibiotic therapy was then
discontinued.
Four types of infectious compli
cations were defined and prospec
tively evaluated.5
• Superficial presternai infection
— defined as drainage of purulent
material from the midline incision
or sternal wound cellulitis with or

without cultures positive for bacte
ria.
• Mediastinitis — defined as a
purulent collection in the retroster
nal tissues, with sternal dehiscence
or instability and cultures from the
wound that were positive for bacte
ria.
• Endocarditis — defined as a
proven bloodstream infection in
which there was clinical, echocardiographic, operative or autopsy evi
dence of cardiac infection.
• Septicemia — defined as two
or more blood cultures that gave
positive results for bacteria associ
ated with systemic signs of infec
tion but without intracardiac local
ization.
Operative mortality included all
deaths occurring during the hospi
talization in which the operation
was performed and all deaths occur
ring after hospitalization but within
30 days of the procedure.6 All pa
tients were examined daily while in
hospital and 4 weeks after dis
charge. In addition, patients were
re-evaluated clinically by the author
at any time after discharge if the
family doctor, cardiologist or visit
ing nurse suspected that there was
a wound infection.
After each operation the arterial
and venous cannulae and the multi
ple perfusion set were rinsed free of
blood and placed in a washer-steril
izer at 140°C for 30 minutes. The
cannulae and perfusion set were
then checked for any breaks or
defects, wrapped in double peelback bags, and sterilized in ethylene
oxide for 3 hours. They underwent
12 hours of aeration under sterile
conditions before subsequent clini
cal use. The cannulae and perfusion
set were recycled an average of 10
to 15 times. Cost savings were
assessed taking the retail cost of
the equipment as of July 1993 and
assuming that each cannula and
perfusion set was discarded after 10
uses.

RECYCLING HEART-LUNG BYPASS CANNULAE

Results
Operative mortality was 2.8% (15
patients). Twelve patients died of
low cardiac output postoperatively,
and two patients died of periopera
tive hemorrhage. Only one postop
erative death was associated with
infection. A 67-year-old woman
with evolving renal and cardiac fail
ure required mechanical ventilation
and inotropic support preoperatively. She underwent emergency coro
nary artery bypass grafting, but this
did not improve her hemodynamic
status, and she died of continued
multiorgan failure and gram-nega
tive sepsis 3 weeks postoperatively.
Clinical follow-up was complete.
No infectious complications oc
curred beyond 3 months postopera
tively. One patient had a superficial
sternal wound cellulitis without
sternal dehiscence 2 weeks after
discharge, but culture of the wound
did not grow any organisms and the
infection resolved after a 10-day
course of antibiotics. The only
other wound complication occurred
in a 42-year-old obese diabetic
woman with a long history of bron
chitis, who had previously under
gone saphenous vein strippings bi
laterally. She underwent triple coro
nary artery bypass grafting with
both internal thoracic arteries. Ster
nal dehiscence and mediastinitis de
veloped, and tissue culture grew
Staphylococcus aureus. Debride
ment followed by sternal reclosure
over irrigating catheters was per
formed on the 11th postoperative
day. Her mediastinum was irrigated
with sterile saline for 4 weeks post
operatively, and she received van
comycin 1 g intravenously every 12
hours for 6 weeks, with satisfactory
sternal healing and no evidence of
recurrent infection after 4 years of
follow-up.
Three other patients (0.5%) had
fever early postoperatively in associ
ation with blood cultures that were

positive for gram-negative (two pa
tients) or gram-positive (one pa
tient) organisms. In all three cases
the source of the offending organ
ism was not identified. With remov
al of central venous and urinary
catheters and appropriate intrave
nous antibiotic therapy, the infec
tions resolved. There were no cases
of endocarditis in the 75 patients
who underwent valve repair, valve
replacement or combined coronary
artery bypass grafting and valve
surgery.
Cost analysis revealed that the
Argyle THI aortic perfusion cannula
costs $18.00 and the no. 30 and
no. 32 French Bard vena caval cannulae cost $32.50 each. The DLP
multiple perfusion set costs $21.40.
If these cannulae were not recycled,
the total cost in the 540 patients
would have been $56 376. Since
the cannulae were reused at least
10 times, the cost of the three items
during the 58 months of the study
was, at most, $5638. There have
been no increases in the number of
full-time or part-time equivalent po
sitions in the department that was
in charge of cannula recycling, be
fore or during the course of this
study, and labour costs have not
increased because of the practice of
cannula recycling. The total cost
saving was therefore $50 738 in the
540 patients in this study.

Discussion
With increasing economic con
straints on the practice of subspe
cialty surgery in Canada has come
an increasing emphasis on quality
control and cost effectiveness.1-4
Even a cursory analysis of cost
shows the considerable economic
impact of nosocomial infection.7
Sternal wound infection as a com
plication of coronary artery bypass
grafting is associated with a more
than twofold increase in the average

hospital stay,8 and an almost three
fold increase in the median hospital
charge.9 Efforts at cost containment
should therefore rank well behind
attempts to reduce infectious com
plications following open heart op
erations, unless it can be demon
strated that cost-containment pro
cedures do not adversely affect the
rate of perioperative infection.
This study presents a prospective
analysis of the risk of infection after
cardiac surgery in nonimmunosuppressed patients in whom recycled
cannulae were routinely used dur
ing CPB. I am unaware of any other
report in the cardiac surgical litera
ture that has focused on this issue.
In this study there was less than a
0.4% incidence of superficial or
deep sternal wound infection, and a
less than 1% incidence of combined
wound and hematogenous infection.
The risk of sternal wound infections
in recent reports has ranged from
1.1% to 3.4%,8-18 and the incidence
of septicemia after open heart sur
gery has ranged from 1.3%12 to
3.2%.14 Clearly, the recycling of
CPB cannulae after sterilization
with ethylene oxide was not associ
ated with an increased risk of
wound or hematogenous infection
in this study.
The only case of serious sternal
wound infection in this series oc
curred in a young diabetic patient
with chronic bronchitis who re
ceived bilateral internal thoracic ar
tery grafts. The use of bilateral
internal thoracic artery bypass
grafts in diabetic patients has been
shown to increase significantly the
risk of sternal wound, whereas the
use of one internal thoracic artery
has not resulted in an increase in
this. It would therefore seem pru
dent to avoid bilateral internal tho
racic artery grafting in diabetics,
especially in the presence of addi
tional risk factors such as chronic
obstructive pulmonary disease and
obesity.
CJS, VOL. 36, NO. 5, OCTOBER 1993
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The recycling of GPB cannulae
and multiple perfusion sets can re
su lt in substantial cost savings, es
pecially if several surgeons in the
sam e institution partake in this
practice. There is a precedent in
Canada for the reuse o f permanent
cardiac pacemakers19 and for the
recycling of homograft aortic valves
from heart transplant patients.20 In
these times of fiscal constraint, all
efforts to generate cost savings by
m eans o f equipment or device recy
cling should be encouraged as long
as they do not adversely affect
patient outcome.
I thank Heather Motloch for her assis
tance in manuscript preparation and Dr.
Neil McKenzie for his constructive re
view of the paper.

References
1. Roper WL, Winkenwerder W, Hackbarth CM et al: Effectiveness in health
care: an initiative to evaluate and im
prove medical practice. N EngI J Med

1988; 319: 1197-1202
2. Detsky AS, Naclie IG: A clinician’s
guide to cost-effectiveness analysis. Ann

Intern Med 1990; 113: 147-154
3. Health Services Research Group: Quality
of care: 1. What is quality and how can
it be measured? Can Med Assoc J 1992;
146:2153-2158
4. Idem: Quality of care: 2. Quality of care
studies and their consequences. Can
Med Assoc J 1992; 147: 163-167
5. Ferrazzi P, Allen R, Crupi G et al:
Reduction of infection after cardiac sur
gery: a clinical trial. Ann Thorac Surg
1986; 42: 321-325

6. Council of the Society of Thoracic Sur
geons: Guidelines for data reporting and
nomenclature for the Annals o f Thoracic
Surgery. Ann Thorac Surg 1988; 46:
260-261
7. McGowan JE: Cost and benefit — a
critical issue for hospital infection con
trol. Am J Infect Control 1982; 10:
100-108
8. N elson RM, Dries DJ: The economic
implications of infection in cardiac sur
gery. Ann Thorac Surg 1986; 42: 240246
9. Loop FD, Lytle BW, Cosgrove DM et
al: Sternal wound complications after
isolated coronary artery bypass grafting:
early and late mortality, morbidity, and
cost of care. Ann Thorac Surg 1990;
49: 179-187
10. Ottino G, De P aulis R, P ansini S et al:
Major sternal wound infection after
open-heart surgery: a multivariate analy
sis of risk factors in 2,579 consecutive
operative procedures. Ann Thorac Surg
1987; 44; 173-179

11. K ouchoukos NT, W areinc TH, Murphy
SF et al: Risks of bilateral internal

mammary artery bypass grafting. Ann
Thorac Surg 1990; 49: 210-219
12. Miedzinski LJ, K eren G: Serious infec
tious complications of open-heart sur
gery. Can J Surg 1987; 30: 103-107
13. Jeevanandam V, S mith CR, R ose EA et
al: Single-stage management of sternal
wound infections. J Thorac Cardiovasc
Surg 1990; 99: 256-263
14. Kohman LJ, Coleman MJ, P arker FB:

Bacteremia and sternal infection after
coronary artery bypass grafting. Ann
Thorac Surg 1990; 49: 454-457
15. Demmy TL, P ark SB, Liebler GA et al:
Recent experience with major sternal
wound complications. Ibid: 458-462
16. B rowdie DA, Bernstein RW, A gnew R
et al: Diagnosis of poststernotomy infec
tion: comparison of three means of
assessment. Ann Thorac Surg 1991; 51:
290-292
17. Ko W, Lazenby D. Z elano JA et al:
Effects of shaving methods and intraop
erative irrigation on suppurative mediastinitis after bypass operations. Ann Tho
rac Surg 1992; 53: 310-315
18. Vander S alm TJ, O kike ON, Pasque MK
et al: Reduction of sternal infection by
application of topical vancomycin. J
Thorac Cardiovasc Surg 1989; 98: 618—
622
19. Rosencarten MD, P ortnoy D, Chiu RCJ
et al: Reuse of permanent cardiac pace
makers. Can Med Assoc J 1985; 133:
279-283
20. Feindel CM, David TE, Bos J et al:
Recycled heart valves from transplant
patients. J Heart Lung Transplant 1991;
10: 614-617

SESAP VII Question / Question SESAP VII
Item 256
A 58-year-old man with cholelithiasis and symptoms of intermittent mild biliary colic is admitted to the hospital
for an operation. He has had three syncopal episodes in the last several m onths, progressive shortness o f breath,
and occasional chest pain with exertion. He has a grade 2 / 6 murmur in the left third intercostal space.
This clinical evidence su ggests
(A) mitral valve prolapse
(B) prior myocardial infarction and ventricular aneurysm
(C) mitral stenosis, atrial fibrillation, and small recurrent cerebral emboli
(D) significant aortic stenosis
(E) carotid artery disease and coronary artery disease
For the five completions given above select the one that is best.
For the critique o f Item 2 56 see page 482.
(Reproduced by permission from SESAP ’9 2 - ’93 Syllabus; Surgical Education and Self-Assessment Program
No. 7. For enrolment in the Surgical Education and Self-Assessm ent No. 7, please apply to the American College
o f Surgeons, 55 E Erie St., Chicago, IL 60611.)
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ORIGINAL ARTICLES

Myocardial and Circulatory Performance
During the Ischemic Phase of Superior
Mesenteric Artery Occlusion
William G. Jamieson, MD, FRCSC; Gaetano DeRose, MD, FRCSC; Kenneth A. Harris, MD, FRCSC;
George Pliagus, MD, FRCSC; Lou Stafford
Objective: To investigate myocardial and circulatory parameters during the acute ischemic phase of
mesenteric artery occlusion.
Design: A prospective, randomized, control trial.
Subjects: Twelve, adult, mongrel dogs.
Interventions: In seven dogs the superior mesenteric artery was occluded with two silk ligatures
(experimental group). In five dogs the ligatures were not tied (control group). Measurements were
made during 7 hours of occlusion.
Main Outcome Measures: Myocardial performance and circulatory performance.
Results: There were significant (p < 0.05) reductions in arterial blood pressure, mean pulmonary
artery pressure, diastolic pulmonary artery pressure and cardiac index in dogs exposed to intestinal
ischemia compared with the control dogs. No differences were identified in ventricular performance,
stroke volume index or peripheral vascular resistance index.
Conclusions: Early cardiac and central circulatory changes in massive intestinal ischemia are due to
intravascular hypovolemia. Sepsis and myocardial depressant factors were not found to be a cause of
death.

Objectif: Mesurer les parametres myocardiques et circulatoires durant la phase d’ischemie aigue d’une
occlusion de l’artere mesenterique.
Conception : Un essai prospectif, controle et randomise.
Sujets : Douze chiens batards, adultes.
Interventions : Chez sept chiens, une occlusion de l’artere mesenterique superieure a ete provoquee
par deux ligatures a l’aide de fil de soie (groupe experimental). Chez cinq chiens, les ligatures n’ont
pas ete nouees (groupe temoin). Des mesures ont ete faites pendant une occlusion de 7 heures.
Principaux effets mesures: Les performances myocardiques et circulatoires.
Res u Itats : On a note par rapport aux chiens temoins, une diminution significative (p < 0,05) de la
tension arterielle, de la pression arterielle pulmonaire moyenne, de la pression arterielle pulmonaire
diastolique et de l’index cardiaque chez les chiens soumis a une ischemie intestinale. Aucune difference
n’a ete enregistree quant a la performance ventriculaire, a l’index de debit systolique ou a l’index de
resistance vasculaire peripherique.
Conclusions : Lors d’une ischemie intestinale massive, les changements immediats des parametres
cardiaques et circulatoires centraux sont dus a une hypovolemie intravasculaire. Les sepsies et les
facteurs de depression myocardique ne paraissent pas avoir cause de mortalite.
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ntestinal ischemia continues to
carry a high death rate despite
new diagnostic modalities and im
proved surgical techniques. Patients
in the early phases of intestinal
ischemia present a diagnostic chal
lenge because gross physical find
ings are lacking until bowel infarc
tion is established. Even those who
undergo successful revasculariza
tion have a high death rate. The
underlying events leading to death
in intestinal ischemia require fur
ther elucidation to permit more ef
fective treatment.
Any ischemic insult may be divid
ed into three phases: the ischemic
phase, the early reperfusion phase
and the late reperfusion phase. In
many studies the first two phases
are not separated.
The hemodynamic consequences
of superior mesenteric artery occlu
sion have been attributed to in
travascular fluid loss, circulating
myocardial depressant factor and
sepsis. To further understand the
continued high mortality of intesti
nal ischemia, the pathophysiology
of the hemodynamic derangements
must be determined and the stage
at which these changes occur clari
fied precisely. This knowledge
would permit more specific direc
tion of therapy in the perioperative
period. In this study we examined
the hemodynamic events and conse
quences of an intestinal ischemic
insult that results in a death rate of
90% in our model. Only the isch
emic phase was studied.

I

Materials and Methods
Twelve, adult, mongrel dogs were
randomly assigned to a control (five
dogs) or an experimental (seven
dogs) group. Anesthesia was in
duced with thiopental sodium (12.5
m g/kg), and the dogs were intubat
ed and ventilated. Anesthesia was
maintained with a mixture of halo436
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thane (1.0% to 2.5%) and oxygen
(6 L/min ). A femoral arterial line
was inserted, and a Swan-Ganz
catheter was positioned in the pul
monary artery for cardiac output
measurements. Continuous record
was kept of systemic blood pressure
measurements, pulmonary artery
pressure measurements and heart
rate. Ringer’s lactate solution was
administered at an hourly rate of
8 mL/kg.
Our animal model of intestinal
ischemia has been described previ
ously.1 Briefly, the superior mesen
teric artery was exposed at its ori
gin from the aorta through a mid
line abdominal incision. Two large
silk ligatures were used to encircle
the superior mesenteric artery. In
the control animals these were left
loosely around the artery, and the
abdomen was closed. In the experi
mental group both ligatures were
tied before closure of the abdomen.
Measurements were made for 7
hours after operation. Animal care
was in accordance with the princi
ples of laboratory animal care,2 and
the protocol was approved by the
University of Western Ontario Ani
mal Ethics Committee.
Measurements

Baseline measurements included:

length, weight, heart rate (HR),
blood pressures (systolic, diastolic
and mean [SBP, DBP and MBP]),
pulmonary artery pressures (systol
ic, diastolic and mean [SPAP, DPAP
and MPAP]), pulmonary capillary
wedge pressure (PCWP), central ve
nous pressure (CVP) and cardiac
output (CO). The body surface area
(BSA) was calculated by means of a
standard nomogram.3 All hemody
namic measurements were made at
2, 4, 6 and 7 hours after the
baseline measurements. Left ven
tricular ejection fractions (LVEFs)
were obtained in a modified left
anterior oblique projection in two
dogs in the control group and in
five dogs in the study group, with
electrocardiographic-gated equilibri
um blood pool scintigraphy (technetium-99m-tagged red blood cells).
The measured hemodynamic varia
bles were used to calculate the
following physiologic parameters:
cardiac index (Cl), stroke volume
index (SVI), peripheral vascular re
sistance index (PVRI), left ventricu
lar end-diastolic volume index
(LVEDVI), left ventricular end-sys
tolic volume index (LVESVI), myo
cardial performance (MP), systolic
function (SF), diastolic compliance
(DC) and, finally, left ventricular
stroke work index (LVSWI) (Ta
ble I).

Table I. Calculated Variables in an Animal Model of Intestinal Ischemia
Parameter
Cardiac index
Stroke volume index
Peripheral vascular resistance index
Left ventricular end-diastolic volume
index
Left ventricular end-systolic volume index
Myocardial performance
Systolic function
Diastolic compliance
Left ventricular stroke work index

Formula
Cardiac output (L/m in) body surface area (m2)
Stroke volume (mL) + body surface area (m2)
Mean pulmonary artery pressure (mm Hg) pulmonary capillary wedge pressure (mm Hg) x
79.9 cardiac index (L/m in-nr2)
Stroke volume index (m L/m 2) left ventricular
ejection fraction (%)
Left ventricular end-diastolic volume index (m L/m 2)
- stroke volume index
Cardiac index (m L/m in-nr2) ^ left ventricular
end-diastolic volume index (m L/m 2)
Systolic blood pressure (mm Hg) ^ left ventricular
end-diastolic volume index (m L/m 2)
Pulmonary capillary wedge pressure (mm Hg) - left
ventricular end-diastolic volume index (m L/m 2)
Stroke volume index (m L/m 2) x mean arterial
pressure (mm Hg) x 0.0136

MESENTERIC ARTERY OCCLUSION

Statistical Analysis

line value. Student’s f-test was used
to detect statistical differences in
the mean change of all variables
except for LVEFs. Mann-Whitney
U statistics were calculated for the
LVEFs. Statistical significance was
assumed for a p value of less than
0.05.

Analysis was carried out to en
sure that there was no statistical
difference between the two study
groups at baseline. Student’s f-test
and the Mann-Whitney U statistic
were calculated to examine poten
tial differences between groups on
all measured baseline variables. To
permit the use of an internal con
trol, the relative difference for each
hemodynamic variable was calculat
ed by determining the difference
between the 7-hour value and the
baseline value divided by the base

Results
The measured and calculated
baseline variables were not signifi
cantly different between the control
and experimental groups of dogs

Table II. Comparison of Myocardial Performance Between Dogs With Induced Intestinal Ischemia
(Study Group) and Dogs Without Intestinal Ischemia (Control Group) (Mean ± Standard Deviation)
Study group (n = 7)
Variable

Baseline

Heart rate, beats/min
SBP, mm Hg
DBP, mm Hg
MBP, mm Hg
SPAP, mm Hg
DPAP, mm Hg
MPAP, mm Hg
PCWP, mm Hg
Cl, L/min
SVI, L/min • rrr2
PVRI, dyn/s • cm5

106
115
74
89
11.3
4.0
7.0
2.1
3.54
33.5
114

± 8
± 25
± 16
±
±
±
rfc
±

±

Control group (n = 5)

7h
114
95
66
77
10.3
2.3
5.6
0.4
2.14
20.4
237

16
3.6
1.4
2.3
1.8
0.79
9.8
38

±
±
±
±
±
±
±
±
±
±
±

7h

Baseline
8
23
16
20
4.2
2.0
2.8
1.7
0.64
7.3
112

97
97
62
74
11.4
3.8
6.6
2.0
3.14
33.2
116

± 8
± 16
11
=fc 12
± 6.4
2.3
± 3.4
± 1.6
± 0.71
± 8.6
± 44

115
124
79
95
14.2
6.0
9.4
2.6
3.12
27.2
191

±
±
±
±
±
±
±
±
±
±
±

11
33
19
24
4.3
2.6
2.7
2.7
0.98
7.0
90

SBP = systolic arterial blood pressure, DBP = diastolic arterial blood pressure, MBP = mean
arterial blood pressure, SPAP = systolic pulmonary artery pressure, DPAP = diastolic pulmonary
artery pressure, MPAP = mean pulmonary artery pressure, PCWP = pulmonary capillary wedge
pressure, Cl = cardiac index, SVI = stroke volume index, PVRI = peripheral vascular resistance
index

Table III. Comparison of Relative Change in Myocardial Performance*
Variable
Heart rate, beats/min
SBP, mm Hg
DBP, mm Hg
MBP, mm Hg
SPAP, mm Hg
DPAP, mm Hg
MPAP, mm Hg
PCWP, mm Hg
Cl, L/min
SVI, mL/min • n r2
PVRI, dyn/s • cm5

Study group
(/r = 7)
0.08
-0 .1 7
- 0 .1 0
- 0 .1 3
- 0 .0 3
- 0 .2 5
- 0 .1 2
-1 .1 3
-0 .3 5
-0 .3 9
1.19

±
±
±
±
±
±
±
±
±
±
±

0.08
0.15
0.17
0.15
0.39
0.69
0.47
0.77
0.19
0.19
1.00

Control group
( n = 5)
0.19
0.30
0.31
0.30
0.55
0.95
0.69
0.48
0.02
-0 .1 5
1.03

±
±
±
±
±
±
±
±
±
±
±

0.14
0.33
0.38
0.35
0.82
1.02
0.65
1.16
0.32
0.20
1.48

/rvalue
0.092
0.008t
0.031 +
0.016+
0.132
0.035+
0.030+
0.029+
0.029+
0.070
0.828

'Relative change = (value at 7 h - baseline) 4- baseline
tSignificant
SBP = systolic arterial blood pressure, DBP = diastolic arterial blood pressure, MBP = mean
arterial blood pressure, SPAP = systolic pulmonary artery pressure, DPAP = diastolic pulmonary
artery pressure, MPAP = mean pulmonary artery pressure, PCWP = pulmonary capillary wedge
pressure, Cl = cardiac index, SVI = stroke volume index, PVRI = peripheral vascular resistance
index

(Table II). The results of the mea
surements taken at 7 hours after
SMA occlusion are shown in Tables
II and III. There was a significantly
greater reduction in all components
of systemic blood pressure in the
experimental animals when com
pared with those of the control
group. Also DPAP and MPAP were
significantly reduced in the experi
mental group. Cardiac index was
significantly reduced. No significant
differences were detected in CVP
and LVSWI. Measurements derived
from the cardiac scintigraphy (Ta
ble I), including LVEF, LVEDVI,
LVESVI, MP, DC and SF, demon
strated no difference in contractility
between the two groups. The cardi
ac index was reduced more in the
experimental group than in the con
trol group with no significant differ
ence in the SVI or PVRI. This
suggests that sepsis was not a
factor in this model.

Discussion
SMA occlusion with ensuing in
testinal gangrene is incompatible
with life. Death rates for this condi
tion have remained constant, pri
marily due to delay in diagnosis.
Patients who present soon after
SMA occlusion with reversible in
testinal ischemia have a paucity of
signs and symptoms, further delay
ing diagnosis. With knowledge of
the underlying pathophysiology, re
suscitation and appropriate treat
ment can be instituted to reduce
mortality. The focus of this study
was the continuous ischemic phase
only, without interference of the
events of reperfusion. A review of
the literature regarding the actual
physiologic derangements during
this early ischemic phase was incon
clusive. The hypotheses for the
early circulatory derangements in
acute mesenteric ischemia are fluid
loss,4-7 sepsis,8-13 or the presence of
CJS, VOL. 36, NO. 5, OCTOBER 1993
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a circulating myocardial depressant
factor.14-18
Myocardial performance can sim
ply be divided into preload, heart
rate, contractility and afterload. We
assessed these factors in an animal
model of acute mesenteric ischemia
to increase our understanding of
the underlying pathophysiologic
changes. We used 7 hours of acute
ischemia because previous work4
had demonstrated a 90% mortality
even after reperfusion.
Systemic arterial pressures and
pulmonary diastolic pressures as
well as PCWP and Cl were de
pressed after 7 hours of intestinal
ischemia, but significantly more so
in the study dogs than in the con
trol dogs. The HR of the animals
remained constant. The remaining
hemodynamic parameters showed
no change throughout the experi
ment. The indicators of myocardial
contractility, including LVEF,
LVESVI and LVEDVI, in the experi
mental group showed no difference
when compared with the control
group. There was no evidence of
right heart failure and the PCWP
was decreased. Our findings sug
gest that hypovolemia is the only
cause of myocardial depression dur
ing the ischemic phase of superior
mesenteric artery occlusion. The
theory that there was underlying
sepsis is not supported by the stable
SVRI and PVRI despite the de
crease in Cl. Our data support a
mechanism of fluid loss and hypo
volemia as being the main circulato
ry derangement in the ischemic
phase of SMA occlusion.
The theory of a myocardial
depressant factor has been suggest
ed in a number of other pathologic
processes. The presence of such a
factor in these conditions has been
questioned. Altimari and associ
ates19 concluded that in experimen
tal pancreatitis, cardiac depression
was related to preload reduction
rather than intrinsic cardiac dys
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function. Cobo and associates20 also
concluded that there was a lack of
support for myocardial depression
in their studies of hemodynamics
and oxygen transport in patients
with acute pancreatitis. Decreased
vascular tone was attributed to flow
redistribution in the microcircula
tion, limiting tissue oxygenation de
spite increased metabolic demands.
Vyden and colleagues21'22 and
Williams and colleagues23 noted a
decrease in Cl in patients with acute
mesenteric ischemia, a concept sup
ported by experimental models.23'24
In 1965, Milliken and Nahor25 re
ported that with 3 to 5 hours of
acute mesenteric ischemia there
was a decrease in CO, systemic
blood pressure and blood volume of
31%. Cross-transfusion experiments
led these authors to believe that
this decrease was secondary to a
toxic factor. Such a finding could
equally well be explained on the
basis of hypovolemia. The findings
of Liilehei, Goott and Miller26 and
Chiu, Scott and Gurd5 support this
concept. Our studies have not ruled
out the presence of a toxic factor
but have demonstrated that its ac
tion is not directly on the myocardi
um.
Martson67 indicated that massive
fluid loss was of prime significance
in the pathogenesis of hypotension
with massive gut ischemia. Accu
mulation of large volumes of fluid
in the bowel lumen, bowel wall,
peritoneal cavity and systemic inter
stitial space were the probable sites
of loss. In our 7-hour model of
ischemia with no reperfusion it ap
pears that the hemodynamic
changes are due to a decrease in
circulating intravascular volume.
This study has failed to support
either direct myocardial dysfunction
or sepsis as a primary cause of
reduced Cl. Further studies are
under way to determine the site of
fluid loss.
Patients who present with acute

mesenteric ischemia will usually
have either poor myocardial func
tion (frequently the source of mes
enteric embolism) or generalized
atherosclerosis (involvement of the
SMA being a frequent cause of
mesenteric thrombosis). These, usu
ally elderly, patients are ill suited to
withstand a mesenteric ischemic in
sult with accompanying hemody
namic changes. The coexisting and
often long-term use of diuretics
may exacerbate the hypovolemic ef
fects of fluid sequestration, causing
the cardiac dysfunction that we
have demonstrated in the ischemic
phase of acute mesenteric ischemia.
Since the outcome of a mesenteric
ischemic episode is uniformly fatal
if not effectively treated, all patients
with this condition warrant laparot
omy. Once infarction is established
there is no chance for salvage of
the ischemic bowel. To prevent in
farction urgent laparotomy is man
datory. Our study suggests that the
best preparation for operation is
fluid replacement. Although many
patients will have concurrent dis
ease, the placement of the central
hemodynamic monitoring lines in
these patients must not delay opera
tive treatment.

Conclusions
Clinical gut ischemia is still a
difficult management problem. The
vague, nonspecific symptoms often
favour conservative management
until frank necrosis is established.
Only with early awareness of the
syndrome, appropriate work-up and
urgent surgical correction will the
high mortality be decreased. This
work suggests that massive fluid
loss is the primary early physiologic
change and vigorous fluid replace
ment combined with treatment of
the underlying arterial occlusion
could lead to a reduction in the
unacceptably high mortality .
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Reconstruction of Composite Facial Defects:
the Combined Application of Multiple
Reconstructive Modalities
Oleh M. Antonyshyn, MD, FRCSC;* Justin L. Paletz, MD, FRCSC;t Kenneth L. Wilson, MD, FRCSCt
Objective: To describe the combined use of craniofacial skeletal reconstruction, tissue expansion and
microvascular free tissue transfer in the repair of major composite facial defects.
Design: Case series with an integrated team approach.
Setting: Craniofacial unit, university teaching hospital.
Patients: Three cases were selected to best illustrate the combined use of the three modalities in
reconstruction of acute traumatic, congenital and post-traumatic facial defects. A 15-year-old boy had a
shotgun wound to the face; a 23-year-old man had Treacher Collins syndrome; and a 55-year-old woman
had a post-traumatic composite defect of the central midface.
Interventions: Preoperatively, complete neurologic, ophthalmologic and dental examinations,
anthropometric analysis, prosthodontic assessment, computed tomography and computer graphics.
Operatively, craniofacial exposure followed established surgical principles. Skeletal reconstruction was
performed to provide accurate positioning of bony segments and three-dimensional stability. Bone
grafting was used when necessary to restore bony continuity and increase stability. Tissue expansion
was used to provide more locally available tissue for wound closure and resurfacing composite defects.
Microsurgical free tissue transfer was used to provide functional replacement of deficient tissues.
Results: The results of the modalities used for reconstruction of these composite facial defects are
illustrated for each case described.
Conclusions: The use of multiple modalities, including craniofacial skeletal reconstruction, tissue
expansion and free tissue transfer, allow the surgeon to address the specific functional and anatomical
requirements associated with composite facial defects that are characterized by a combined deficiency of
multiple tissues in the craniofacial region.

Objectif: Decrire l’utilisation combinee de la reconstruction osseuse craniofaciale, de l’expansion
tissulaire et du transfert fibre de tissu microvascularise dans la reparation des anomalies faciales
composees.
Conception : Une serie de cas avec une approche collaborative integree.
Contexte: Le service de soins craniofaciaux d’un hopital universitaire.
Patients : Trois cas ont ete choisis pour illustrer au mieux les resultats combines de trois modalites
utilisees dans la reconstruction des anomalies faciales de nature traumatique immediate, congenitale ou
post-traumatique. Un garfon de 15 ans ayant subi une blessure de fusil au visage; un homme de 23 ans
souffrant du syndrome de Treacher Collins; une femme de 55 ans presentant une anomalie composee
post-traumatique affectant la partie centrale moyenne du visage.
Interventions : Des examens preoperatoires neurologiques complets, ophtalmologiques et dentaires.

From the *Division o f Plastic Surgery, Sunnybrook Health Science Centre, University o f Toronto, Toronto, Ont., and the fD ivision o f Plastic
Surgery, Victoria General Hospital, Dalhousie University, Halifax, NS
Presented at the 46th annual meeting o f the Canadian Society o f Plastic Surgeons, London, Ont., May 1992
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O N M 4N 3M 5

CJS, VOL. 36, NO. 5, O CTO BER 1993

441

ANTONYSHYN, PALETZ. WILSON

Une analyse anthropometrique et une evaluation prothetique. Une tomographie par ordinateur
accompagnee de graphiques sur ordinateur. A l’operation, l’exposition craniofaciale a ete faite selon
des principes chirurgicaux etablis. La reconstruction osseuse a ete effectuee de fa^on a permettre un
positionnement precis des segments osseux et une stability tridimensionnelle. Une greffe osseuse fut
pratiquee quand cela etait necessaire pour restaurer la continuity osseuse ou pour ameliorer la
stability. L expansion tissulaire fut utilisee pour fournir davantage de tissu pour refermer la plaie et
pour refaire la surface des anomalies composees. Le transfert libre de tissu microvascularise fut utilise
pour retablir le fonctionnement d’un tissu carence.
Resultats : Les resultats des modalites utilisees pour la recontruction de ces anomalies composees sont
illustres pour chacun des cas decrits.
Conclusions : L’emploi de modalites multiples comprenant reconstruction osseuse craniofaciale,
expansion tissulaire et transfert libre de tissu, permet au chirurgien de repondre aux exigences
fonctionnelles et anatomiques specifiques aux anomalies faciales composees qui sont caracterisees par
les carences combinees de multiples tissus de la region craniofaciale.

C

omposite facial defects have
unique and highly variable re
constructive requirements. These
deformities are characterized by a
combined deficiency of multiple tis
sues. Facial skin, muscle, fat, bone
and mucosal lining are involved to
varying degrees. The defects are
extensive and frequently encroach
upon adjacent anatomical sites in
cluding the orbits, cranium, nasal
or oral cavities. As such, the ab
sence of tissue frequently results in
both impaired function and aesthet
ic problems.
In the past, the options for recon
struction were limited. The surgeon
repairing major composite defects
relied upon the use of large region
al flaps to simply obliterate or cover
a cavity. Both form and function
were frequently compromised.
However, facial reconstructive
surgery has evolved and expanded
considerably in the past decade as a
result of recent innovations and
modifications in surgical technique.
Increasing sophistication of tools
for imaging and analysis provides
unprecedented visualization of cra
niofacial anatomy and facilitates ac
curate preoperative planning. The
integration of craniofacial skeletal
reconstruction, tissue expansion
and microvascular tissue transfer
have made it possible for the recon
structive team to address deficient
tissues specifically and to restore
the normal anatomy more precisely.
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In this paper recent developments
in reconstructive modalities and
their combined use in the repair of
composite facial defects are de
scribed. Case reports are selected to
illustrate the benefits and the inad
equacies of interfacing these tech
niques.

Preoperative Assessment
Composite facial defects general
ly result from high-velocity trauma
or ablative procedures for head and
neck cancer or occur in association
with congenital craniofacial malfor
mations featuring profound hypo
plasia or aplasia of multiple tissues.
The scope and complexity of these
deformities demand a comprehen
sive multidisciplinary assessment of
the patient preoperatively. The inte
grated team approach facilitates
combined operative procedures to
reduce the number of hospital ad
missions and offers the best pros
pects for rehabilitation.
The preoperative assessment
comprises a complete neurologic
and ophthalmologic examination, in
addition to the specific evaluation
of soft-tissue and skeletal compo
nents of the defect. Many patients
have associated upper airway prob
lems, and a preanesthetic consulta
tion is frequently indicated. A com
plete dental examination, with a
review of plaster dental models and

radiographs in selected cases, is
required to define the occlusion and
dental status. Anthropometric anal
ysis provides a quantitative descrip
tion of facial surface morphology
and is useful in treatment planning.
In particularly extensive defects,
preoperative prosthodontic assess
ment permits modification of recon
structive procedures to accommo
date subsequent placement of max
illofacial prosthetic devices.
The preoperative radiographic
evaluation of major craniofacial de
formities relies primarily on an anal
ysis of computed tomography (CT)
scans. High-resolution axial CT
scans clearly define bony elements
and defects of the facial skeleton,
while associated soft tissues are
visualized with unprecedented de
tail. An absence of geometric mag
nification error in the generated
images further permits accurate
quantitation of defect size.
Most recently, computer graphics
have been used to produce accurate
three-dimensional images from twodimensional data obtained from
standard CT scanners. The osseous
reconstructions resemble black-andwhite photographs of a dry skull
and can be displayed from any de
sired perspective. These threedimensional images are particularly
valuable to the craniofacial sur
geon, because of their capacity to
reveal asymmetries and dispropor
tions, the spatial relationships of
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critical anatomical structures, and
the size, shape and location of
skeletal defects.

Skeletal Reconstruction
The reconstruction of a compos
ite facial defect relies upon initial
restoration of a stable three-dimen
sional bony structure that approxi
mates normal anatomy as closely as
possible. This provides a symmetri
cal facial skeleton with normal di
mensions and proportions and a
supportive framework that main
tains the position, projection and
volume of all associated soft tis
sues. Recent technical innovations
and developments in surgical tech
nique have enabled the craniofacial
surgeon to realize these reconstruc
tive goals.

Craniofacial Exposure
The field of craniofacial surgery
emerged as a distinct subspecialty
in the 1960s, thanks to the pioneer
ing work of Paul Tessier. In collab
oration with excellent neurosurgical
and ophthalmologic groups at
Hopital Foch in Paris, he estab
lished the basic principles that form
the foundation of current craniofa
cial surgical techniques:1-3
• Segments of the facial skele
ton can be completely denuded of
their periosteal blood supply, osteotomized and repositioned, and
yet survive.
• Wide subperiosteal elevation
through camouflaged incisions per
mits direct exposure of the entire
craniofacial skeleton.
• Dissection of the periorbita
enables all bony displacements to be
effected without interference with
ocular, oculomotor, palpebral or
lacrimal functions.
• An intracranial exposure al
lows the cranial contents and me

ninges to be protected through di
rect visualization, in any procedures
on the fronto-orbital or nasoethmoid regions.
• The orbits and eyes can be
translocated horizontally or verti
cally over a considerable distance
without impairing vision.
These principles govern the sur
gical approach to virtually any cra
niofacial deformity. Incisions are
planned to provide maximum expo
sure while minimizing the apparent
scar. Wide subperiosteal dissection
provides direct access to the entire
facial skeleton. The reconstruction
is then performed under direct visu
alization, with optimal protection of
both intracranial and intraorbital
contents.

earlier, thus minimizing the occur
rence of temporomandibular joint
arthropathy, yet increasing patient
comfort and speeding rehabilitation.
Rigid internal fixation systems
are now routinely employed in cra
niofacial reconstruction. Miniature
bone plates and screws are specifi
cally designed to allow stable threedimensional reconstruction. Multi
ple osseous segments can be se
quentially positioned and rigidly im
mobilized to re-establish the normal
anatomy. Gaps in bony continuity
can be bridged with contoured
plates, producing a stable recon
struction that resists subsequent
deformation.

Case Reports and Discussion
Rigid Skeletal Fixation

Case 1

Skeletal reconstruction relies
upon an accurate positioning of
bony segments, thorough adapta
tion of adjoining bone surfaces and
absolute three-dimensional stability.
Failure to provide a rigidly stable
skeletal framework may lead to de
layed union or nonunion of bone
segments, resorption and loss of
volume in bone grafts, and ulti
mately to collapse of the facial
skeleton, dysgnathia and deforma
tion.
Stability is based on the effect of
frictional binding between bone seg
ments. Internal fixation devices ap
proximate fragments under tension,
producing a frictional force between
corresponding bone surfaces. Rigid
stability is achieved as long as the
frictional binding is greater than
the external functional forces acting
on the bone.4 In these circum
stances, the mechanical properties
of healing bone are superior,5 and
primary bone healing occurs even in
open, contaminated wounds or in
the presence of infection.6 Mobiliza
tion of the jaw can be initiated

A 15-year-old boy presented with
a self-inflicted 12-gauge shotgun
wound to the face. The entry
wound was submandibular, the exit
wound was through the nasoethmoid region. There was no associat
ed intracranial injury, and vision in
both eyes remained intact.
Preoperative examination re
vealed a composite defect of the
palate and central midface, a skele
tal defect of the central mandible
and comminuted fractures involving
the nasoethmoid and orbitozygomatic regions bilaterally (Fig. 1).
Skeletal reconstruction was per
formed immediately (Fig. 2). Naso
ethmoid, zygomatic and maxillary
fractures were sequentially reduced
and rigidly fixed with miniplates
and screws to provide a stable outer
facial frame. Residual defects in the
orbits, central midface and palate
were then reconstructed with split
cranial and iliac-crest bone grafts,
which completely restored bony
continuity. The mandibular defect
was simply bridged with an internal
stainless steel reconstruction plate.
CJS, VOL. 36, NO. 5, OCTOBER 1993
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Upon completion of the skeletal
reconstruction, the entire palate
and central midface remained ex
posed intraorally (Fig. 2, top right).
Sufficient soft tissue was not avail
able locally to permit resurfacing of
the defect.
A radial forearm flap was there
fore elevated from the volar radial
surface of the patient’s forearm
(Fig. 2, bottom left and right). This
flap provides thin, well-perfused
non-hair-bearing skin pedicled on
the radial artery and vein. The flap
was transferred and anastomosed to
the facial artery and veins, provid
ing well-vascularized tissue to re
store intraoral lining. The wounds
healed without complication (Fig.
3).
Bone Graft Reconstruction

Bone grafting specifically ad
dresses the skeletal deficiency asso

ciated with composite facial defects.
Restoration of bony continuity, re
gardless of the extent of the defect,
is of primary importance. Osteosyn
thesis is increased and stability is
significantly enhanced, minimizing
the degree of relapse and secondary
deformity.
Autogenous bone grafts provide
the optimal material for the replace
ment of skeletal defects. Cortical
bone is capable of bearing stress
and resisting deformation. New
bone formation is stimulated both
by surviving cellular elements in the
graft7 and by the ability of the bone
matrix to induce transformation of
osteogenic precursors in the recipi
ent site.8 This encourages early
union of the graft to the margins of
the defect and complete incorpora
tion within the facial skeleton.
To optimize consolidation and re
tention of bone grafts, a favourable
environment must be furnished. A

well-perfused recipient site is re
quired to encourage early revascu
larization of the transplant. When
the defect is extensive or surround
ing tissues are scarred or irradiated,
pedicled vascularized bone trans
plants or circumferential coverage
of bone grafts with revascularized
soft-tissue flaps are necessary.
Rigid immobilization is further re
quired to eliminate shearing motion
and allow rapid vascular penetra
tion.9 Accurate apposition of the
graft to the bony margins of the
defect is important in ensuring a
superior osteogenic response10 and
maximizing the retention of volume
in the transplant.11
Case 2

A 23-year-old man presented with
facial features characteristic of
Treacher Collins syndrome. Preop
erative evaluation revealed bilateral

FIG. 1. Case 1. Man with shotgun wound to face. (Left) Intraoperative view demonstrating composite defect of midface. (Right)
Three-dimensional computed tomography (CT) scan shows bone defect in mandible and central maxilla.
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composite deficiencies in the orbitozygomatic region, with com
plete aplasia of the zygoma and
inferolateral orbits and hypoplasia
of the overlying soft tissues (Fig.
4) .
Due to the magnitude of the
skeletal deficiency, a vascularized
bone transfer was employed in orbitozygomatic reconstruction (Fig.
5) . A T-shaped cranial bone flap
was elevated on a temporalis muscle
and pericranial pedicle. The bone
flap was rotated into the cheek to

reconstruct a malar prominence, zy
gomatic arch and lateral orbital rim
in one segment. Free bone grafts
were then applied to the inferolater
al orbit to restore bony continuity
and provide support to the orbital
contents.
After the skeletal anatomy was
restored, the residual deformity
comprised primarily a lateral canthal dystopia and associated defi
ciency in lower eyelid skin (Fig. 6).
This was addressed in a second
stage. Tissue expanders were intro

duced into subcutaneous pockets in
the temporal region and gradually
inflated over 3 months to a volume
of 50 mL; this provided a surplus of
skin and soft tissue for eyelid recon
struction. The expanded temporal
skin flaps were transposed into the
lower eyelids, providing sufficient
tissue to resurface the lower lids
and permit repositioning of the lat
eral canthi (Fig. 7). The final result
of the composite reconstruction of
this young man’s face is shown in
Fig. 8.

FIG. 2. Case 1. Immediate facial reconstruction. (Top left) Schematic diagram indicating position of miniplates and screws.
Stippled segments represent bone grafts used in reconstruction of maxilla, palate, nose and orbits. (Top right) Intraoral view.
Anterior maxillary and palatal defects have been bone grafted and rigidly fixed. (Bottom left) Radial forearm flap, comprising
skin, subcutaneous tissue and fascia, is shown isolated on forearm. (Bottom right) Vascular pedicle to flap is demonstrated.
Radial forearm flap resurfaces lining of reconstructed palate after free transfer and anastomosis to facial artery and vein.
CJS, VOL. 36. NO. 5, OCTOBER 1993
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Microsurgical Free Tissue Transfer

The evolution of microsurgical
techniques in plastic and recon
structive surgery over the past 30
years has most significantly poten
tiated the goal of precise anatomical
and functional replacement of defi
cient tissues. Clinical research has
resulted in accurate descriptions of
selectively vascularized donor sites
for numerous types of composite
tissue, and this has facilitated re
construction with distant tissue that
most appropriately meets the re
quirements of the recipient site.
Clinical microsurgical transfer of
composite tissue was first accom
plished by McLean and Buncke12 in
1972. These investigators success
fully revascularized transferred
omentum for resurfacing of a scalp
defect. Subsequently, Daniel and
Taylor13 and O’Brien and col
leagues14 independently described
the use of vascularized free groin
flaps for coverage of lower extremi
ty defects.
Free transplantation of vascula
rized cutaneous flaps, muscle and
bone are now routinely used in

FIG. 3. Case 1. Final result, 1 year
postoperatively. Frontal view.
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clinical practice. In the reconstruc
tion of composite facial defects, free
tissue transfer is relied upon pri
marily to provide lining of intraoral
defects, obliteration of cavities and
exposed sinuses, vascularized cover
of the cranial base and augmenta
tion of subcutaneous tissue defi
ciencies.
Tissue Expansion

The cutaneous surface of the
head and neck is composed of sev
eral distinct anatomical areas, each
distinguished by specific skin col
our and texture characteristics,
hair-bearing qualities, and thickness
of subcutaneous tissues. Cutaneous
defects are therefore optimally re
surfaced by local tissue of similar
quality. However, the size of com
posite defects and the inadequacy of
adjacent tissues frequently preclude
the use of local flaps.
Tissue expansion is a means of
generating a surplus of locally
available tissue to enhance wound
closure. This technique employs an
inflatable silicone envelope, which is
placed in a subcutaneous pocket
adjacent to the defect. The implant
is gradually inflated by serial percu
taneous injections of saline into a
remote port. Progressive enlarge
ment of the implant results in ex
pansion of the overlying soft tis
sues.
Rather than simple stretching of
the overlying tissues, an increase in
epidermal mitotic activity15 and der
mal collagen synthesis16 has been
dem onstrated in experimental
studies in response to the mechani
cal stress of expansion. A stable
increase in skin surface area is thus
obtained. Adnexal structures such
as glands and hair follicles maintain
activity and remain quantitatively
the same.17 Tissue expansion is fur
ther associated with an increase in
vascularity and in skin-flap viabili
ty.18

The concept of tissue expansion
by gradual inflation of a prosthesis
was first applied clinically in breast
reconstruction.19 Subsequently, ex
tensions of these same principles
prompted the use of this technique
in the reconstruction of cutaneous
defects of the face20 and scalp.21
The ability to generate a surplus of
locally available tissue with the de
sired colour, texture and hair-bear
ing characteristics provides a supe
rior means of resurfacing virtually
any composite defect. Tissue expan
sion is therefore currently used with
increasing frequency in cheek and
neck resurfacing, in nasal recon
struction and in the coverage of
craniofacial defects that might oth
erwise have required the use of
distant flaps.
Case 3

A 55-year-old woman presented
with a post-traumatic composite de
fect of the central midface. One
year previously, she had sustained a
gunshot wound to the face. An
initial reconstructive effort, per
formed elsewhere, was complicated
by an early postoperative infection
and further tissue loss. The result
ing deformity consisted of a full
thickness composite defect of the
nose and midface, extending trans
versely from the right to the left
zygoma and from the cranial base
superiorly to the palate interiorly
(Fig. 9).
Because of the anatomical loca
tion and magnitude of the defect,
initial resurfacing of the cranial
base and obliteration of the interor
bital space with vascularized tissue
were necessary (Fig. 10). Local
flaps based on the margin of the
defect were reflected medially and
used to reconstruct an anterior pha
ryngeal wall, completely sealing the
nasal airways. Rib grafts were used
in building a facial frame to support
the orbital contents and soft-tissue

FACIAL RECONSTRUCTION

FIG. 4. Case 2. Patient with Treacher Collins syndrome. (Top left) Frontal view. (Top right) Profile. (Bottom left) Brow-up view.
(Bottom right) Three-dimensional, CT oblique view of skull. Note complete aplasia of zygoma and inferolateral orbital cavity
bilaterally.
GAS, VOL. 36, NO. 5, OCTOBER 1993
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FIG. 5. Case 2. Skeletal reconstruction. (Left) Schematic diagram showing method of temporalis muscle-one flap transfer for
orbitozygomatic reconstruction. (Right) Right temporalis muscle-bone flap elevated.

FIG. 6. Case 2. Result, post-skeletal reconstruction. Residual soft-tissue deficiency in lower eyelids is clearly seen. (Left) Frontal
view. (Right) Oblique view.
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reconstruction. A free gracilis mus
cle flap, anastomosed to the facial
artery and vein, was then draped
over the frame and anchored to
bone, effectively obliterating the en
tire defect.
Inadequate local tissues preclud
ed an immediate nasal reconstruc

tion and cutaneous resurfacing.
Eight months after the initial recon
struction, five tissue expanders
were inserted into separate subcuta
neous pockets in the forehead, both
cheeks and bilateral anterior neck
regions (Fig. 11). Over 8 weeks,
these were inflated to a total com

bined volume of 600 mL, providing
abundant non-hair-bearing skin.
The expanded forehead flap was
elevated and draped over a cantile
ver bone graft to reconstruct the
nose. Expanded cheek-neck flaps
were elevated and transposed bilat
erally to resurface the midface. The

FIG. 7. Case 2. Intraoperative views of expanded left temporal flap. (Left) Left temporal flap is marked out over tissue expander.
(Right) Temporal skin flap has been transposed. Note that sufficient tissue has been provided to allow complete resurfacing of
lower eyelid after correction of lateral canthal dystopia (i.e., after correction of obliquity of palpebral fissure).

FIG. 8. Case 2. Final result, 4 months postoperatively. (Left) Frontal view. (Middle) Profile. (Right) Brow-up view.
CJS, VOL. 36. NO. 5, OCTOBER 1993
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patient’s postoperative course was
uncomplicated. The final result is
shown in Fig. 12.

Summary
In the reconstruction of compos

ite craniofacial defects, consider
ation must be given to the specific
associated functional and anatomi
cal requirements. An integrated
team approach in which multiple
modalities are used offers an opti
mal means of craniofacial recon
struction.
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FIG. 12. Case 3. Final result. (Left) Frontal view. (Middle) Profile. (Right) Oblique view.
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Iodine Replacement in Fibrocystic Disease
of the Breast
William R. Ghent, MD, FRCSC, FACS;* Bernard A. Eskin, MD, FACOG;t
Donald A. Low, MD, FRCSC;$ Lucius P. Hill, MD, FACSJ
Objective: To determine the response of patients with fibrocystic breast disease to iodine replacement
therapy.
Design: Review of three clinical studies beginning in 1975: an uncontrolled study with sodium iodide
and protein-bound iodide; a prospective, control, crossover study from iodide to molecular iodine; and a
prospective, control, double-blind study with molecular iodine.
Setting: University affiliated breast-treatment clinics.
Patients: Study 1: 233 volunteers received sodium iodide for 2 years and 588 received protein-bound
iodide for 5 years. Study 2: the treatment of 145 patients from study 1 treated with protein-bound
iodide for several months who still had symptoms was switched to molecular iodine 0.08 m g /k g; 108
volunteers were treated initially with molecular iodine. Study 3: 23 patients received molecular iodine,
0.07 to 0.09 m g /k g body weight; 33 received an aqueous mixture of brown vegetable dye and quinine.
The numbers in study 2 increased over the review period so that 1365 volunteers were being treated
with molecular iodine by 1989.
Interventions: All patients in study 3 had pre- and post-treatment mammography and measurement of
serum triiodothyronine, thyroxine and thyroid-stimulating hormone levels.
Main Outcome Measures: Subjective evaluation — freedom from pain — and objective evaluation —
resolution of fibrosis.
Results: Study 1: 70% of subjects treated with sodium iodide had clinical improvement in their breast
disease, but the rate of side effects was high; 40% of patients treated with protein-bound iodide had
clinical improvement. Study 2: 74% of patients in the crossover series had clinical improvement, and
objective improvement was noted in 72% of those who received molecular iodine initially. Study 3: in
the treatment group 65% had subjective and objective improvement; in the control group there was a
subjective placebo effect in 33% and an objective deterioration of 3%.
Conclusions: The fibrocystic breast reacts differently to sodium iodide, protein-bound iodide and
molecular iodine. Molecular iodine is nonthyrotropic and was the most beneficial.

Objectif: Mesurer la reponse des patientes souffrant de mastose sclerokystique a un traitement de
suppleance a Tiode.
Conception : Une revue de trois etudes cliniques amorcees en 1975 : une etude ouverte de Tiodure de
sodium et de Tiode lie aux proteines; une etude prospective, controlee, en chasse-croise de Tiodure et
de Tiode moleculaire; et une etude prospective, controlee, a double insu avec de Tiode moleculaire.
Contexte : Des cliniques de traitement des maladies du sein affiliees a une universite.
Patientes : Premiere etude : 233 volontaires qui ont re?u de Tiodure de sodium pendant 2 ans et 588
qui ont re?u de Tiode lie aux proteines pendant 5 ans. Deuxieme etude : le traitement de 145 patientes
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qui avaient participe a la premiere etude et qui avaient re$u de l’iode lie aux proteines pendant
plusieurs mois et qui montraient des signes residuels de mastose, fut modifie pour de l’iode moleculaire
a 0,08 m g/kg; 108 volontaires refurent initialement de l’iode moleculaire. Troisieme etude : 23
patientes re?urent de l’iode moleculaire, a raison de 0,07 a 0,09 m g/kg; 33 refurent une solution
aqueuse de colorant brun vegetal et de quinine. Les nombres dans la deuxieme etude augmenterent
pendant son deroulement de sorte qu’ils atteignirent 1365 volontaires traites a l’iode moleculaire en
1989.
Interventions : Toutes les patientes ayant participe a la troisieme etude subirent mammographie pre et
post-traitement ainsi que des determinations des taux seriques de triiodothyronine, de thyroxine et
d’hormone thyreotrope.
Principaux effets mesures : Subjectif — l’absence de douleur — et objectif — la disparition de la
fibrose.
Resultats : Premiere etude : 70 %des sujets traites a l’iodure de sodium eurent une amelioration
clinique mais montrerent un taux eleve d’effets secondaires; 40 %des patientes recevant de l’iode lie
aux proteines beneficierent d’une amelioration clinique. Deuxieme etude : 74 %des patientes dans la
serie en chasse-croise eurent une amelioration clinique et une amelioration objective fut notee chez
72 %de celles qui avaient re?u de l’iode moleculaire initialement. Troisieme etude : dans le groupe
traite, 65 % montrerent une amelioration subjective et objective; dans le groupe temoin, on enregistra
une amelioration subjective placebo dans 33 % des cas et une deterioration objective de 3 %.
Conclusions : La mastose sclerokystique reagit differemment a l’iodure de sodium, a l’iode lie aux
proteines et a l’iode moleculaire. L’iode moleculaire n’est pas thyreotrope et a donne les meilleurs
resultats.

ibrocystic breast disease (FBD)
is characterized by lumpy, pain
ful breasts, generally in reproduc
tive-aged women. Initially the syn
drome occurs in the premenstrual
phase but can progress to involve
the whole cycle. Symptoms can also
occur in menopause, particularly if
estrogens are being used.
Histologically, FBD shows mi
crocysts, epithelial hyperplasia, apo
crine metaplasia and fibrosis. The
fibrosis is the basic hallmark of the
disease. Macrocysts greater than 1
cm in diameter occur in 10% of
patients with the syndrome. Bio
chemical and cytologic analysis of
macrocyst fluid shows that 55%
contain high levels of potassium
(more than 120 mmol/L) and low
levels of sodium (less than 20
mmol/L) and are associated with
apocrine changes; the other 45%
contain high levels of sodium (more
than 120 mmol/L) and low levels
of potassium (less than 5 mmol/L)
and are associated with flat epitheli
al cells.12 Observations indicate that
the cyst fluid in the microcysts has
a high potassium content with apo
crine cells present.3
The diagnosis of FBD is increas

F
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ing in frequency. In 1928 an autop
sy series reported a 3% incidence,4
whereas in 1973 an autopsy report
quoted an 89% incidence.5 The lat
est review by the American Acade
my of Pathology gives a minimum
incidence of 50% but suggests that
80% of North American women are
afflicted with the syndrome during
their reproductive lifetime.6
The suggested etiology of the
syndrome has included a prolonged
luteal phase,7 an upset in the estrone-estriol ratio,8 increased estro
gen levels9 and other hormonal dys
functions.910 A dietary theory impli
cating coffee and tea has been pop
ular,11 but this has been disproved
by several studies.1213 Some au
thors14' 17 have stated that FBD is a
normal but exaggerated physiologic
cycle and that it may be a “nondis
ease.”
The term “iodine” has been mis
used for many years to describe any
iodine compound. Chemically the
elemental form of iodine (I2), with
an atomic weight of 125.9015, is
the only substance that should be
called iodine. However, there are
some 130 compounds containing
the element iodine. These have, by

common usage, been called generic
iodine. Each compound is different
and consists of simple bindings
such as sodium or potassium to
produce iodides (I~). Potassium io
dide has been added to our salt in
Canada since 1929 and has reduced
the incidence of cretinism and
goitre. The fact that sodium or
potassium iodide, when mixed with
water, forms a solution that is 95%
iodide (I~) and 5% free iodine (I2) is
of relevance to our findings in this
study. More complex bindings of
the iodine molecule to organic com
pounds produce substances that are
chemically different but again are
called “iodine,” such as iodine ca
seinate. In this presentation, the
term iodine (I2) will refer to aqueous
molecular iodine whereas all other
iodine-containing compounds will
be indicated as iodide (I- ) or gener
ic iodine.
In this paper we report on three
clinical trials of iodide (I~) and
iodine (I2) replacement therapy to
ascertain the response of the fi
brocystic breast: iodide (I- ) replace
ment therapy with (a) sodium iodide
(Lugol’s iodine) and (b) iodine casei
nate; a crossover study from iodide

IODINE REPLACEMENT IN THE FIBROCYSTIC BREAST

to iodine; and a double-blind pro
spective study with iodine.

Patients and Methods
Study 1
Initially, 233 volunteers were
treated with Lugol’s iodine (sodium
iodide [I- ]) for 2 years. Compliance
was difficult owing to the vile taste
of this compound. Lugol’s iodine is
95% iodide and 5% iodine. The
dosage was 5 to 10 drops daily, on
a body-weight basis. This study was
an open-ended trial without con
trols because we found it was im
possible to create a placebo that
was realistic.
In the second arm of this study
588 patients were treated with io
dine caseinate (iodized casein [I- ]).
The study period was 5 years and
the dosage of iodine caseinate was
10 mg daily. This study was also
conducted without controls.
Study 2
When it became evident in the rat
model that there was a differential
reaction in the breast tissue to
iodides and to molecular iodine,18 it
was decided that molecular iodine
should be tried on human volun
teers with FBD. Study 1 included
145 subjects who had been treated
with iodine caseinate for a number
of months but still had residual
symptoms and signs of FBD. Thera
py in these patients was switched to
aqueous molecular iodine at a dos
age of 0.08 mg I2/k g , and the
patients were assessed at 9.9
months after crossover.
One hundred and eight more sub
jects (de novo group) were treated
initially with aqueous molecular io
dine and were evaluated at 8.9
months.
The original series of 233 volun
teers was enlarged to 1365, ob

served through 4813 women-years
of treatment (Table I). These
women were assessed at 4 to 6
months (group 1), 7 to 18 months
(group 2) and more than 18 months
(group 3). The mean age of these
women was 41.6 years (range from
11 to 87 years) and the mean
duration of symptoms was 44.6
months (range from 1 to 360
months).
Scoring system for study 2 sub
jects. A precise method of recording
our data was developed with a nu
merical scoring system. This simple
method numbers the quadrants of
the breast from 1 to 4 (Fig. 1). The
following five pathological changes
that can occur in the fibrocystic
syndrome were noted: micronodu
larity, tenderness, fibrous tissue
plaques, macrocysts and turgidity
(hyperactivity). The presence or ab
sence of these changes was record
ed. For example, if the mi
cronodularity of microcystic disease
was present in the upper half of the
breast, the numerical score would
be 1 (micronodularity) + 2 (two
breast quadrants) = 3. If all five
changes occurred in all quadrants
in one breast the score would be 1
+ 2 + 3 + 4 (all four breast
quadrants) X 5 (all five changes) =
50, and for both breasts 100.
Subjective evaluation. The pa
tient’s evaluation of her own symp
tomatology was expressed numeri

cally: 0 — symptoms worse, 1 —
symptoms unchanged, 2 — less
pain, only premenstrual discomfort,
3 — no pain, unable to predict
menstruation.
Objective evaluation. The subjec
tive scoring system was employed
and graded as follows: 0 — no
palpable abnormalities (normal), 1
— a score of less than 7, 2 — a
score greater than 7 but less than
the pre-treatment score and 3 — a
score greater than the pre-treat
ment score.
Study 3
Fifty-six volunteers were enrolled
in a prospective double-blind study
at the Virginia Mason Clinic in
Seattle, Wash. This study was su
pervised by D.A.L. and L.D.H. The
patients were enrolled over 2
months and were treated for 6
months. All had mammography be
fore and after treatment. In addi
tion, serum triiodothyronine, thy
roxine and thyroid-stimulating hor
mone levels were measured for all
patients before and after treatment.
The patients were randomly as
signed by the pharmacist to the
treatment or the placebo arm.
The patients were assessed at
2-month intervals, with a final as
sessment at a mean of 191 days.
Subjective evaluation in this study

Table I. Demographic Data on Volunteers
With Fibrocystic Disease in Study 2 — A
Clinical Trial of Replacement Therapy With
Molecular iodine (N = 1365)
Demographic characteristic
Premenopausal
Postmenopausal
Taking birth control pills
Taking estrogen
Parous
Previous breast surgery
Biopsy
Mastectomy
Family history of fibrocystic
breast disease

No. (%) of
women
871
494
915
252
1081

(63.8)
(36.2)
(67.0)
(18.5)
(79.2)

304 (22.3)
25 (1.8)
333 (24.4)

FIG. 1. Numerical designation of
breast quadrants for fibrocystic breast
disease.
CJS. VOL. 36. NO. 5. OCTOBER 1993
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FIG. 2. Results of replacement therapy with iodized casein. 1 = return to normal
without pain, 2 = residual premenstrual pain and fibrosis, 3 = slight reduction in
pain and cysts and 4 = no change.

was in three categories: 0 — worse,
1 — no change and 2 — less pain
or pain free. Objective evaluation
was carried out by two examiners,
who used a numerical grading sys
tem slightly modified from the one
described earlier. They were un
aware of the treatment status of the
patients under study.
Twenty-three patients (mean age
43.6 years) received aqueous mo
lecular iodine, 0.07 to 0.09 mg of
I2/k g body weight daily. The place
bo group (mean age 39.2 years),
received an aqueous mixture of a
brown vegetable dye with quinine
added for flavour.

Results
Study 1

IODIZED CASEIN

MOLECULAR l 2

TRANSFER TO MOLECULAR l 2

IODIZED CASEIN

DE NOVO

MOLECULAR I ,
% Frequency

FIG. 3. Comparison of results of replacement therapy in patients treated first with
iodized casein and then with molecular iodine and in patients treated with
molecular iodine alone. 1 = return to normal without pain, 2 = residual
premenstrual pain and fibrosis, 3 = slight reduction in pain and cysts and 4 = no
change.

Table II. Objective Numerical Score fo r Patients in Study 2, Before and A fter Trea tm e n t*
Group 1
(n = 292)

Group 2

Group 3

Total

[n = 6 39)

(n = 434)

(n= 1365)

30.12
1-80

31.29
3-80

31.16
4-100

30.99
1 -1 0 0

Range

3.15
0-46

1.18
0-62

1.51
0-40

0-62

p v a lu e t

0.0001

0.0001

0.0001

T im e of scoring
B efore tre a tm e n t
Mean
Range
A fte r tre a tm e n t
Mean

1.97

'D u ra tio n o f treatm ent: group 1, 4 to 6 m o, group 2, 7 to 18 mo group 3, n ore than 18 m o
t x z analysis
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Iodide replacement therapy.
Clinically the improvement rate was
70%. Side effects included changes
in the thyroid indices in 4% of
patients, the development of iodism
in 3% and the occurrence of acne,
which was unacceptable to the pa
tients.
Iodine caseinate replacement
therapy. A good response was
noted in 40% of the patients (Fig.
2). Side effects involved 9.5% of the
patients and have been described in
detail elsewhere.18’19
Study 2

Of the 145 patients in the cross
over series, 108 (74.5%) showed an
improvement, having pain-free
breasts; the remainder still had
some premenstrual pain and residu
al fibrosis.
In the de novo group, the 108
patients responded more swiftly,
with complete disappearance of
their microcysts within 5 months;
98% were pain free at evaluation,
and objective improvement was
noted in 71.8% (Fig. 3).

JCC, VOL. 36, NO 5 , OCTOBRE 1993
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FIG. 4. Effect of duration of treatment with molecular iodine evaluated subjectively.
0 = worse, 1 = unchanged, 2 = improved (less pain with only premenstrual
discomfort) and 3 = freedom from pain and lumps. Group 1 = 4 to 6 months, group
2 = 7 to 18 months and group 3 = more than 18 months.

These results indicate the superi
ority of molecular iodine over io
dides when treating fibrocystic
breast disease.
Both subjective and objective improvments, according to the evalua
tion scale, were time dependent (Ta
ble II, Figs. 4 and 5). Sixty-five
percent of women experienced a
reduction in breast size as the fi
brocystic condition was corrected
(Fig. 6).
The side effects of treatment with
molecular iodine were minor and
involved 149 (10.9%) of the pa
tients, including 78 (5.7%) who had
a short-lived period of increased
pain (Table III). This period of pain
seemed to correspond to a softening
of the breast and disappearance of
fibrous tissue plaques on clinical
examination.
During this period of observation
six women failed to respond to any
type of therapy, including aqueous
molecular iodine (I2), tamoxifen, danazol, bromcriptine or progester
one. These women subsequently
underwent subcutaneous mastecto
my. Histologic examination indicat
ed a total disruption of the normal
breast architecture (Fig. 7). The
pathological review of the mamma
ry tissue from these patients was
remarkably similar, with dense fi
brosis that isolated breast acini
from the duct system. We conclude,
therefore, that there is a “ point of
no return’’ in fibrocystic disease.
Once this point is crossed, surgical
excision of the diseased tissue is the
only method of treatment. This
state can be suspected when a total
white-out is observed on the mam
mogram.

Study 3
FIG. 5. Effect of duration of treatment with molecular iodine assessed objectively by
numerical scoring. 1 represents numerical score of 0, 2 represents numerical score
less than 7, 3 represents numerical score less than pretreatment score, 4 represents
numerical score greater than pretreatment score. Group 1 = 4 to 6 months, group
2 = 7 to 18 months and group 3 = more than 18 months.

There was a placebo effect in 11
(33%) women of the control group,
which is in keeping with previous
reports on the treatment of benign
breast disease.20
CJS, VOL. 36. NO. 5. OCTOBER 1993
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On objective evaluation, the con
trol group’s numerical assessment
deteriorated by 3% during the study
compared with a 65% improvement
in the treated group (p < 0.001, x2
analysis) (Table IV).
On subjective evaluation, 15

(65%) women in the treated group
showed improvement, compared
with 11 (33%) in the control group
(Table IV). The laboratory results
were unchanged, and no side effects
were reported.
Repeat mammography failed to

show any significant change (2 to 5
years are required for any mammographic change to be manifest and
the final evaluation in this study
was at 6 months).
Despite the small size of the two
participating groups, the results
clearly indicate that the placebo
effect in the control group was at
the rate expected for studies of the
treatment of benign breast disease.
The objective findings worsened in
this group in the 6 months under
study. In contrast, the treated
group demonstrated unequivocal
objective results by x2 analysis (Ta
ble IV).

Discussion

FIG. 6. Effect of duration of treatment on breast size: percentage of women who
reported decrease in breast size measured by brassiere size. This varied from
one-half cup size to five cup sizes and was time dependent. Group 1 = 4 to 6
months, group 2 = 7 to 18 months and group 3 = more than 18 months.

Eskin worked for many years in
the animal laboratory on the hy
pothesis that a low iodine or an
iodine-deficient state rendered the
rat breast more susceptible to dys
plasia and carcinoma.21 His model
consisted of Sprague-Dawley rats
raised from birth on a Remington
diet, which is iodine free with per
chlorate blockade and causes an
iodine-deficient state. His rat model
approximated the microscopic find
ings seen clinically with the triad of
cystic spaces, epithelial and apo
crine hyperplasia and interacinar fi
brosis. Previous rat models pro
duced by hormonal manipulation
T a b le III. S ide E ffe c ts o f A q u e o u s
M o le c u la r Io d in e T h e ra p y in S tu d y 2
W om en
S id e effect

FIG. 7. Histologic appearance of breast tissue refractory to treatment with
molecular iodine. Note complete absence of normal acinar intraductular structure
(hematoxylin-eosin stain).
458

JCC, VOL. 36, N ° 5, OCTOBRE 1993

A cne
N ausea
D iarrhea
H air th in n in g
H y p e rth y ro id is m
H y p o th y ro id is m
S kin rash
lo d is m
H eadaches
Incre a sed pain
O ther
T o ta l

No. ( % ) of w om en
1 5 ( 1 .1 )
8 (0 .6 )
2 (0 .1 )
1 3 ( 1 .0 )
2 (0 .1 )
4 (0 .3 )
3 (0 .2 )
2 (0 .1 )
3 (0 .2 )
7 8 (5 .7 )
2 2 (1 .6 )
1 4 9 (1 0 .9 )

IODINE REPLACEMENT IN THE FIBROCYSTIC BREAST

resulted in excess fluid and hyper
plasia but lacked the fibrotic ele
ment.22'23
Eskin showed that there is a
hierarchical response in the rat
mammary gland to the type of io
dine compound administered to cor
rect the changes induced by iodine
deprivation. Lugol’s iodine (I- ) cor
rects the cystic spaces and partially
corrects the epithelial hyperplasia
and the fibrosis. The 5% free iodine
(I2) in Lugol’s iodine could explain
the partial resolution of the syn
drome. Iodine caseinate (I- ) partial
ly corrects the cysts and the hyper
plasia but does not ameliorate the
fibrosis. Iodine in its elemental
form, I2, corrects the entire disease
process. Thus, it seems that I2 is
the preferential form of iodine for
breast metabolism. This activity is
localized in the terminal and in
tralobular duct cells.24' 26
The human response to sodium
iodide (I'), protein-bound iodide
(I') or iodine (I2) paralleled Eskin’s
findings in the experimental model.
Our previous findings with sodium
iodide and protein-bound iodide (I- )
have been reported; they showed a
lesser response than we have ob
tained with molecular iodine (I2).1819
In addition, all iodides are thyro
tropic, as Eskin has demonstrated,
whereas I2 seems to be involved
primarily in extrathyroidal activi
ties. Our complication rate of ab
normal thyroid indices was not
above the expected incidence in the
Great Lakes goitre region in un
treated controls.
The exact mechanism of action of

I2 on breast tissue is not under
stood. We do know that there is a
differential absorption of iodides
(I") and iodine (I2) from the gut of
the Sprague-Dawley rat.27 It has
been established that the only areas
of the breast in which iodine can be
found are in the terminal and in
tralobular duct cells, a minuscule
proportion of the total breast volu
me.24-26 It is this area that is pri
marily involved in cystic and malig
nant changes. We theorize that the
trace element, molecular iodine, is
necessary for breast normality. Its
absence renders the epithelium of
the terminal and intralobular ducts
more sensitive to estrogen stimula
tion. This hypersensitivity can pro
duce excess secretions over the
limit of absorption, thus distending
the acini to produce microcysts.
The fluid in microcysts is extremely
high in potassium,3 and this could
act as an irritant, producing fibrosis
and eventually cyst isolation.
Iodides are necessary for thyroi
dal normality and are trapped by
the thyroid. Thyroid tissues are rich
in peroxidase, which oxidizes iodide
(I~) to iodine (I2) on the way to the
formation of monoiodotyrosine, diiodotyrosine and finally triiodothy
ronine and thyroxine. Breast tissue
is peroxidase poor, and as such it
cannot extract iodine (I2) from the
circulating iodides. This has been
d em onstrated by E skin and
others.24-28
It appears that the trace element
I2 is essential for breast normality.
The effect of the molecule on the
terminal and intralobular duct cells

may be to render them less sensitive
to circulating estrogens. As such it
could be classed as a natural “an
tiestrogen.” If this premise is borne
out by further animal testing and
larger clinical trials, it will be of
importance for breast health, nor
mality and longevity.
We thank the volunteers in the Kings
ton and Seattle areas who participated
in these studies. We thank the referring
physicians for their continuing support.
We thank Mrs. Jane Derrick for comple
tion and analysis of the data and Dr.
Arlene Crowe for her invaluable assis
tance in the preparation of this paper.
We also express our sincere apprecia
tion to Mrs. Marie Gallagher for the
countless revisions she has endured.
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ARTICLES ORIGINAUX

Patellectomie : resultats a long terme
Simon Cantin, MD; Claude Laroche, PhD; Pierre Lavallee, MD; Jean-Marc Lessard, MD
Les auteurs sont en disaccord avec la litterature au sujet du futur des genoux patellectomises suite a
une fracture comminutive de la rotule. Ils ont evalue de facon retrospective 17 patients ayant subi une
patellectomie unilateral post-traumatique entre 1955 et 1980. Une evaluation subjective et
objective (examen clinique, radiologique et etude de force sur appareil Cibex II) a ete faite pour chaque
patient en utilisant le genou sain controlateral comme temoin. Les resultats demontrent un haut niveau
de satisfaction (88 %), l’absence d’instabilite ligamentaire et d’arthrose precoce, mais une diminution de
la force de l’appareil extenseur du genou a 75 %. Les auteurs concluent que la patellectomie totale est
une chirurgie bien toleree et moins morbide que ne le suggere la litterature.
The authors are in disagreement with the literature on the results of patellectomy after comminuted
fracture of the patella. They assessed retrospectively 17 patients who underwent unilateral total
patellectomy between 1955 and 1980. Subjective and objective (clinical examination, radiologic
examination and Cibex II studies) assessment was carried out for each patient using the contralateral
healthy knee as a control. The results demonstrated 88% patient satisfaction, no ligamentous
instability and no early arthrosis but a decrease in extensor muscle strength to 75% of normal. The
authors conclude that total patellectomy is better tolerated and causes less morbidity than suggested in
the literature.

cription, par Lister, remonte a
1877. Depuis ce temps, de nombreuses etudes ont decrit [’interven
tion en bien ou en mal.
Actuellement, la patellectomie est
consideree comme traitement de
dernier recours lors d’une fracture.1
On dit qu’elle est a l’origine d’insta
bilite du genou,2 d’arthrose au ni
veau des condyles femoraux.134 On
dit egalement qu’elle est inesthetique et qu’elle diminue la force d’extension.1-2-4'6
Notre experience clinique ne semble pas corroborer cette optique.
Nous avons decide de proceder a
une etude clinique afin de faire le
point sur ce sujet.

lectomie unilateral, postfracture
entre 1955 et 1980 au centre hospitalier de l’Enfant-Jesus, Quebec,
(Que). Le genou controlateral sain
fut utilise comme temoin.
Le groupe comprend 6 femmes et
11 hommes dont l’age moyen a
l’examen etait de 49 ans. Le suivi
moyen est de 21,5 ans. Les fractu
res etaient en majorite a droite.
Elies etaient toutes comminutives:
dix etaient ouvertes. La majorite
etait secondaire a un accident d’automobile.
Les fractures associees au membre inferieur ipsilateral se trouvaient surtout au niveau de la partie
distale du femur (trois fractures au
niveau des condyles femoraux et
une fracture du tibia).

Patients et methode

Technique operatoire

L’etude porte sur un groupe de
17 patients qui ont subi une patel

Une incision transverse sur la
peau et les fascias avec enucleation

est une chirur
L agiepatellectomie
ancienne. La premiere des

de la rotule fut utilisee le plus
souvent (16 cas sur 17). L’appareil
extenseur fut par la suite rapproche
pour combler la lacune laissee par
la rotule, selon la methode de
Brooke.
L’immobilisation postoperatoire,
dans un cylindre platre a 0° de
flexion, dura en moyenne 41,7
jours. La physiotherapie a ete utili
see chez huit patients. A court
terme, une ankylose du genou fut
traitee par mobilisation sous anesthesie generate et, a long terme,
une exerese de calcification sur le
tendon extenseur fut pratiquee.

Evaluation
L’evaluation du genou fut basee
sur un questionnaire, un examen
clinique, des radiographies ainsi
qu’un test sur Cibex II (Lumex
Corp., Cyber Division, Ron Kon
Koma, NY).

Du departement de chirurgie orthopedique, Hopital de TEnfant-Jesus, Universite Laval, Quebec (Que.)
Accepte pour publication le 10 decembre 1992
Les demandes de tires a part doivent etre adressees au O' Simon Cantin, Departement d ’orthopedie, H opital de TEnfant-Jesus, 1401, 18e rue,
Quebec. Q CC1T 1Z4
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Le questionnaire est base sur le
“ Cincinnati Rating System”7 developpe par Noyes, McGinnis et
Mooar.8 Celui-ci permet d’evaluer
l’etat fonctionnel du genou lors
d’activites.
Examen physique a ete fait par le
meme membre de l’equipe (S.C.).
L’examen verifiait la presence d’atrophie au quadriceps, de liquide
intra-articulaire, la stability des liga
ments collateraux et croises, le
deplacement de l’axe de rotation,
l’extension, la flexion et la douleur
a la palpation des differents compar
tm ents du genou. Au meme mo
ment, des radiographies des genoux
furent faites en antero-posterieur,
lateral et vue rotulienne.
Les forces des quadriceps furent
etudiees sur Cibex II dans un mode
isocinetique, selon la technique
usuelle.7>9 Le travail total du quadri
ceps fut etudie a une vitesse de
6 0 ° /s sur la moyenne de cinq cy
cles pour le cote sain et patellectomise. Cette partie de l’examen fut
faite par le physiotherapeute de
l'equipe (C.L.).

Resultats
De fagon subjective, le genou
patellectomise ne presente aucune
douleur chez 59 %10 des patients,
des douleurs a l’activite intense
chez 35 %6 des patients et au travail
ou sport modere chez 6 %l des
patients, aucun patient ne presentait des douleurs a l’effort leger (p
= 0,05).
Un seul patient decrit un gonflement du genou patellectomise lors
de sport ou de travail intense (p >
0,05).
Le derobement se presente au
niveau du genou patellectomise en
aucun moment chez 41 % (sept) des
patients, seulement a l’activite in
tense chez 41 % (sept) des patients,
a l’activite moderee chez 18 %
(trois) des patients. Aucun patient
462
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ne presente de derobement a l’acti
vite legere (p < 0,001).
Quatre-vingt huit pourcent (15)
des patients ont decrit aucune modi
fication de leur travail, 12 % (2) des
patients ont decrit une diminution
de leur capacite de travail.
En ce qui a trait a la satisfaction
subjective, 59 % des patients (10)
decrivent avoir eu un excellent
resultat avec absence d’handicap,
29 % (5) un bon resultat avec un
leger handicap qu’ils decrivent surtout comme un derobement, 6 % (1)
des patients decrivent un resultat
moyen et 6 % (1) un resultat mauvais. Le mauvais resultat est surve-

nu chez un patient avec une frac
ture sus et intercondylienne qui
presente un deficit important de
flexion et d'extension (10° et 35°).
A l'examen physique, aucune dif
ference n’est notee quant a l’epanchement intra-articulaire, aux dou
leurs a la palpation, aux mouvements et a la stability ligamentaire
(collateral et croisee). II existe une
atrophie du quadriceps du cote pa
tellectomise, de 1,2 cm (p < 0,05).
A l’examen radiologique aucune
difference entre les deux genoux
en ce qui a trait aux signes
d’arthrose femoro-tibiale n’est de
montree.

PATELLECTOMIE

L’evaluation des forces d’extension demontre une perte de force
sur toute l’extension, mais surtout
dans les 15 derniers degres de l’extension. En moyenne, le genou patellectomise est de 25 % moins puis
sant. Paradoxalement, dans deux
cas, le genou pallectomise etait plus
puissant.

Discussion
L’evaluation a long terme nous
demontre que 88 % des patients
sont subjectivement satisfaits de la
patellectomie totale (excellents et
bons resultats) mais ceux-ci presentent un peu de derobement et des
douleurs legeres comme principales
plaintes. Ceci est corrobore par
d’autres auteurs4-6’10-12
Nous n'avons pu retrouver chez
nos patients aucune difference a
long terme quant a l’arthrose1'3'4 et
de l’instabilite2 telle que decrite par
d’autres. L’examen physique n’a
demontre aucune difference au ni
veau de la stability ligamentaire des
mouvements de flexion et d’extension. Une atrophie moyenne de 1,2
cm est observee ce qui semble etre
moins que ce que la litterature
decrit.212 Nous n’avons observe
aucun «extension lag# suite aux
patellectomies transverses.
La presence d’une fracture au
niveau femoral et tibial, nous sem
ble etre un facteur defavorable (douleur au travail, diminution de la
flexion et de l’extension). D’autres
facteurs tels que l’age au trauma, le
cote fracture et le fait d’avoir une
fracture ouverte n’influencent pas le
pronostic.
L’evaluation sur Cibex II a
demontre une diminution moyenne
de 25 % de la force d’extension
moyenne du genou. Cette diminu
tion est etalee sur toute l’extension
mais surtout au niveau des 15 der
niers degres d’extension comme le
confirme d’autres auteurs.9

Si nous utilisons le ((Cincinnati
Rating System# tel que modifie par
Saltzman dans son etude des patel
lectomies partielles, nous retrouvons les resultats suivants : 18 %
excellent (trois patients), 53 % bon
(neuf patients), 24 % moyen (quatre
patients) et 6 % (un patient) mauvais.
Si nous comparons nos resultats
avec les resultats de Saltzman et
collegues7 sur les patellectomies
partielles, en utilisant les memes
criteres, les genoux ayant une patel
lectomie partielle presentent plus de
douleurs (58 % contre 40 %) et
d’epanchement (10 % contre 6 %).
La patellectomie totale presente
plus de derobement (59 % contre
12 %) et d’atrophie du quadriceps
(1,2 cm contre 0 cm). Au niveau
cinetique, la patellectomie partielle
preserve 85 % de la force d’exten
sion par rapport a 75 % pour la
patellectomie totale. La radiologie
montre la presence d’arthrose patello-femorale importante chez les pa
tellectomies partielles (53 %). Au
niveau des complications a long
terme, 3 des 40 patellectomies par
tielles ont du subir une conversion
en patellectomie totale, comparativement a un patient ayant eu une
exerese d’une calcification chez nos
patellectomies totales. Au niveau du
pointage final la patellectomie par
tielle presente 77 % de bons et
d’excellents resultats apres 8,4 ans
de suivi, comparativement a 71 %
pour les patellectomies totales apres
21,5 ans de suivi.

Conclusions
Notre etude semble confirmer
notre impression clinique, la patel
lectomie totale est une chirurgie qui
permet un etat fonctionnel adequat
apres une fracture comminutive de
la rotule. II nous semble clair que
celle-ci n’amene aucune arthrose ou
instabilite mais provoque une dimi

nution de la force d’extension.
11 semble que la patellectomie
partielle preserve un etat fonction
nel plus grand du genou, mais
celle-ci apporte plus de douleur et
demande plus souvent une seconde
chirurgie que la patellectomie tota
le.
Done devant une fracture commi
nutive de la rotule, nous pouvons
orienter le traitement selon l’etat de
comminution et les besoins du pa
tient.
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Intramedullary Nailing of Femoral Shaft
Fractures: Reoperation and Return to W ork
Drew A. Bednar, MD, CM, FRCSC, FAAOS; Pervez Ali, MD
Objective: To define the functional outcome and residual disability in adults treated for isolated femoral
shaft fractures.
Design: A retrospective case study of HMRI records. The mean follow-up was 34.5 months from the
time of injury.
Setting: A tertiary-care teaching hospital.
Patients: One hundred and thirty adults with femoral shaft fractures. Of these, 47 were isolated and
qualified for study.
Interventions: Primary reamed intramedullary nailing performed between April 1987 and September
1990.
Main Outcome Measures: Reoperation and return to work.
Results: Of the 47 patients, primary healing occurred in 41 (87%) patients; 6 (13%) patients had
delayed union or nonunion. Twenty (43%) patients had delayed implant-related pain after fracture
healing; 85% of these had relief of pain after implant removal. Of 41 patients available for analysis of
function based on return to work, 33 (80%) had returned to work full time in their original occupation
at the time of follow-up, and 4 (10%) were working in other full-time employment; 3 (7%) were working
part time. Only one (2%) patient was disabled and unable to work.
Conclusions: Primary reamed intramedullary nailing is an effective method of achieving consistent
primary union in adults with femoral shaft fractures. However, the majority of patients will require
secondary surgery. Most patients will be able to return to work after these injuries.

Objectif : Definir les resultats fonctionnels et l’incapacite residuelle chez des adultes traites pour une
fracture isolee de la tige du femur.
Conception : Une etude retrospective de cas, a partir des dossiers d’hopitaux. La periode moyenne de
surveillance des suites therapeutiques a ete de 34,5 mois, a partir du moment de la blessure.
Contexte : Un hopital universitaire de soins tertiaires.
Patients : Cent trente adultes qui avaient subi une fracture isolee de la tige du femur. Parmi ceux-ci,
47 rencontrerent les criteres d’admissibilite.
Interventions : Les enclouages medullaires primaires realises entre avril 1987 et septembre 1990.
Principaux effets mesures: Les reoperations et la reprise du travail.
Resultats : Une guerison primaire est survenue chez 41 des 47 patients (87 %); 6 (13 %) eurent une
fusion retardee ou une absence de fusion. Vingt patients (43 %) souffrirent de douleurs persistantes
associees a l’implant; 85% de ceux-ci eurent un soulagement de la douleur apres le retrait de l’implant.
Des 41 patients permettant une analyse fonctionnelle s’appuyant sur la reprise du travail, 33 (80 %)
avaient repris leur travail anterieur a plein temps au moment du suivi et 4 (10 %) vaquaient a d’autres
emplois a plein temps; 3 (7 %) avaient un emploi a temps partiel. Seulement un patient (2 %) avait une
incapacity ne lui permettant pas de reprendre le travail.
Conclusions : L’enclouage medullaire primaire est une methode efficace d’obtenir regulierement une
fusion primaire chez les adultes qui subissent une fracture de la tige du femur. Toutefois, la majority
des patients necessitent une chirurgie secondaire. La plupart des patients sont capables de reprendre le
travail apres de telles blessures.
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INTRAMEDULLARY NAILING

intramedullary nailing
Reamed
of femoral shaft fractures in
adults is accepted as the treatment
of choice in North America.1-4 The
operative technique and postopera
tive management are well defined5' 7
and predictably lead to union in
most cases.
The extensive literature dealing
with this subject has generally ad
dressed the clinical end point of
radiographic union as the goal of
management. Little attention has
been paid to return to work and
residual debility after this treat
ment.
A retrospective study of the expe
rience of adult patients treated for
isolated femoral shaft fractures was
undertaken to define functional out
come and residual debility in this
population.

Patients and Methods
The medical records of 130
adults treated with primary reamed
intramedullary nailing between
April 1987 and September 1990
were reviewed after retrieval from
the Hospital Medical Records Insti
tute (HMRI).
Patients whose injuries included
other lesions affecting weight bear
ing were excluded, as were those
treated by other means. Eightythree (64%) patients did not qualify
for this review; they included 9
patients treated primarily with
plates, 8 patients with bilateral fem
oral shaft fractures, 15 patients
with floating knees, 31 patients
suffering massive multiple injuries
and 20 patients whose mobility was
compromised by comorbid disease
or prior injury. Only 47 index cases
(39 male, 8 female) were thereby
available for review.
After appropriate review of the
HMRI records and radiographic
files, the study patients were con
tacted by telephone for current sta

tus review and to confirm the accu
racy of the data on file.

Results
Demographics

The mean age of the patients was
22 years. Thirty-eight (81%) frac
tures were closed and 9 (19%) were
open. Three patients were known to
be unemployed at the time of inju
ry, and another was an unemploy
able schizophrenic. One geriatric
patient was retired. The mean
length of follow-up at the time of
review was 34.5 months from inju
ry.

in 67% of fractures [6 of 9] in this
group) and three were initially stati
cally locked (primary healing in
92% of fractures [34 of 37] in this
group).
Three patients requiring reopera
tion to achieve union had open
fractures (primary union in 67% [6
of 9]), and the other three were
initially closed (primary union in
92% [35 of 38]).
Delayed or nonunion was ma
naged by reoperation involving
overreaming and static renailing. In
these six patients, five fractures
united and one demonstrated per
sisting nonunion radiographically,
but the patient refused further in
tervention in the absence of symp
toms.

Etiology
Secondary Surgery fo r Pain

In all patients the fractures were
caused by blunt trauma: 35 (74%)
were driving a motor vehicle at the
time of injury, and 4 (9%) were
pedestrians struck by a vehicle; 4
(9%) were injured in falls, 3 (6%)
were injured at sport and 1 (2%)
was injured otherwise.
Prim ary Surgery

All patients underwent internal
fixation with either primary reamed
Grosse-Kempf or standard RussellTaylor nails. Eighty-nine percent of
primary operations were undertaken
within 72 hours of injury. Only one
nail was not locked; 37 (79%) were
statically locked, and 9 (19%) were
dynamic nailings, most of these
from early in the series.
Secondary Surgery for Nonunion

Six patients had delayed or non
union, defined by persisting pain
and tenderness with open fracture
lines radiologically 3 months or
more after the intramedullary nail
ing. Three of these were initially
dynamic nailings (primary healing

Twenty (43%) patients presented
with activity-related hip (14 pa
tients, 30%) or knee (6 patients,
13%) pain that appeared clinically
to be related to the implant. Remov
al of the implant was undertaken
electively at a mean of 20 months
after injury.
There were no repeat fractures
after implant removal (mean follow
up 15 months). Seventeen (85%) of
these patients had subsequent pain
relief, including 12 (86%) of the 14
patients who had hip pain and 5
(83%) of the 6 patients who had
knee pain.
Secondary Surgery fo r Im plant
Removal

In 19 patients not complaining of
pain, elective implant removal was
undertaken at a mean of 21 months
after injury on the advice of the
treating physician. Four (21%) pa
tients in this group noted that their
residual discomfort improved after
implant removal. No patient had
any increase in pain after secondary
surgery.
CJS, VOL. 36, NO. 5, OCTOBER 1993
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Secondary Surgery for Reinjury

One patient had a second motor
cycle accident 6 months after the
original injury, suffering fractures
through the locking screws at both
ends of his Grosse-Kempf nail (a
displaced subcapital fracture of the
femoral neck and a transcondylar
fracture of the distal femur). De
spite reoperation he did not do well
and remains disabled.
Return to Work

The reinjured patient’s devastat
ing injuries excluded him from this
analysis. The unemployable schizo
phrenic was also excluded as was
the retiree. Of the remaining 44
patients, 3 were unemployed at the
time of injury, leaving 41 patients
for analysis of return to work.
Patients returned to work on
average 4 months after injury. At
follow-up 33 patients (80%) had
returned to full-time preinjury em
ployment. Another four patients
(10%) were working full-time in
other jobs, and three (7%) were
working part-time. Only one patient
(2%) remained disabled at the time
of follow-up.

Discussion
Extensive documentation in the
current literature has established
reamed intramedullary nailing of
adult femoral shaft fractures as a
consistent, reliable treatment.1'3' 5
Technique in achieving optimum
radiographic and clinical union is
well described.2'67 Very little atten
tion has been given to the clinically
important issues of requirement for
secondary operation in united frac
tures, return to work or residual
disability.
Our review confirms the recog
nized high rate of primary fracture
union with this treatment1' 4 and the

low rate of complications after im
plant removal.2
We found that 43% of patients
with united fractures experienced
hip or knee pain after reamed in
tramedullary nailing. The cause of
this pain may be multifactorial.2'8 Of
these patients, 85% obtained signifi
cant relief of pain after implant
removal.
Ninety percent of patients re
turned to full-time employment. An
other 7% returned to part-time
work. Only 2% of adult patients
treated with primary reamed in
tramedullary nailing for isolated
fractures of the femoral shaft will
remain disabled 3 years after injury.

(enalaprilat)
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INDICATIONS AND CLINICAL USE
VASOTEC® is indicated in the treatment of essential or renovascular
hypertension; usually administered in association with other drugs,
particularly thiazide diuretics. Consider the risk of angioedema (see
WARNINGS). Normally used when a diuretic or beta-blocker was ineffective
or associated with unacceptable adverse effects. Can also be tried as initial
agent where a diuretic and/or beta-blocker is contraindicated or could
cause serious adverse effects.
Oral enalapril is also indicated in the treatment of congestive heart failure,
as adjunctive therapy in patients not responding adequately to digitalis and
diuretics.
Use of ACE inhibitors during the second and third trimesters of
pregnancy can cause injury or death of a developing fetus.
When pregnancy is detected, discontinue VASOTEC® as soon as
possible (see WARNINGS; Use in Pregnancy).
VASOTEC® I.V. (enalaprilat) is an active metabolite of enalapril; the onset
of action after administration occurs within 15 minutes, with the maximum
effect within 1 to 4 hours.
VASOTEC® I.V. is indicated for the treatment of hypertension when oral
therapy is not practical. VASOTEC® I.V. has been studied with only one
other antihypertensive agent, furosemide, which showed additive effects on
blood pressure. Due to insufficient experience in the treatment of acceler
ated or malignant hypertension, VASOTEC® I.V. is not recommended in
such situations (see DOSAGE and ADMINISTRATION).

CONTRAINDICATIONS
Hypersensitivity to any component; history of angioneurotic edema related
to ACE inhibitor therapy.
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WARNINGS
Angioedem a, with laryngeal edema and/or shock, have been reported
and may be fatal. In such cases, discontinue drug promptly and observe
patient until swelling subsides. Swelling confined to the face, lips, and
mouth usually resolves without treatment, although antihistamines may be
useful in relieving symptoms. However, where there is involvement o f the
tongue, glottis and larynx, likely to cause airway obstruction, prompt
adm inistration of subcutaneous adrenaline (0.5 mL 1:1000) may be
indicated. Patients with a history of angioedema, unrelated to ACE inhibitor
use, may be at increased risk (see CONTRAINDICATIONS).
Symptomatic hypotension has occurred, usually during initial therapy
or when the dose was increased, and is more likely in patients who are
volume-depleted. In patients with severe congestive heart failure, excessive
hypotension may be associated with oliguria and/or progressive azotemia.
For patients in whom the excessive hypotension could result in severe or
fatal complications, i.e. those with severe congestive heart failure, ischemic
heart or cerebrovascular disease - start therapy under close medical
supervision, usually in a hospital. Such patients should be followed closely
for the potential fall in blood pressure during first two weeks of therapy or
when enalapril or a diuretic is increased. If hypotension occurs, place
patient in supine position and if needed, administer IV infusion of normal
saline. A transient hypotensive response is not a contraindication to further
doses of enalapril or enalaprilat.
Neutropenia/agranulocytosis and bone marrow depression have been
caused by ACE inhibitors. Current experience with enalapril shows
incidence to be rare. Consider periodic monitoring of white blood cell
counts in patients with collagen vascular disease and renal disease.
Use of ACE inhibitors in pregnancy can cause fetal and neonatal
m orbidity and m ortality. When pregnancy is detected, discontinue
VASOTEC® as soon as possible. Rarely, no alternatives to an ACE inhibitor
will be found and mothers should be apprised to the potential hazards to
the fetus. Ultrasound should be performed to assess fetal development,
well-being and volume of amniotic fluid. If oligohydramnios is observed,
discontinue VASOTEC unless lifesaving for the mother. A non-stress test
and/or a biophysical profiling may be appropriate however, if concerns
persist, a contraction stress testing should be considered. O ligo
hydramnios may only appear after fetus has sustained irreversible injury.
Closely observe infants exposed in utero\o ACE inhibitors for hypotension,
oliguria and hyperkalemia, and initiate appropriate corrective medical
procedures.
Hum an Data: Exposure to ACE inhibitors during second and third
trim esters has been associated w ith hypotension, neonatal skull
hypoplasia, anuria, reversible or irreversible renal failure and death of the
fetus. O ligohydram nios, associated with fetal lim b contractures,
craniofacial deformation, and hypoplastic lung development also has been
reported. Prematurity and patent ductus arteriosus also reported but
unknown if due to ACE inhibitor use. It is not known whether exposure
limited to the first trimester can adversely affect fetal outcome.

PRECAUTIONS
Im paired renal function: Renal function should be assessed before
in itia ting therapy w ith enalapril or enalaprilat. Patients with renal
insufficiency may require reduced or less frequent doses, and their renal
function must be monitored appropriately (see DOSAGE). Renal failure,
which has been reported mainly in patients with severe congestive heart
failure or underlying renal disease including renal artery stenosis is
usually reversible when treated promptly.
Some hypertensive patients with no apparent renal disease have developed
increases in BUN and creatinine while on concurrent diuretic/ enalapril
therapy. Dosage reduction or discontinuation of one or both drugs may be
required.
®Trademark Merck & Co., Inc./Merck Frosst Canada Inc., R.U.
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H yp e rkalem ia : In clinical trials, hyperkalemia (>5.7 m m ol/L) was
observed in approximately 1% of hypertensive patients, and caused
discontinuation of therapy in 0.28% of such patients. Risk factors tor
hyperkalemia development may include renal insufficiency, diabetes
m ellitus, and concom itant use of agents to treat hypokalemia (see
ADVERSE REACTIONS).
Valvular Stenosis: Theoretically, patients with aortic stenosis, who do
not develop as much afterload reduction, might be at risk of decreased
coronary perfusion when treated with vasodilators.
S urg e ry/A n aes th esia: During major surgery or anaesthesia with
hypotensive agents, enalapril blocks angiotensin II formation secondary to
compensatory renin release. Hypotension that develops due to this
mechanism can be corrected by volume expansion.
Im paired liver function: Hepatitis, jaundice (hepatocellular and/or
cholestatic),elevation of liver enzymes and/or serum bilirubin, which have
occurred in patients with or without pre-existing liver abnormalities, were
usually reversed on discontinuation of enalapril or enalaprilat. For any
unexplained symptoms, particularly within the first months of treatment, a
full set of liver function tests and other necessary investigations are recom
mended. Consider discontinuation of enalapril or enalaprilat when
appropriate. Use enalapril or enalaprilat with particular caution in patients
with pre-existing liver abnormalities. Obtain baseline liver function tests
before initiating drug and monitor response and metabolic effects closely.
Cough: A dry, persistent cough has been reported, w hich usually
disappears after withdrawal or lowering the dose or enalapril or enalaprilat.
Nursing mothers: Enalapril and enalaprilat are secreted in human milk in
trace amounts therefore, nursing should be interrupted.
Pediatric use: This use is not recommended because enalapril and
enalaprilat have not been studied in children.
Hem odialysis patients: Anaphylactoid reactions have been reported
with high-flux membranes (eg. polyacrylonitrile [PAN]) and treated
concom itantly w ith an ACE inhibitor. If symptoms such as nausea,
abdominal cramps, burning, angioedema, shortness of breath and severe
hypotension occur, stop dialysis immediately. The symptoms are not
relieved by antihistamines and the use of a different type of dialysis
membrane or class of antihypertensive agent should be considered.
Drug Interactions
Hypotension - Patients on D iuretic Therapy: Particularly when
diuretics recently initiated, patients occasionally experience hypotension
after initiating therapy with enalapril or enalaprilat. To minimize the
hypotensive effects, discontinue the diuretic or increase the salt intake prior
to starting the drug. If the diuretic cannot be discontinued, patients should
be placed under close medical supervision for at least one hour after the
initial dose of enalaprilat (see WARNINGS).
Agents Increasing Serum Potassium: Since enalapril and enalaprilat
decrease aldosterone production, elevation of serum potassium may occur.
Diuretics such as spironolactone, triamterene or amiloride, or potassium
supplements should be given cautiously for documented hypokalemia only
and should be monitored frequently. Potassium containing salt substitutes
should be used with caution.
Agents Causing Renin Release: Diuretics, fpr example, augment the
antihypertensive effect of enalapril and enalaprilat
Agents Affecting Sympathetic Activity: Ganglionic blocking agents
or adrenergic neuron blocking agents, for example, may be used with
caution. Beta-adrenergic blockers add some further antihypertensive effect
to enalapril.
Lithium Salts: Lithium clearance may be reduced; therefore, monitor
serum lithium levels carefully if they are administered.

ADVERSE REACTIONS
VASOTEC®: In controlled clinical trials involving 2314 hypertensive
patients and 363 heart failure patients, the most severe adverse reactions
were: angioedema (0.2%), hypotension (2.3%) and renal failure (5 cases).
In hypertensive patients, hypotension occurred in 0.9% and syncope in
0.5%, with a discontinuation rate of 0.1%. In heart failure patients,
hypotension occurred in 4.4% and syncope in 0.8%, with a discon
tinuation rate of 2.5%. The most frequent clinical adverse reactions in
controlled clinical trials were: headache (4.8%), dizziness (4.6%) and
fatigue (2.8%). Discontinuation of therapy was required in 6.0% of the
2677 patients.
Hypertension
Heart Failure
%

(2314 Patients)
CARDIOVASCULAR
Hypotension
Chest Pain
Palpitations
Myocardial Infarction, Acute
Myocardial Infarction, Recurrent
GASTROINTESTINAL
Nausea
Vomiting
Dysphagia
Diarrhea
Abdominal pain
RENAL
Renal failure
Oliguria
Proteinuriat
DERMATOLOGIC
Rash
Pruritus
NERVOUS SYSTEM
Headache
Dizziness
Insomnia
Nervousness
Somnolence
Paresthesia
ALLERGIC
Cough
Angioedema
HEMATOLOGIC
Anemia
Leukopenia
MISCELLANEOUS
Muscle cramps
Dyspnea

%

(3 6 3 P a tie n ts )

0.9
0.9
0.6
0.2
—

4.4
1.7
0.3
0.6
0.3

1.4
0.8
0.1
1.4
0.7

1.1
1.7

0.1
1 case
0.1

0.6
—
—

—

3.0
1.4

MISCELLANEOUS (cont'd)
0.7
Hyperhidrosis
0.4
0.3
Impotence
1.4
3.0
Fatigue
0.4
0.3
Taste disturbance
t Defined as > 1g/24h or >0.5 g/12h on two consecutive measurements,
at least one month apart.
ABNORMAL LABORATORY FINDINGS
Hyperkalem ia: (see PRECAUTIONS).
Creatinine, Blood Urea Nitrogen: Increases were reported in about
20% of patients with renovascular hypertension and about 0.2% of patients
with essential hypertension on enalapril alone. Increases, which usually
were reversible upon discontinuation of enalapril or concomitant therapy,
were reported in 9.7% of heart failure patients who were receiving diuretics
and/or digitalis.
Hemoglobin and Hem atocrit: Decreases (mean approximately 0.34
g% and 1.0 vol% , respectively) occurred frequently, but were rarely of
c lin ic a l im portance. In clin ic a l trials, less than 0.1% of patients
discontinued therapy due to anemia.
Hepatic: Elevations of liver enzymes and/or serum bilirubin have occurred
(see PRECAUTIONS).
ADVERSE REACTIONS REPORTED IN UNCONTROLLED TRIALS
AND/OR MARKETING EXPERIENCE
W ith an in c id e n c e of 0 .5 to 1% : Insom nia, impotence, renal
dysfunction, renal failure and oliguria.
W ith an incidence < 0.5% :
C ardiovascular: Myocardial infarction or cerebrovascular accident,
possibly secondary to excessive hypotension in high risk patients (see
WARNINGS); cardiac arrest; pulmonary embolism; rhythm disturbances;
angina pectoris. G a s tro in te s tin a l: Anorexia; ileus; pancreatitis;
dyspepsia; constipation. Hemopoeitic: Neutropenia; thrombocytopenia;
bone marrow depression. Hepatic: Liver function abnormalities; hepatitis;
jaundice (hepatocellular and/or cholestatic) Nervous S y s te m /
Psychiatric: Vertigo; depression; confusion; ataxia. Respiratory:
Bronchospasm /asthm a; rhinorrhea. O ther: Erythema m ultiform e;
exfoliative derm atitis; Stevens-Johnson syndrome; toxic epidermal
necrosis; urticaria; photosensitivity; alopecia; flushing; tinnitus; hearing
impairment; glossitis; blurred vision. A symptom complex has been
reported w hich may include fever, serositis, vasculitis, m yalgia,
arthralgia/arthritis, a positive ANA, elevated erythrocyte sedimentation rate,
e o s in o p h ilia and leuko cytosis. Rash, photo se n sitiv ity or other
dermatologic manifestations may occur. These symptoms have disap
peared after discontinuation of therapy.
LABORATORY TEST FINDINGS: Hyponatremia
VASOTEC® I.V .: Since enalapril is converted to enalaprilat, those
adverse reactions associated w ith VASOTEC® tablets might also be
expected to occur with VASOTEC® I.V. The incidence of symptomatic
hypotension is 3.4% with VASOTEC® I.V. Other adverse experiences
occurring in greater than 1% of patients were headache (2.9%) and nausea
(1.1 %). Adverse reactions occurring in 0.5 to 1.0% of patients in controlled
clinical trials include myocardial infarct, fatigue, dizziness, fever, rash and
constipation.

_

SYMPTOMS AND TREATMENT OF OVERDOSAGE
Lim ited human data are available. The most likely manifestation of
overdosage would be hypotension, which can be treated by I.V. infusion of
normal saline solution. Enalaprilat may be removed from the general
circulation by hemodialysis.

DOSAGE AND ADMINISTRATION
VASOTEC® FOR ORAL ADMINISTRATION ONLY
Dosage must be individualized. The absorption of enalapril maleate is not
affected by food.
HYPERTENSION
Initiation of enalapril requires consideration of extent of blood pressure
elevation, salt restriction and recently used anti hypertensive agents, the
dosage of which may need to be adjusted.
The recommended initial dose of enalapril maleate in patients not on
diuretics is 5 mg once a day. Adjust dosage according to blood pressure
response; the usual range is 10 to 40 mg daily, in a single dose or divided
in two doses. Some patients on once-daily dosage may have diminished
antihypertensive effect toward the end of dosing interval and require an
increase in dosage, or twice daily administration. If blood pressure is not
controlled, a diuretic may be added. Raising the daily dose above 40 mg is
not recommended because adverse reactions may be increased.
Occasionally symptomatic hypotension may occur following the initial
dose, more likely in patients currently taking a diuretic. Therefore, if
possible, discontinue the diuretic two to three days before initiating
enalapril therapy (see WARNINGS). If the diuretic cannot be discontinued,
use an initial dose of 2.5 mg.
In the absence of sufficient experience in the treatment of accelerated or
malignant hypertension, enalapril is not recommended in such situations.
Dosage in the Elderly (over 65 years): Start at 2.5 mg daily. Some
elderly patients may be more responsive than younger patients.
Dosage Adjustment in Renal Im pairm ent: (see PRECAUTIONS Hemodialysis patients)
Guidelines for reducing doses in hypertensive patients:

Renal Status
1.4
0.4

1.9
1.4

5.2
4.3
0.5
0.6
0.6
0.6

2.2
6.6
0.3

1.3
0.2

1.4
—

0.1
1 case
0.6
0.6

—

—
—

_

—
0.3
1.1

Normal renal
function
Mild impairment
Moderate to
severe impairment
Dialysis patients

Creatinine
Clearance
m L/m in(m L/s)
>80 mL/min
(>1.33 mL/s)
< 80 >30 mL/min
(<1.33 >0.50 mL/s)
£ 3 0 mL/min
(<0.50 mL/s)

Initial Dose
mg/day

When in itia tin g enalapril consider the recent diuretic therapy and
possibility of severe salt/ volume depletion. Before beginning enalapril
reduce diuretic therapy if possible.
The recom m ended in itia l d a ily dose is 2.5 mg. W hile m anaging
sym ptom atic hypotension, increase dose gradually, depending on
individual response, to the usual maintenance dose of 10-20 mg daily,
given in a single dose or divided in two doses. This dose titration may be
performed over a two- to four-week period, or more rapidly if indicated by
residual signs and symptoms of heart failure. The maximum daily dose is
40 mg.
VASOTEC® I.V . FOR INTRAVENOUS ADMINISTRATION ONLY
VASOTEC® I.V. vials should be inspected visually and should not be used
if particulate matter or discoloration is observed.
VASOTEC® I.V. may be administered intravenously as supplied, or mixed
with up to 50 mL of one of the following diluents:
5% Dextrose Injection
0.9% Sodium Chloride Injection
0.9% Sodium Chloride Injection in 5% Dextrose
5% Dextrose in Lactated Ringer’s Injection
Diluted solutions should be used within 24 hours.
The dose is 1.25 mg every 6 hours administered intravenously over at least
5 minutes. A clinical response is usually seen within 15 minutes. Peak
effects after the first dose may not occur for up to four hours after dosing.
The peak effects of the second and subsequent doses may exceed those of
the first.
No dosage regimen for VASOTEC® I.V. has been clearly demonstrated to'
be more effective in treating hypertension than 1.25 mg every 6 hours.
However, in controlled clinical studies in hypertension, doses as high as 5
mg every 6 hours were well tolerated for up to 36 hours. There has been
inadequate experience with doses greater than 20 mg per day.
In studies of patients with hypertension, VASOTEC® I.V, has not been
administered for periods longer than 48 hours. In other studies, patients
have received VASOTEC® I.V. for as long as 7 days.
The dose for patients being converted to VASOTEC® I.V. from oral therapy
for hypertension w ith enalapril maleate is 1.25 mg every 6 hours
administered intravenously over at least 5 minutes. For conversion from
intravenous to oral therapy, the recommended initial dose of VASOTEC®
tablets is 5 mg once a day with subsequent dosage adjustm ents as
necessary.
Patients on D iuretic Therapy
For patients on diuretic therapy, the recommended starting dose for
hypertension is 0.625 mg adm inistered intravenously over at least
5 minutes. A clinical response is usually seen within 15 minutes. Peak
effects after the first dose may not occur for up to 4 hours after dosing,
although most of the effect is usually apparent within the first hour. If after
1 hour there is an inadequate clinical response, the 0.625 mg dose may
be repeated. Additional doses of 1.25 mg may be administered at 6 hour
intervals.
For conversion from intravenous to oral therapy, the recommended initial
dose of VASOTEC® tablets for patients who have responded to 0.625 mg of
enalaprilat every 6 hours is 2.5 mg once a day with subsequent dosage
adjustment as necessary.
Dosage Adjustm ent in Renal Im pairm ent
The usual dose of 1.25 mg of enalaprilat every 6 hours is recommended for
patients with a creatinine clearance >30 mL/min [> 0.50 mL/s] (serum
creatinine up to approximately 3 mg/dL [265.2 pmol/L]). For patients with
creatinine clearance < 30 m L/m in [< 0.50 m L/s] (serum creatinine
> 3 mg/dL [> 265.2 |jmol/L]), the initial dose is 0.625 mg (see WARNINGS).
If after 1 hour, there is an adequate clinical response, the 0.625 mg dose
may be repeated. Additional doses of 1.25 mg may be administered at
6 hour intervals.
For dialysis patients, the initial dose should be 0.625 mg every 6 hours,
(see PRECAUTIONS - Hemodialysis patients).
For conversion from intravenous to oral therapy, the recommended initial
dose of VASOTEC® is 5 mg once a day for patients w ith creatinine
clearance >30 mL/min [>0.50 mL/s] and 2.5 mg once daily for patients with
creatinine clearance <30 mL/min [<0.50 mL/s]. Dosage should then be
adjusted according to blood pressure response.

AVAILABILITY OF DOSAGE FORMS
Barrel-shaped, biconvex tablets, engraved with code number on one side
and VASOTEC on other.
VASOTEC® 2.5 mg - yellow, scored, engraved 14.
VASOTEC® 5 mg - white, scored, engraved 712.
VASOTEC® 10 mg - rust-red, engraved 713.
VASOTEC® 20 mg - peach, engraved 714.
All strengths available in bottles of 100 tablets.
VASOTEC® I.V. 1.25 mg per mL, is a clear, colourless solution and is
supplied in vials containing 2 mL.

PRODUCT MONOGRAPH AVAILABLE ON REQUEST
(490iv-a.11.92)
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Anterior and Posterior Spinal Fusion:
Comparison of One-Stage and Two-Stage
Procedures
G. Richard Viviani, MD, FRCSC;* Viorel Raducan, MD, FRCSC;t
Drew A. Bednar, MD, CM, FRCSC, FAAOS;* Waldemar Grandwilewski, MD*
Objective: To compare postoperative morbidity and length of hospital stay after combined anterior and
posterior spinal fusion for patients treated by a one-stage procedure and those treated in two stages, 1
to 2 weeks apart.
Design: Retrospective review of all cases handled by the first author between July 1989 and November
1991. The patients had been referred for treatment of severe spinal deformity, scoliosis or kyphosis by
combined anterior and posterior spinal fusion.
Setting: The operations were performed at McMaster University Medical Centre, Hamilton, Ont., by the
first author, who was assisted by another specialist in spinal surgery and a fellow or resident.
Patients: Eleven operations of each type were performed. The mean age of the 22 patients was 16.6 and
14.6 years for those who underwent the one-stage and the two-stage procedures respectively. The
diagnoses included neuromuscular disease, neurofibromatosis, spina bifida, congenital kyphoscoliosis
and severe idiopathic spinal curvature. The one-stage procedure was used after the surgical team
became able to provide the care associated with this type of major surgery; selection of patients also
involved preoperative risk assessment and the feasibility of combining two surgical procedures that
would take a maximum of 9 hours. The preoperative plan was to spend a maximum of 9 hours in
performing the one-stage procedure.
Interventions: Similar surgical procedures were performed in both groups. The average number of
intervertebral levels fused during the anterior component of the operation was 4.6 in the one-stage
procedure and 6.0 in the two-stage procedure. Thoracolaparotomy was performed in four patients who
underwent the two-stage procedure. During the posterior component of the operation, instrumentation
was inserted through an average of 11.6 and 12.6 intervertebral levels in the groups undergoing the
one-stage and the two-stage procedures respectively. Total operating time averaged 7 hours and 15
minutes for the one-stage procedure and 11 hours for the two-stage procedure. Mean blood loss was
1830 mL for the one-stage procedure and 2270 mL for the two-stage procedure.
Main Outcome Measures: The number of days spent in the intensive care unit (ICU) and the total
number of days spent in hospital, as well as morbidity after the operation, were determined.
Results: Postoperative morbidity included five minor complications in patients who underwent a
one-stage procedure; all of these complications resolved well. Among those who underwent the
two-stage procedure there were 11 complications; in two patients further surgery was required. The
patients’ stay in the ICU averaged 2.6 and 7.7 days respectively for one-stage and two-stage
procedures, and the total stay in hospital averaged 14 and 33 days respectively.
Conclusions: When possible, the one-stage procedure for anterior and posterior spinal fusion is
preferred over the two-stage procedure because of a significant reduction in the length of stay in the
ICU and in hospital, as well as reduced morbidity. However, this analysis should be interpreted
cautiously because of the small number of cases and the variables encountered in treating this type of
spinal deformity.
From the *Division o f Orthopedic Surgery, Department o f Surgery, McMaster University, Hamilton, Ont., and the f Division o f Orthopedic Surgery
Department o f Surgery, University o f Manitoba, Winnipeg, Man.
Accepted fo r publication Apr. 6, 1993
Reprint requests to: Dr. C. Richard Viviani, McMaster University Medical Centre, 1200 Main St. W „ Hamilton, ON L8N 3Z5
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Objectif: Comparer la morbidite postoperatoire et la duree de l’hospitalisation apres une fusion
anterieure et posterieure simultanee des vertebres chez les patients traites au moyen d’une
intervention en une etape et chez ceux qui sont traites au moyen d’une intervention en deux etapes
espacees d’une ou 2 semaines.
Conception : Etude retrospective de tous les cas dont le premier auteur a ete responsable entre juillet
1989 et novembre 1991. Les patients avaient ete presentes pour traitement de malformation grave de la
colonne vertebrale, de scoliose ou de cyphose au moyen d’une fusion anterieure et posterieure
simultanee des vertebres.
Contexte : Le premier auteur a realise les operations au Centre medical de l’Universite McMaster avec
l’aide d’un autre specialiste en chirurgie de la colonne vertebrale et d’un associe ou d’un resident.
Patients : On a effectue 11 operations de chaque type. En moyenne, les 22 patients qui ont subi
l’intervention en une etape etaient ages de 16,6 ans et ceux qui ont subi 1’intervention en deux etapes
etaient ages de 14,6 ans. Les diagnostics portaient sur des maladies neuromusculaires, la
neurofibromatose, le spina-bifida, la cyphoscoliose congenitale et une grave courbure rachidienne
idiopathique. Lorsque l’equipe chirurgicale a ete en mesure de fournir les soins lies a ce type de
chirurgie lourde, on a pratique l’intervention en une etape; la selection des patients comportait aussi
une evaluation des risques preoperatoires et de la faisabilite de combiner deux interventions
chirurgicales d’une duree de 9 heures. La planification chirurgicale a donne lieu a un plan
preoperatoire qui consistait a consacrer 9 heures au maximum a la realisation de l’intervention en une
etape.
Interventions : Dans les deux groupes, on a effectue des interventions chirurgicales semblables. Au
cours de la composante anterieure de l’operation, on a fusionne un nombre moyen de 4,6 etages
intervertebraux dans le cadre de l’intervention en une etape et de 6,0 etages intervertebraux dans le
cadre de l’intervention en deux etapes. Chez quatre patients qui ont subi l’intervention en deux etapes,
on a pratique une thoracolaparotomie. Au cours de la composante posterieure de l’operation, on a
introduit des instruments dans 11,6 et 12,6 etages intervertebraux en moyenne pour les groupes qui
ont subi respectivement les interventions en une etape et en deux etapes. La duree totale de l’operation
etait de 7 heures et 15 minutes en moyenne pour l’intervention en une etape et de 11 heures pour
l’intervention en deux etapes. La perte sanguine moyenne etait de 1 830 mL pour l’intervention en une
etape et de 2 270 mL pour l’intervention en deux etapes.
Principales mesures des resultats : On a determine le nombre de jours passes a l’unite des soins
intensifs (USI) et le nombre total de jours d’hospitalisation, de meme que la morbidite apres
l’operation.
Resultats : La morbidite postoperatoire regroupait cinq complications legeres chez des patients qui ont
subi l’intervention en une etape; toutes ces complications ont eu une issue positive. Chez ceux qui ont
subi l’intervention en deux etapes, 11 complications sont survenues ; deux patients ont eu besoin de
chirurgie supplemental. Le sejour des patients a l’USI a dure en moyenne 2,6 et 7,7 jours
respectivement pour les interventions en une etape et en deux etapes, et la duree respective
l’hospitalisation etait de 14 et 33 jours au total.
Conclusions : Dans la mesure du possible, il faut preferer l’intervention en une etape pour la fusion
anterieure et posterieure des vertebres a 1’intervention en deux etapes etant donne une reduction
significative de la duree du sejour a l’USI et de l’hospitalisation, de meme qu’une morbidite reduite.
Cependant, cette analyse devrait etre interpretee prudemment en raison du petit nombre de cas et des
variables rencontrees dans le traitement de ce type de malformation de la colonne vertebrale.

he treatment of severe spinal
deformity represents a major
challenge, one that often requires
both anterior and posterior ap
proaches to spinal fusion to achieve
optimal realignment and consistent
arthrodesis. The advantages of this
aggressive approach are well docu
mented.1-10 Such major reconstruc
tive surgery has traditionally been
performed in stages because of con

T

cerns about the length of the proce
dure and surgeon fatigue. However,
it has recently been recognized that
appropriately trained and prepared
surgical teams can perform such
operations in one stage. The major
potential advantages include de
creased morbidity and diminished
length and cost of the stay in
hospital.11
Staged procedures have been the

routine at our centre, but recent
recruitment of staff presented the
opportunity for a team of two quali
fied surgeons to undertake such
procedures in one stage. A protocol
was devised to allow for the com
parison of a series of patients treat
ed by the one-stage procedure with
a previous series of the same num
ber of patients who had been treat
ed in two stages. This study was
CJS, VOL. 36, NO. 5, OCTOBER 1993
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not randomized or blinded, as such
a design was not possible for treat
ing patients with these abnormali
ties. Consequently, the results of'
the comparison should be interpret
ed cautiously.
Planning for the one-stage proce
dure was complex, because such
surgery necessitates multidiscipli
nary support both during and after
the operation. Contributions from
the departments of anesthesia and
critical care were of particular im
portance.

Patients and Methods
Between July 1989 and Novem
ber 1991, 22 consecutively referred
patients underwent combined ante
rior and posterior spinal fusion for
severe spinal deformity. Eleven pa
tients underwent the operation in
two stages separated by 1 to 2
weeks, and 11 underwent the onestage procedure, in which one of
the authors (G.R.V.) was supported
by another trained spinal surgeon
and a senior resident.
Preoperative evaluation for the
patients scheduled to undergo the
one-stage procedure included con
sultations with the anesthetist and a
critical care physician. Several pa
tients made preoperative autolo
gous blood donations, but no in
traoperative blood salvage was pos
sible. During preoperative planning
an arbitrary goal of a maximum of
9 hours operating time was estab
lished in consideration of the pa
tients’ well-being, the availability of
time in the operating room and the
availability of an anesthetist.
After surgery, every patient was
admitted to the intensive care unit
(ICU), where his or her condition
was monitored routinely until it was
stable enough for the patient to be
moved to the ward. Patients who
underwent the two-stage procedure
were admitted to the ICU twice.
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The surgical technique included
rigid internal fixation to allow rapid
primary mobilization without orthotic support or restriction.

Results

for a mean of 2.2 levels in the
one-stage group and 4.7 levels in
the two-stage group.
Fusion and instrumentation dur
ing the posterior component were
of similar extent in the two groups
(Table II).

Demographics

D uration o f the O peration

The three females and eight
males who underwent the one-stage
procedure ranged in age from 7 to
40 years (mean 16.6 years); six
were between the ages of 7 and 13
years.
The eight females and three
males who underwent the two-stage
procedure ranged in age from 7 to
30 years (mean 14.6 years). Seven
of the patients in this group were
between the ages of 7 and 13 years.

For patients who underwent the
one-stage procedure the mean dura
tion of the anterior component was
3 hours (range from 2 to 4 hours)
and of the posterior component 4
hours (range from 3.5 to 6.0
hours); the mean total operating
time was 7 hours.
For patients who underwent the
two-stage procedure the mean dura
tion of the anterior component was
6.5 hours (range from 4 to 7
hours); the mean total operating
time was 11 hours. The mean dura
tion of the posterior component was
5.5 hours (range from 3.5 to 8
hours); the mean total operating
time was also 11 hours.

Diagnoses

The patients in both groups ex
hibited a wide variety of conditions
producing major spinal deformity
(Table I). These conditions included
neuromuscular disease, neurofi
bromatosis, dysraphism, congenital
scoliosis and kyphosis, as well as
high-grade idiopathic curvature
(Fig. 1).
S urgical Procedure

The surgical undertaking was of
a similar magnitude in the two
groups, the major difference being
the anatomic extent of the anterior
surgery. Thoracolaparotomy was
not performed in the one-stage
group but was performed four times
in the two-stage group. This differ
ence may have led to the greater
postoperative morbidity observed in
the latter group.
The anterior component involved
fusion of a mean of 4.6 interverte
bral levels in the one-stage group
and 6.0 levels in the two-stage
group. Instrumentation was used

B loo d Loss

The mean blood loss was 1830
mL (range from 500 to 5400 mL)
among patients who underwent the
one-stage procedure and 2270 mL
(range from 650 to 2850 mL)
among those who underwent the
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two-stage procedure. In spite of the
similar amounts of blood lost, the
latter group received substantially
more blood product replacement
(mean of 4.9 and 12.5 units for the
one-stage and the two-stage groups
respectively). Most blood product
replacement occurred after the op
eration, in the ICU; the higher
amount of blood product replace
ment among the patients who un
derwent the two-stage procedure
may relate to attempts to optimize
the hemodynamic variables before
the second stage.

Length of Stay
Patients who underwent the one-

stage procedure spent an average
of 2.6 days (ranging from 1 to 5
days) in the ICU, whereas those
who underwent the two-stage pro
cedure spent an average total of
7.7 days in the ICU. This included
a mean of 4.9 days (ranging from
1 to 12 days) after the first stage
and a mean of 2.9 days (ranging
from 1 to 6 days) after the second
stage.
The total number of days spent in
hospital averaged 14 (range from
10 to 20) for the patients who
underwent the one-stage procedure.
The mean length of stay in the
other group was more than twice as
long: 33 days (range from 20 to 73
days).

Complications
Major complications, all of a
medical nature (Table III), occurred
in only five of the patients who
underwent the one-stage procedure.
These complications included one
case of sepsis and one of respiratory
failure secondary to crystalloid
overload; both patients recovered
well. There were no neurologic in
juries or failures of instrumentation
in these patients, nor were there
any thrombotic episodes.
Eight of the 11 patients in the
group that underwent the two-stage
procedure suffered serious compli
cations, including three episodes of
infection and two of pulmonary

FIG. 1. (Left) Spinal curvature of 85° and 55° in 23-year-old man with sequela of meningitis and hemiparesis. He was
treated by one-stage spinal fusion, which included thoracotomy of fourth rib, diskectomy of third to ninth thoracic vertebrae (T3
to T9) and insertion of Dwyer instrumentation through T4 to T8, and Cotrel-Dubousset instrumentation through T2 to T12.
Operation took 9 hours, and patient received 4 units of blood. (Right) Six months later spinal curvature has been reduced to 30°
and 25°.
CJS, VOL. 36, NO. 5, OCTOBER 1993
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complications. One patient experi
enced foot drop, which resolved
after revision surgery, and one ex
perienced deep vein thrombosis,
which necessitated placement of a
Greenfield filter.

Cost
We were unable to arrange a
case-specific cost analysis before
this study was undertaken, and at
tempts to perform a retrospective
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analysis yielded inconsistent infor
mation.
However, a good approximation
of costs can be drawn from the data
concerning length of stay. Per diem
costs at McMaster University Medi
cal Centre average $625, so the
mean reduction in duration of hos
pital stay (17 days) in the patients
who underwent the one-stage pro
cedure could represent a net cost
saving of $10 625 per patient. This
analysis almost certainly represents
an underestimate of the savings,
since time spent in the operating
room and the ICU is even more
expensive.

Discussion
The combined anterior and poste
rior approach with fusion and in
strumentation for the treatment of
severe spinal deformities is increas
ingly well accepted. Numerous au
thors from around the world have
documented the advantages of this
approach in various settings.3-5-12
Leatherman and Dickson12 and
Winter, Moe and Lonstein13 advo
cated a two-stage approach in deal
ing with congenital spinal deformi
ties. Swank, Cohen and Brown10
and O’Brien9 arrived at the same
conclusion in treating neuromuscu
lar scoliosis, and Banta14 proved the
same point in treating spinal defor
mities in dysraphic patients.
These authors unanimously
stressed the benefits of two-stage
surgery in achieving optimal correc
tion of deformity and consistent
arthrodesis. This principle holds
even when the results for lesser
curves treated by more traditional
single-stage posterior surgery are
compared with those for severe
curves treated in two stages.10-13
The reported complication rates
for two-stage spinal fusion range
from as low as 10%12 to as high as
42%14 and 50%.2 The potential for
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frequent major complications in
such operations is considerable,
particularly during the interval be
tween stages when the patient may
undergo enforced bed rest. Most
complications do not necessitate
surgery or are of a medical na
ture;2’14 they often involve respira
tory, urinary, cardiac, thrombotic or
coagulopathic conditions. The com
promised metabolic status in pa
tients approaching the second stage
of surgery may also be an adverse
factor.8
Another potential difficulty is the
loss of benefit from anterior release
in patients who become too ill to
undergo the second stage of the
procedure at an appropriate time.
The concept of one-stage com
bined surgery is not new; it was
first discussed more than 15 years
ago.11 In 1991 Schufflebarger and
colleagues15 published a retrospec
tive analysis of 75 patients. They
compared staged and same-day sur
gery and defined benefits similar to
those that we found in a similarly
heterogeneous group of patients.
Mendelbaum and colleagues8
stressed the potential for nutritional
and immunologic compromise in
patients who underwent a two-stage
operation and found a high frequen
cy of compromise after both the
first and especially the second
stages. There was a statistically
significant association between
staged surgery and the occurrence
of infection. Similar conclusions,
recently presented to the American
Academy of Orthopaedic Surgeons,
were reached by Dick, BoachieAdjei and Wilson.1 The lesson that
orthopedic trauma is better ma
naged in one stage than in multiple
stages seems to be reinforced by
these findings.
Our data suggest that there are
significant benefits to performing
anterior and posterior spinal fusion
in one stage; these benefits include
decreased length of stay in hospital

and the associated cost savings, as
well as a possible reduction in mor
bidity. These conclusions must be
judged cautiously, as the patients
were not prospectively randomized,
and differences in the diagnoses and
the patients’ conditions may explain
some of the results. Nevertheless,
this experience represents a trend
that is now occurring and reflects
how we have changed the treatment
of most such patients at our centre.
The one-stage treatment is current
ly preferred for resolving these diffi
cult spinal deformities, although
each case must be carefully as
sessed to determine whether this
option is the most appropriate. The
principal surgeon involved in this
review acknowledges that several of
the patients who were treated with
the two-stage procedure would be
treated with the one-stage proce
dure if they presented today.
The main consideration in not
choosing the one-stage operation is
the existence of spinal deformities
involving the thoracic and lumbar
spine, for which thoracolaparotomy
is required. We still consider this
procedure to be excessive if com
bined with an extensive posterior
surgical approach during the same
session. As the surgeons gain more
experience, this belief may change.
For ethical reasons and because of
the nature of the diagnoses and the
low number of patients, it does not
appear feasible to perform a pro
spectively randomized trial.

Conclusions
The one-stage combined anterior
and posterior procedure for fusion
in cases of severe spinal deformity
is a valid, safe and perhaps optimal
approach to these difficult clinical
problems. It allows for a significant
ly decreased length of hospital stay
and corresponding cost savings, as
well as possible decreased morbidity.
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attained after one day of Q.I.D. dosing. Following ora! administration, peak plasma concentra
tions of 0.7 to 1.1 ng/mL occurred at an average of 44 minutes after a single 10 mg dose. The
terminal plasma elimination half-life ranged between 2.4 and 9.0 hours in healthy adults, while in
elderly subjects (mean age = 72 years), it ranged between 4.3 and 7,6 hours. A high fat meal
decreased the rate, but not the extent, of absorption of oral ketorolac tromethamine.
The use of an antacid had no effect on the pharmacokinetics o f ketorolac. Following intramus
cular administration, peak plasma concentrations of 2.2 to 3.0 (ig/mL occurred an average of
50 minutes after a single 30 mg dose, The terminal plasma half-life ranged between 3.5 and 9.2
hours in young adults and between 4,7 and 8,6 hours in elderly su b ject (mean age = 72 years).
In renally impaired patients there is a reduction in clearance and an increase in the terminal
half-life of ketorolac tromethamine (see table below), The primary route of excretion of ketoro
lac tromethamine and its metabolites (conjugates and the p-hydroxy metabolite) is in the urine
(91,4%) with the remainder (6.1%) being excreted in the feces, More than 99% of the ketorolac
in plasma is protein bound over a wide concentration range, The hemodynamics of anaes
thetized patients were not altered by parenteral administration of Toradol.
THE INFLUENCE OF AGE, LIVER AND KIDNEY FUNCTION ON THE CLEARANCE
AND TERMINAL HALF-LIFE OF TORADOL IM1AND ORAL2
TYPES OF SUBJECTS

TOTAL CLEARANCE
(in L/h/kg)s
ORAL
MEAN
(range)

IM
MEAN
(range)

TERMINAL HALF-LIFE
(in hours)
ORAL
MEAN
(range)

IM
MEAN
(range)

Normal Subjects
IM(n=54)
Oral (n=77)

0.023
(0.0100.046)

0,025
(0.0130.050)

5.3
(3.5-9.2)

5.3
(2.4-9.0)

Healthy Elderly Subjects
IM (n=13). Oral (n=12)
(mean age = 72,
range = 65-78)

0.019
(0.0130.034)

0.024
(0.0180.034)

7,0
(4.7-86)

6.1
(4.3-76)

Patients with Hepatic
Dysfunction IM and Oral
(n=7)

0.029
(0.0130,066)

0.033
(0,0190.051)

5,4
(2.26.9)

4.5
(1.6-76)

Patients with Renal
Impairment IM and Oral
(n=9)(serum creatinine
1.9-5.0 m g/dL)

0,014
(0.0070,043)

0.016
(0.0070.052)

10,3
(8.1-15.7)

10,8
(3.4-18.9)

Renal Dialysis
Patients IM (n=9)

0.016
(0.0030.036)

13.6
(8.0-39.1)

' Estimated from 30 mg single IM doses of ketorolac tromethamine
2 Estimated from 10 mg single oral doses of ketorolac tromethamine
3 Litres/hour/kilogram
INDICATIONS:
Oral Route: Orally administered Toradol (ketorolac tromethamine) is indicated for the short
term m anagem ent of mild to m oderately severe pain, including post-surgical pain (such as
general, orthopaedic and dental surgery), acute musculoskeletal trauma pain and post-partum uterine cramping pain.
Intramuscular Route: Intramuscular injection of Toradol is indicated for the short-term man
agement of moderate to severe pain, including pain following major abdominal, orthopaedic
and gynecological operative procedures.
CONTRAINDICATIONS:
H y p e rs e n s itiv ity : Like o th e r n o n -s te ro id a l a n ti- in fla m m a to r y d ru g s, T o ra d o l
(ketorolac tromethamine) has been associated with hypersensitivity reactions, Toradol should
not be used when there is a known or suspected hypersensitivity to the drug. Because of the
possibility of cross-sensitivity, Toradol should not be used in patients with the complete or partial
syndrome of nasal polyps, angioedema, bronchospastic reactivity (e.g, asthma) or other aller
gic manifestations to acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory drugs.
Severe a n d fa ta l a n a p h y la c to id re a c tio n s h a ve o c c u rre d in such in d ividu a ls.
Gastrointestinal: As with other NSAIDs, Toradol also should not be used in patients with peptic
ulcer or active inflammatory disease of the gastrointestinal system. Severe and fatal reactions
have occurred in such individuals.
WARNINGS:
The lo n g -te rm a d m in is tra tio n o f T oradol (k e to ro la c tro m e th a m in e ) is n o t recom
mended. The most serious risks associated with NSAIDs including Toradol are:
Gastrointestinal Ulcerations, Bleeding and Perforation: Serious gastrointestinal toxicity, such
as bleeding, ulceration, and perforation, can occur at any time, with or without warning symp
toms, during therapy with non-steroidal anti-inflammatory drugs. To date, studies with NSAIDs have
not identified any subset of patients not at risk for developing peptic ulceration and bleeding.
Post-marketing experience with Toradol suggests that there may be a greater risk of gastrointesti
nal ulcerations, bleeding, and perforation in the elderly, and most spontaneous reports of fatal
gastrointestinal events are in the aged population.

LONG-TERM USE OF TORADOL: The oral use of Toradol 10 mg QID on a long-term basis is associat
ed with more gastrointestinal tract adverse effects than is ASA 650 mg QID.
In a clin ica l trial in 823 patients with chronic pain states com paring Toradol tablets 10
mg QID (553 patients) with ASA 650 mg QID (270 patients), during the first week there was a
2.4% dropout rate because of upper Gl complaints in the Toradol tablets treated patients as
compared with 0,4% rate in the ASA treated group. After the first 2 weeks, the dropout rates
due to Gl pain or discomfort were comparable in both treatment groups. The time-adjusted
percentages, which are not statistically significantly different, of patients who developed ulcers
or upper Gl bleeding are as follows:
CUMULATIVE OCCURRENCE
INTERVAL
KETOROLAC
ASA
<3 months
0,69*
0*
£ 6 months
1.59*
0.73*
'There was no statistically significant difference between ketorolac and ASA at either of the
intervals tested.
PHYSICIANS SHOULD CAREFULLY WEIGH THE POTENTIAL RISKS AND BENEFITS OF USING TORADOL
TABLETS ON A LONG-TERM BASIS. PATIENTS SHOULD BE INSTRUCTED TO WATCH FOR SIGNS OF
SERIOUS Gl ADVERSE EVENTS AND THEY SHOULD BE MONITORED MORE CLOSELY THAN IF THEY
WERE ON ANOTHER NSAID.
Renal Toxicity: The following renal abnorm alities have been associated with Toradol
and other drugs that inhibit renal prostaglandin biosynthesis: acute renal failure, nephrotic
syndrome, interstitial nephritis, renal papillary necrosis.
Haemorrhage: Postoperative haematomas and other symptoms of wound bleeding have
been reported in association with the perioperative use of intramuscular Toradol. If Toradol is
to be administered to patients who have coagulation disorders or who are receiving drug ther
apy that interferes with haemostasis, careful observation is advised.
Hypersensitivity Reactions: The possibility of severe or fa ta l hypersensitivity reactions
should be considered, even for patients with no known history of previous exposure or hyper
sensitivity to Toradol or other NSAIDs. As with other NSAIDs, patients should be questioned for
history of allergy to NSAIDs or ASA or for the syndrome consisting of nasal polyps, ASA allergy
and asthma before being prescribed Toradol, Asthmatic patients with triad asthma (the syn
drome of nasal polyps, asthma and hypersensitivity to ASA or other NSAIDs) may be a t particu
lar risk for severe hypersensitivity reactions.
Other NSAIDs: Ketorolac tromethamine is not recom m ended for concurrent use with other
NSAIDs because of the potential for additive side effects.
Use in Pregnancy and Lactation: The administration of ketorolac tromethamine is not recom
mended during pregnancy or lactation. After 1 day at 10 mg QID. oral dosing, Toradol has
been detected in the milk of lactating women a t a maximum concentration of 7.9 ng/mL.
Use in Labour: Ketorolac trom etham ine is not re co m m en d e d for use as an obstetrical
preoperative medication or for obstetrical analgesia because of the known effects of NSAIDs
on uterine contraction and fetal circulation.
Use in Children: Safety and e ffic a c y in children have not been established, Therefore,
Toradol is not recommended for use in children under age 16.
Use in the Elderly: Because ketorolac is cle a re d som ew hat m ore slowly by the elder
ly (See PHARMACOKINETICS) who are also more sensitive to the gastrointestinal and renal
effects of NSAIDs (See WARNINGS and PRECAUTIONS), extra caution and the lowest effective
dose (See DOSAGE AND ADMINISTRATION) should be used,
PRECAUTIONS:
Physicians should be alert to the pharmacologic similarity o f Toradol (ketorolac tromethamine)
to other non-steroidal anti-inflammatory drugs that inhibit cyclo-oxygenase. Toradol is not an
anesthetic agent and possesses no sedative or anxiolytic properties.
Gastrointestinal Effects: Close m e d ic a l supervision is re co m m e n d e d in p a tie n ts
prone to gastrointestinal tract irritation, particularly those with a history of peptic ulcer, diverticulosis or other inflammatory disease of the gastrointestinal tract. In these cases, the physician
must weigh the benefits of treatment against the possible hazards, P atients ta k in g any
NSAID in c lu d in g k e to ro la c tro m e th a m in e should be instructed to contact a physician
immediately if they experience symptoms or signs suggestive of peptic ulceration or gastroin
testinal bleeding. These reactions can occur at any time during the treatment. If peptic ulcer
ation is suspected or confirmed, or if gastrointestinal bleeding occurs, ketorolac tromethamine
should be discontinued and appropriate treatment instituted with close patient monitoring.
Renal Effects: As w ith oth er drugs th a t inhibit p ro sta g la n d in biosynthesis, elevations
of blood urea nitrogen (BUN) and creatinine have been reported in clinical trials with (ketoro
lac tromethamine). Since ketorolac tromethamine and its metabolites are excreted primarily
by the kidney, the following precautions are indicated for patients with: Severely impaired
renal function (serum creatinine values greater than 5 mg/dL, 442 pmol/L): Toradol is not rec
ommended; Moderately impaired renal function (serum creatinine values ranging from 1,9 to
5,0 mg/dL, 168 to 442 pmol/L) - The total daily dose of ketorolac tromethamine should be
reduced by half. In these patients the rate of ketorolac tromethamine clearance was reduced
to approximately half of normal. Patients who are volume depleted may be dependent on
renal prostaglandin production to maintain renal perfusion and, therefore, glomerular filtration
rate. In such patients, the use of drugs which inhibit prostaglandin synthesis has been associa
ted with further decreases in renal Dlood flow. Predisposing factors include sepsis, impaired
renal function, heart failure, liver dysfunction, diuretic therapy, and advanced age, Caution is
advised if ketorolac tromethamine is used in such circumstances. Close monitoring of urine out
put, serum urea and serum creatinine is recommended until renal function recovers.
Hepatic Effects: Meaningful elevations (greater than 3 times normal) of serumtransaminases (glutamate pyruvate (SGPT or ALT) and glutamic oxalacetic (SGOT or AST)), occurred in
controlled clinical trials in less than 1% of patients. If clinical signs and symptoms consistent with
liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), ketoro
lac tromethamine should be discontinued. Patients with impaired hepatic function from cirrho
sis do not have any clinically important changes in ketorolac tromethamine clearance. Studies
in patients with active hepatitis or cholestasis have not been performed.
Fluid and Electrolyte Balance: Fluid retention and edema have been observed in patients
treated with Toradol. Therefore, as with many other NSAIDs, the possibility of precipitating con
gestive heart failure in elderly patients or those with compromised cardiac function should be
considered. Toradol should be used with caution in patients with cardiac decompensation,
hypertension or other conditions which cause a predisposition to fluid retention.
Hematologic Effects: Ketorolac tromethamine inhibits platelet function and may prolong
bleeding time. It does not affect platelet count, prothrombin time (PI) or partial thromboplas
tin tim e (PTT). Unlike the prolonged effects from ASA the inhibition of platelet function by
ketorolac tromethamine is normalized within 24 to 48 hours after the drug is discontinued.
Potients on full anti-coagulation therapy (e.g. heparin or dicumarol derivatives) may be at
increased risk of bleeding if given Toradol concurrently. Thus, the benefit should be weighed
against this risk. The concomitant use of Toradol and heparin (5000 U s.c. BID) appears to be
associated with less risk (see DRUG INTERACTIONS), In patients receiving anticoagulants, the risk
of intramuscular haematoma formation from Toradol IM injections may be increased. In post
marketing experience, postoperative wound haemorrhage has been reported with the use of
Toradol. Therefore, caution should be exercised when strict haemostasis is critical. Toradol IM is

not recommended as a pre-operative or intra-operative medication because of the risk of
excessive bleeding. Blood d y sc ra sia s a sso c ia te d w ith the use o f N SA ID s a re rare,
but could occur with severe consequences.
infection: In common with o th e r no n -ste ro id a l anti-infla m m a to ry drugs, ketorolac
tromethamine may mask the usual signs of infection.
DRUG INTERACTIONS:
Protein Binding: Toradol (ketorolac trom etham ine) is highly bound to human plasma
protein (mean 99,2%) and b ind ing is inde p endent o f concentration. As ketorolac
tromethamine is a highly potent drug and present in low concentrations in plasma, it would not
be expected to displace other protein-bound drugs significantly. Therapeutic concentrations
of digoxin, warfarin, acetaminophen, phenytoin, and tolbutamide did not alter ketorolac
tromethamine protein binding.
Anticoagulant Therapy: Prothrombin tim e should be carefully monitored in all patients
receiving oral anticoagulant therapy concomitantly with ketorolac tromethamine. Toradol IM
given with two doses of 5000 U of heparin to 11 healthy volunteers resulted in a mean tem
plate bleeding time of 6.4 min (3.2-11.4 min) compared to a mean of 6.0 min (3.4-7.5 min) for
heparin alone and 5,1 min (3.5-8 5 min) for placebo, The in vitro binding of warfarin to plasma
proteins is only slightly reduced by k e to ro la c trom etham ine (99.5% control vs. 99,3%)
at plasma concentrations of 5 to 10 pg/mL.
Digoxin: Ketorolac tromethamine does not alter digoxin protein binding.
Salicylates: In vitro studies indicated that, at therapeutic concentrations of salicylates
(300 ng/mL), the binding of ketorolac tromethamine was reduced from approximately 99.2% to
97.5% representing a potential two-fold increase in unbound Toradol plasma levels.
Enzyme Induction: There is no evidence, in anim al or human studies, tha t ketorolac
tromethamine induces or inhibits the hepatic enzymes capable of metabolizing itself or other
drugs. Hence, it would not be expected to alter the pharmacokinetics of other drugs due to
enzyme induction or inhibition mechanisms.
Probenecid: Concomitant adm inistration of ketorolac tromethamine and probenecid
results in the decreased clearance of ketorolac and a significant increase in ketorolac plasma
levels (approximately three-fold increase) and terminal half-life (approximately two-fold
increase).
Furosem ide: Ketorolac trom etha m ine reduces the diuretic resp onse to furo se m ide
by approxim ately 20% in normovolemic subjects.
Lithium: Some NSAIDs have been reported to inhibit renal lithium clearance, leading to
an increase in plasma lithium concentrations and potential lithium toxicity, The effect of
ketorolac tromethamine on lithium plasma levels has not been studied.
Methotrexate: The concom itant adm inistration of methotrexate and some NSAIDs has
been reported to reduce the clearance of methotrexate, thus enhancing its toxicity, The
effect of ketorolac tromethamine on methotrexate clearance has not been studied.
Morphine: Intram uscular Toradol has been adm inistered concurrently with morphine
in several clinical trials of postoperative pain without evidence of adverse interactions.
ADVERSE EVENTS:
.
TORADOL TABLETS: Short-Term Patient Studies - The incidence of adverse reactions in 371
patients receiving multiple 10 mg doses of Toradol (ketorolac tromethamine) for pain resulting
from surgery or dental extraction during the post-operative period (less than 2 weeks) is listed
below. These reactions may or may not be drug related. Incidence between 4 and 9%:
Nervous system - somnolence, insomnia: Digestive system - nausea, Incidence between 2 and
3%: Nervous system - nervousness, headache, dizziness: Digestive system - diarrhea, dyspep
sia, gastrointestinal pain, constipation. Body as a whole - fever. Incidence 1% or Less: Nervous
system - abnormal dreams, anxiety, dry mouth, hyperkinesia paresthesia, increased sweating,
euphoria, hallucinations; Digestive system - anorexia, flatulence, vomiting, stomatitis, gastritis,
g astrointestinal disorder, sore throa t; Body as a whole - a sthenia, pain, back pain;
Cardiovascular system: vasodilatation, palpitation, migraine, hypertension; Respiratory system cough increased, rhinitis, dry nose; Musculo-skeletal system - myalgia, arthralgia; Skin and
appendages - rash, urticaria; Special senses - blurred vision, ear pain; Urogenital system:
dysuria.
Long-Term Patient Study - The adverse reactions listed below were reported to be probably
related to study drug in 553 patients receiving long-term oral therapy (approximately 1 year)
with Toradol. Incidence between 10 and 12%: Digestive system - dyspepsia gastrointestinal
pain.

Incidence Between 4 and 9%: Digestive system - nausea, constipation; Nervous system headache. Incidence Between 2 and 3%: Digestive system - diarrhea, flatulence, gastrointesti
nal fullness, peptic ulcers; Nervous system - Dizziness, somnolence; Metabolic/Nutritional disor
der - edema Incidence 1% or Less: Digestive system - eructation, stomatitis, vomiting, anorex
ia, duodenal ulcer, gastritis, gastrointestinal haemorrhage, increased appetite, melena, mouth
ulceration, rectal bleeding, sore mouth; Nervous system - abnormal dreams, anxiety, depres
sion, dry mouth, insomnia nervousness, paresthesia; Special senses - tinnitus, taste perversion,
abnormal vision, blurred vision, deafness, iacrimation disorder; Metabolic/Nutritional disorder Weight gain, alkaline phosphatase increase, BUN increased, excessive thirst, generalized
edema, hyperuricemia; Skin and appendages - pruritus, rash, burning sensation skin; Body as
a whole - asthenia, pain, back pain, face edema, hernia; Musculo-skeletal system - arthral
gia, myalgia, joint disorder: C ardiovascular system: chest pain, chest pain substernal,
migraine; Respiratory system - dyspnea, asthma epistaxis; Urogenital system - hematuria,
increased urinary frequency, oliguria, polyuria; Hemic and lymphatic - Anemia purpura.

TORADOL IM: The adverse reactions listed below were reported in Toradol IM clinical effica
cy trials. In these trials patients (n=660) received either single 30 mg doses (n=151) or multiple
30 mg doses (n=509) over a time period of 5 days or less for pain resulting from surgery.
These reactions may or may not be drug related. Incidence Between 10 and 13%: Nervous
System - somnolence; Digestive system - Nausea. Incidence Between 4 and 9%: Nervous sys
tem - headache; Digestive system - vomiting; Injection site - injection site pain Incidence
Between 2 and 3%: Nervous System - sweating, dizziness: Cardiovascular system - vasodilata
tion. Incidence 1% or Less: Nervous system - insomnia, increased dry mouth, abnormal
dreams, anxiety, depression, paraesthesia, nervousness, paranoid reaction, speech disorder,
euphoria, libido increased, excessive thirst, inability to concentrate, stimulation; Digestive sys
tem - flatulence, anorexia, constipation, diarrhea, dyspepsia, gastrointestinal fullness, gastroin
testinal haemorrhage, gastrointestinal pain, melena, sore throat, liver function abnormalities,
rectal bleeding, stomatitis; Cardiovascular system - hypertension, chest pain, tachycardia,
haemorrhage, palpitation, pulmonary embolus, syncope, ventricular tachycardia, pallor, flush
ing; Injection site - injection site reaction; Body as a whole - asthenia, fever, back pain, chills,
pain, neck pain; Special senses - taste perversion, tinnitus, blurred vision, diplopia, retinal
haemorrhage; Musco-skeletal system - myalgia, twitching; Respiratory system - asthma,
cough increased, dyspnea, epistaxis, hiccup, rhinitis; Skin and appendages - pruritus, rash, sub
cutaneous hematoma, skin disorder; Urogenital system - dysuria, urinary retention, oliguria,
increased urinary frequency, vaginitis, Metabolic/nutritional disorders - edema, hypokalemia,
hypovolemia Hemic and lymphatic system - anemia, coagulation disorder, purpura.

Post-Marketing Experience: The following post-marketing adverse experiences, although
rare (1 % or less), have been reported for patients who have received either formulation of Toradol.

Renal events - acute renal failure, flank pain with or without haematuria and/or azotemia;
Hypersensitivity reactions: bronchospasm, laryngeal edema, hypotension, flushing, rash, and
anaphylactoid reactions, such reactions have occurred in patients with no prior history of
hypersensitivity. Gastrointestinal events - gastrointestinal hemorrhage, peptic ulceration, gas
trointestinal perforation; Hematologic events - postoperative wound haemorrhage, rarely
requiring blood transfusion (see PRECAUTIONS), thrombocytopenia; C e ntra l n e rv o u s sy ste m co nvulsio ns, abnormal dreams, ha llu c in a tio n s, hyperkinesia, hearing loss; C a rd iova scu la r pulmonary edema; Dermatology - Lyell's syndrome, Stevens - Johnson syndrome, exfoliative
dermatitis, maculopapular rash.
OVERDOSAGE: The absence of experience with acute overdosage precludes characteriza
tion of sequelae and assessment of antidotal efficacy at this time. In a gastroscopic study of
healthy subjects, daily doses of 360 mg given over an 8-hour interval for each of five consecu
tive days (3 times the highest recommended dose) caused pain and peptic ulcers which
resolved after discontinuation of dosing,

DOSAGE AND ADMINISTRATION:
Adults: Dosage should be adjusted according to the severity of the pain and the response
of the patient. Oral; The usual oral dose of Toradol (ketorolac tromethamine) is 10 mg every
4 to 6 hours for pain as required. Doses exceeding 40 mg per day are not recommended.
Toradol is recommended for short-term use only, i.e„ for a maximum of a few weeks.

Parenteral: The recommended usual initial dose is 30 mg. Subsequent dosing may be 10 mg
to 30 mg every 4-6 hours as needed to control pain. It is recommended that the administration
of Toradol IM be limited to short-term therapy (not over 5 days) and the total daily dose should
not exceed 120 mg.
This is because the risk of toxicity appears to increase with longer use at recommended doses
(see WARNINGS and PRECAUTIONS). The administration of continuous multiple daily doses of
Toradol IM has not been extensively studied. There has been limited experience with intramus
cular dosing for more than 3 days since the vast majority of patients have transferred to oral
medication or no longer required analgesic therapy after this time, In the initial post-operative
period, more frequent dosing (e.g, every 2 hours) may be employed but the total daily dosing
should not exceed 120 mg/day. If supplementary analgesia is required, a concomitant low
dose of opiate can be used.
Patients under 50 kg, over age 65 years, or with less severe pain at baseline: the lower end
of the dosage range (10-15 mg 4 times a day) is recommended.

Im paired Renal Function - M oderate - In patients with impaired renal func tio n (serum
creatinine values ranging from 1.9 to 5.0 mg/dL or 168 to 442 pmol/L), the total daily dose of
Toradol should be reduced by half;

Severe - In patients with severely impaired renal function (serum creatinine values greater than
5 mg/dL or 442 pmol/L) Toradol is not recommended.

Conversion from Parenteral to Oral Therapy: Toradol tablets may be used either as monothera
py or as foliow-on therapy to parenteral ketorolac. Toradol IM should be replaced by an oral
analgesic as soon as feasible. When Toradol tablets are used as a follow-on therapy to par
enteral ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not
exceed 120 mg on the day the change of formulation is made. Subsequent oral dosing should
not exceed the recommended daily maximum of 40 mg.

Directions for Use of the Prefilled Syringes: Insert the plunger into the syringe barrel and thread
it onto the screw. WITHOUT REMOVING THE NEEDLE GUARD, apply quick, firm pressure to the
plunger to break the inner seal. (You will feel it let go). Pull back on the plunger slightly to
relieve pressure. Remove the needle guard by twisting as you pull. Use the unit as you would a
normal syringe. Dispose of properly. Single use only. Discard Unused Portions, Parenteral drug
products should be inspected visually for particulate material and discoloration prior to use.
Toradol (ketorolac tromethamine) is a Schedule F drug.
Stability and Storage Recommendations:
Toradol Tablets: Store at room temperature with protection from light.
Toradol IM: Store at room temperature with protection from light.
Availability ot Dosage Forms: Toradol (ketorolac tromethamine) is available as 10 mg white
round film coated tablets containing ketorolac tromethamine, microcrystalline cellulose, lac
tose and magnesium stearate with one side printed in red with TORADOL inside bold T and
other side with Syntex. Toradol (ketorolac tromethamine) 10 mg tablets are available in bottles
of 100 and 500 tablets.
Toradol IM is available in 1 mL ampoules (trays of 10) containing 10 or 30 mg/mL,
Toradol IM is also available in 1 mL syringes (1 /box) containing 15 or 30 mg/mL.
Product Monograph available on request.
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Bochdalek Hernia With Hemorrhage in an
Adult
Brian J. Miller, MD, FRCSC, FRACS;* Ian J.G. Martin, MB, BSf
Life-threatening herniation of intra-abdominal viscera through a patent Bochdalek foramen is well
recognized in neonates. Persistent foramina, leading to clinical problems in adult life, are very
rare. In the case of the 17-year-old girl described in this paper, two-thirds of the stomach had inverted
and passed into the left side of the chest as had the splenic flexure of the colon and most of the greater
omentum. There was 500 mL of blood free in the peritoneal cavity and 1200 mL in the left pleural
cavity, with no hernial sac. The defect measured 5 cm in diameter. It was repaired primarily after
reduction of the viscera. Prompt operative intervention is recommended in such cases to prevent
strangulation and bleeding from engorged viscera.

Une hernie d un viscere abdominal a travers un foramen de Bochdalek permeable, hernie capable de
mettre en peril la vie du malade, est un phenomene bien connu chez le nouveau ne. La persistance d’un
foramen pouvant causer des problemes cliniques a Page adulte est tres rare. Dans le cas d’une jeune
fille de 17 ans faisant l’objet de cette communication, les deux tiers de l’estomac se sont retournes dans
la cavite thoracique gauche, avec l’angle gauche du colon et la plus grande partie du grand epiploon.
On a retrouve 500 mL de sang dans la cavite peritoneale et 1200 mL dans la cavite pleurale gauche; il
n y avait pas trace de sac herniaire. L’orifice mesurait 5 cm de diametre. On proceda a une reparation
primaire apres reduction des visceres. Une intervention chirurgicale immediate est recommandee dans
de tels cas afin de prevenir l’etranglement et l’hemorragie des visceres engorges.

ersistence of the pleuroperito
neal canal of embryonic life can
permit life-threatening extrusion
of abdominal viscera into the chest
in neonates. It is very unusual
for this canal to persist and cause
trouble in adults. However, when
this does happen there is the poten
tial for strangulation of viscera in
the left upper quadrant of the abdo
men. The purpose of our report is
to draw attention to this entity in
adults and to recommend prompt
operative correction to avoid viscer
al hemorrhage and ischemia.

P

Case Report
A 17-year-old girl was seen in the
emergency department of the Prin
cess Alexandra Hospital, Brisbane,
with a history of dry retching and
severe upper abdominal pain in
creasing over 48 hours after an
episode of laughing. She told of
four shorter episodes over the pre
ceding 6 weeks, each apparently
triggered by physical exertion such
as swimming. Previously, the pain
had been relieved by gaseous eruc
tation and vomiting of dark fluid,

but she had been unable to do that
on this occasion. Otherwise, she
was entirely fit and had no signifi
cant personal or family history.
On examination, she was pale,
sweating and tachycardic, with a
pulse rate of 120 beats/m in. Her
body temperature was normal.
There was dullness on percussion
and diminished air entry at the left
lung base. Examination of the abdo
men revealed marked tenderness
and involuntary guarding in the
upper half of the abdomen. There
was no distension. Bowel sounds
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were present. Results of rectal ex
amination were normal. The leuko
cyte count was 15.0 X 109/I>, but
otherwise the results of all laborato
ry investigations were normal. An
upright chest film (Fig. 1) showed
left basal atelectasis and a massive
air fluid level in the lower part of
the left side of the chest.
A nasogastric tube was inserted
without difficulty, and 1500 mL of
coffee-grounds material was re
moved. This resulted in some reduc
tion in the patient’s symptoms and
signs. However, she remained
tachycardic, and repeated physical
examination still revealed considera
ble tenderness in the left upper
quadrant of the abdomen.
Radiologic study of the upper
gastrointestinal tract with Gastrografin (Fig. 2) demonstrated inver
sion of the stomach into the left
side of the chest through a post
erolateral diaphragmatic defect,
with the gastroesophageal junction
in the normal position. There was
no flow of Gastrografin into the
duodenum. Ultrasonography of the
upper and lower abdomen showed
evidence of free fluid but no other
abnormalities.
Because of the patient’s continu
ing tachycardia and upper abdomi
nal tenderness, she was taken to
the operating room immediately.
The peritoneal cavity, opened

FIG. 1. Preoperative upright chest film
shows gastric dilatation in left hemithorax.

through a left subcostal incision,
contained 500 mL of free blood.
The greater curvature of the stom
ach, including about two-thirds of
the total volume of the stomach,
the splenic flexure of the colon and
most of the greater omentum had
passed into the left side of the chest
through a patent Bochdalek fora
men in the posterolateral aspect of
the left hemidiaphragm, measuring
5 cm in diameter. The peritoneum
and pleura were continuous, and
there was no hernial sac. The
spleen had remained in the abdo
men. Reduction of the stomach and
the splenic flexure of the colon into
the abdomen produced further flow
of 1200 mL of non-clotted blood
from the left pleural cavity through
the foramen. The greater omentum
was adherent to the medial aspect
of the left pleural cavity. After this
had been reduced it was noted that
the lesser omentum of the stomach
was edematous, but all viscera were
viable. A discrete bleeding site was
not discovered although the portion
of omentum from the left pleural
cavity was engorged. This portion
of the omentum was removed, and a

The Bochdalek foramen, or pa
tent pleuroperitoneal canal, can lead
to life-threatening herniation of vis
cera into the left side of the chest
as a neonate draws its first breath.1
It is the most common congenital
hernia of the diaphragm in infants,
with an incidence of about 1 in
4000 live births. A death rate of
50% in infants has been reported.2
However, it is extremely uncommon
for Bochdalek hernia to present in
adult life as a surgical emergency.3
Fewer than 200 cases have been
reported in the world literature,4
including only 51 during the last 25
years.2

FIG. 2. Gastrografin introduced
through nasogastric tube demonstrates
acutely inverted and obstructed stom
ach, which is above left hemidia
phragm.

At the end of the 4th embryonic
week, the stomach is a fusiform
dilatation of the foregut in the
median plane, connected to the
body wall by a short dorsal mesen
tery owing to the presence of the
pleural and peritoneal canals lateral
ly.1 The formation of the diaphragm
is usually complete by the 8th week
of embryonic life. The developing
pleural membrane separates the
inner layer of muscle from the tho
racic wall to form the lateral mus
cular part of the diaphragm. This
results in only two layers of inter
costal muscles with the homologue
of the transversus abdominis mus
cle becoming the muscle of the
diaphragm. The central tendon de
velops from the original septum
transversum and the dorsal portion
of the diaphragm develops from the

size 28 chest tube was placed percutaneously into the left pleural
cavity. The Bochdalek foramen was
then closed primarily with heavy (0
gauge) interrupted nylon sutures.
There were no complications, and
the patient left hospital on the 7th
postoperative day. One month later
she was well and her chest x-ray
film appeared normal.

Discussion
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esophageal mesentery. The dorsal
paired pleuroperitoneal membranes
close the pleuroperitoneal canals.
The congenital posterolateral dia
phragmatic defect, well described by
Bochdalek in 18485 is caused by
failure of the septum transversum
and the pleuroperitoneal mem
branes to fuse. No sac is present in
70% of cases, and 30% have incom
plete muscularization of the pleu
roperitoneal membrane leaving a
filmy layer that separates the ab
dominal cavity from the chest. Ap
proximately 80% of these hernias
are on the left side.6
An episode of increased intra
abdominal pressure appears to be
important in the etiology of adult
herniation, and six patients with
acutely symptomatic Bochdalek
hernias during pregnancy have been
reported.7 The incidence of strangu
lation is 34% in patients who have
an acute condition, and this empha
sizes the need for early diagnosis
and prompt operative management.2
Gastric volvulus has been reported
with Bochdalek hernia, the rotation
occurring around the gastric mes
enteric axis in the sagittal plane.8
Severe bleeding, causing hemo
thorax and hemoperitoneum with
loss of 1700 mL of blood, has not
been reported before. Without early
operation the patient’s blood loss
would likely have been greater.
A plain x-ray film of the chest
and contrast studies of the gastroin
testinal tract are necessary to con
firm the diagnosis. A previously
normal chest x-ray film does not
rule out a diaphragmatic hernia, as
the defect may be occluded by the
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spleen or by the presence of a
confining sac. Up to 20% of patients
have no symptoms at presentation,
and this condition has been diag
nosed incidentally on magnetic res
onance imaging.9 Computed tomog
raphy has been recommended for
making the diagnosis, but in our
case the need for operation was
quickly established by a contrast
study with Gastrografin.10
The principle of reduction of the
viscera from the left side of the
chest and repair of the defect with
strong non-absorbable suture mate
rial is well established. Direct clo
sure of the diaphragmatic defect
has been reported as possible in
92% of patients.2 The posterior rim
of the diaphragm was easy to define
in our patient, and it was not
necessary to dissect up the muscle
of the posterior leaf of the dia
phragm from the superior aspect of
the left kidney. Most groups favour
thoracotomy to approach right
sided defects, and there are advo
cates of laparotomy and thoracoto
my, or a combined approach, for
left-sided defects.5 We had no diffi
culty with exposure and repair of
the defect through a left subcostal
incision. Postoperative gastric
atony has been thought clinically
significant in over 50% of patients
but was not a problem in our
patient.11
In summary, a patent Bochdalek
foramen cannot be dismissed even
in adult life as a cause of acute
gastric outlet obstruction. The diag
nosis should be suspected whenever
symptoms occur after physical exer
tion and are associated with signs in

the left lung base and a nondistended abdomen. Prompt operative in
tervention is necessary to prevent
the complications of visceral isch
emia and hemorrhage into the pleu
ral and peritoneal cavities.
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Aortoesophageal Fistula Secondary
to Benign Barrett’s Ulcer: a Rare Cause
of Massive Gastrointestinal Hemorrhage
Deepak Katyal, MD;* Laurence D. Jewell, MD, FRCPC;t Walter W. Yakimets, MD, FRCSC*
Aortointestinal fistula is a rare cause of massive upper gastrointestinal bleeding. The authors report
on an 82-year-old man who had an aortoesophageal fistula due to a benign Barrett’s ulcer. The patient
presented with a sentinel hemorrhage followed by fatal exsanguination despite vigorous attempts at
resuscitation. Management of the entity requires awareness, appropriate radiologic and endoscopic
investigation and early surgery. Even with appropriate management, the mortality remains high.

Une fistule aorto-oesophagienne est une cause rare d’hemorragie massive des voies digestives
superieures. Les auteurs decrivent le cas d’un homme de 82 ans qui presenta une fistule
aorto-oesophagienne due a un ulcere benin de Barrett. A son arrivee, le patient souffrait d’une
hemorragie sentinelle qui degenera en une exsanguination fatale, malgre de vigoureux efforts de
reanimation. Le traitement de cette affection exige de l’experience, des examens radiologiques et
endoscopiques appropries et une intervention chirurgicale precoce. Meme avec un traitement adequat,
la mortality demeure elevee.

assive upper gastrointestinal
bleeding is most often caused
by gastroduodenal ulcers or esopha
geal varices. Rarely, aortointestinal
fistulae become a source of bleed
ing. In a review by Kane, Meyer and
Kozoll1 they accounted for 6.1% of
deaths due to gastrointestinal he
morrhage. The duodenum is in
volved with aortointestinal fistulae
in the majority of cases, usually
after surgery for aortic aneurysms.
However, 20% involve the esopha
gus.
The cause of aortoesophageal fis
tula (AEF) in 75% of cases is a
ruptured thoracic aneurysm.2 Less
commonly, esophageal foreign bo
dies, malignant tumours of the
esophagus or bronchus and instru

M

mental perforation of the esopha
gus may lead to fistula formation.
Chronic ulcerative esophagitis is an
extremely rare cause of AEF, repre
senting less than 0.5% of reported
cases.3 We report a rare case of a
benign perforated ulcer in Barrett’s
esophagus, resulting in a fatal
upper gastrointestinal hemorrhage.

Case Report
An 82-year-old man was admitted
to a peripheral hospital after col
lapsing at home. He had been tak
ing cimetidine for 3 years because
of vague symptoms of dyspepsia
but was otherwise well. No cause
for the collapse was found, and

aside from one episode of epigastric
pain that was relieved by antacids
his initial hospital course was sta
ble. Six days after admission he
collapsed again, had a transient
hypotensive episode and passed a
melena stool. The following morn
ing he vomited bright red blood,
and his hemoglobin level was 41
g/L .
Arrangements were made for ur
gent transfer to the Walter C. Mac
kenzie Health Sciences Centre. On
arrival, the patient was conscious
with a systolic blood pressure of
80 mm Hg. He was vigorously re
suscitated with intravenous fluids
and blood. Urgent upper gastroin
testinal endoscopy revealed a large
hiatus hernia with bright red blood
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oozing from the gastroesophageal
junction. Closer examination re
vealed a large ulcer in the hiatus
hernia with what was thought-to be
a visible vessel at its base. Scleroth
erapy was attempted but this in
creased the bleeding. Consequently,
the patient aspirated blood and re
quired intubation.
Brisk bleeding and refractory hy
potension necessitated immediate
transfer to the operating room.
Through a midline laparotomy inci
sion, a gastrotomy was performed,
and large amounts of fresh blood
and clots were evacuated. Blood
was noted to be coming from above
the gastroesophageal junction.
Manual compression was attempted
while a left thoracoabdominal ex
tension of the original midline inci
sion was made. Entrance into the
thorax revealed extensive scarring
in the region of the aorta and distal
esophagus with the two structures
closely adherent to each other. At
tempt at proximal control of the
aorta was difficult. As a result, the
patient continued his downward spi
ral and sustained a cardiac arrest

secondary to exsanguination. Re
suscitation was unsuccessful.
At autopsy, the lower two-thirds
of the tubular esophagus exhibited
glandular metaplasia. The epitheli
um was architecturally disorganized
with patchy intestinal metaplasia
characteristic of Barrett’s ulcer. No
dysplasia or carcinoma was identi
fied. A perforation 3.5 cm in diame
ter was apparent on the posterior
wall at the junction of lower and
middle thirds and had eroded into
the aorta (Fig. 1). The aorta, al
though atherosclerotic, was not
aneurysmal. The degree of athero
sclerosis was surprisingly mild in all
major vessels, including the thorac
ic aorta. No other significant find
ings were noted.

Discussion
AEF is a rare cause of upper
gastrointestinal hemorrhage that is
frequently diagnosed only at autop
sy. It was first described by Dubrueil in 1818,4 but there have been
few reported survivors despite ad

FIG. 1. Aortoesophageal fistula (identified by string passing from esophagus into
aorta [A]) is viewed from esophageal aspect. Arrows mark squamocolumnar
junction, which is junction of upper and middle thirds of tubular esophagus.

vances in cardiovascular surgery.
The key to survival in these pa
tients is maintaining awareness of
the condition to allow early diagno
sis and operative management of
this treatable lesion.
Clinically, AEF presents in two
ways. If the fistula forms abruptly,
rapid exsanguination results. How
ever, in 80% of cases, the presenta
tion is Chiari’s classic triad of midthoracic pain, “sentinel” hemorrh
age and exsanguination following a
symptom-free interval.5 Possible
reasons for this latent period in
clude spasm of the arterial wall
closing the orifice, hypotension
from the initial hemorrhage and
occlusion of the fistula by clot,
which is later digested by infection
or gastrointestinal contents.6
To institute prompt and proper
therapy, the diagnosis must be
made shortly after the sentinel he
morrhage has occurred. As only
25% of patients will rebleed within
6 hours,7 there is ample time for
radiologic investigation. Plain chest
radiographs may suggest the pres
ence of a thoracic aneurysm, which
can be confirmed by aortography or
computed tomography. However,
aortography will only delineate the
fistulous tract if the rate of bleeding
is 0.5 to 1 m L/m in,3 and computed
tomography with oral water-soluble
contrast has demonstrated the fistu
la only occasionally.8-9 Air-contrast
barium esophography has been re
ported as the most sensitive method
for demonstrating the fistula,1011
but there still remains a high rate of
false-negative or inconclusive re
sults. Endoscopy is useful in diag
nosing mass lesions, esophagitis,
ulcerations or foreign bodies. On
rare occasions, as in this case, the
fistula site may be seen. Biopsy of a
mass lesion, injection of a bleeding
esophageal ulcer and sclerotherapy
of a “visible vessel” are to be
avoided in any patient suspected of
having an AEF in order to prevent
CJS, VOL. 36. NO. 5, OCTOBER 1993
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disastrous consequences.
Frequently, bleeding is so rapid
as to preclude endoscopy and other
diagnostic tests. In this setting,
insertion of a Sengstaken-Blakemore tube has been used as a useful
temporizing measure to prevent exsanguination and to allow stabiliza
tion of the patient for surgery.1213 A
case of embolization of an AEF
under radiologic guidance in an
unstable patient has also been re
ported.14
The surgical approach to AEF is
through a left thoracotomy. After
the aorta has been controlled, treat
ment options include simple clo
sure, resection with insertion of a
prosthetic graft, or bypass grafting
from aortic arch to distal thoracic
aorta. Management of the esopha
gus depends on the size of the
perforation and the cause of the
fistula. Small perforations due to
aneurysmal erosion can usually be
closed primarily after debridement
and then reinforced with pericardial
fat.2 When the esophagus contains
the primary pathologic process, as
in reflux esophagitis, it will usually
be too friable to close primarily. In
this situation, thoracic esophageal

resection, end cervical esophagostomy and gastrostomy are indicated.
Gastrointestinal continuity can be
restored by gastric “pull-up” or
colonic interposition. Interposition
of a pericardial or pleural flap or
vascularized intercostal muscle flap
between the aorta and reconstruct
ed gastrointestinal tract is recom
mended to prevent repeat fistulization.12 Although all untreated cases
of AEF are fatal, prompt recogni
tion and early surgery still result in
a death rate of 55% to 75%.1516
We thank Colleen Gardner and Rose
marie Henley for preparation of this
manuscript.
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SESAP VII Critique / Critique SESAP VII
Item 256
Patients with aortic stenosis typically present with congestive heart failure, angina pectoris, and syncope.
Systemic embolization may occur. This patient’s systolic murmur corroborates an aortic valve problem. The
importance of prompt and correct diagnosis cannot be overemphasized, especially in a patient who requires
operation for unrelated disease. The left ventricle hypertrophies, which then results in changes in ventricular
compliance. These patients are sensitive to increased volume and can develop pulmonary edema and cardiogenic
shock with induction of anesthesia. Significant aortic stenosis must be diagnosed and treated prior to any
elective surgical procedure.
D
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P R E S C R IB IN G IN F O R M A T IO N
Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi-synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.
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Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract infe c tio n s: pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterococci, e.g. S. faecalis), Staphylococcus
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract infe c tio n s: caused by Escherichia coli, unspecified Klebsiella species (including K pneumoniae),
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacteremia / Septicem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens.
Skin infe c tio n s: caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdominal infe c tio n s: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological infe c tio n s: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E. coli, Group A streptococci and Staphylococcus epidermidis: anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow-up was not available.
Central nervous system in fe c tio n s: meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan, Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re-evaluated once these results become available.
Prophylactic U se: The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudomembranous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
antibiotics); therefore, it is im portant to consider its diagnosis in patients w ho develop diarrhea during
the adm inistration of Claforan. This colitis can range from mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplementation as indicated
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
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Precautions
Claforan (cefotaxime sodium) should be prescribed with caution in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient’s condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coombs' test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
As with other beta-lactam antibiotics, granulocytopenia and, more rarely, agranulocytosis may develop during
treatment with Claforan, particularly if given over long periods. For courses of treatment lasting longer than 10
days, blood counts should therefore be monitored.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are
Hypersensitivity (1.8%): Rash, pruritus, fever. Local (5% ); Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%); Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. Hematologic System ( < 1%): Neutropenia, transient leukopenia, eosinophilia, thrombocytopenia and
agranulocytosis have been reported. Some individuals have developed positive direct Coombs’ test during

treatment with Claforan and other cephalosporin antibiotics. Rare cases of hemolytic anemia have been reported.
Genitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGFT, serum
LDH and serum alkaline phosphatase levels have been reported. Kidney ( < 1% ); Increased serum creatinine and
BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table
with recommended mode of reconstitution according to route of administration).
Dosage
A dults: The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the
infection and condition of the patient.
Guidelines for Dosage or Claforan (cefotaxime sodium)

Type of Infection

Daily Dose
(g)

Frequency and Route

Uncomplicated Gonorrhea

1

1 g IM (single dose)

Uncomplicated infections

2

1 g every 12 hours IM or IV

Moderately severe to severe infections

3-6

1-2g every 8 hours IM or IV

Very severe infections (e.g. septicemia, CNS)

6-8

2g every 6-8 hours IV

Life-threatening infections

up to 12

2g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows;
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery;
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery;
(c) 1 g IM or IV administered within 2 hours following completion of surgery.
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed; persistent infections may
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient)
may be used to convert these values into creatinine clearance.
M ales:

Weight (kg) x (140 - age)

Females:

0.85 x above value

72 x serum creatinine
Administration
Intra m uscular: Claforan should be injected well within the body of a relatively large muscle such as the upper
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a
blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia, bacterial septicemia, or other severe
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue
temporarily the administration of other solutions at the same site.
Stability
Claforan reconstituted in the original vial as described under RECONSTITUTION maintains satisfactory potency for
24 hours at room temperature (25°C) and for 48 hours under refrigeration (0-5°C).
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium
(expressed as acid on a dry basis).
Storage: Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
*Reg’d TM of Abbott Laboratories.
©Trademark of Roussel UCLAF, Paris
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ORIGINAL ARTICLES

T h e Anatomical Basis for Laparoscopic
Splenectomy
Eric C. Poulin, MD, FRCSC; Claude Thibault, MD
The anatomy of the splenic blood supply is extremely variable. Two principal patterns, the distributed
and the magistral types, include the majority of variations. These two types differ with respect to the
length of the splenic trunk, the number of arterial branches and the proportion of the medial surface of
the spleen occupied by the branches as they enter the organ. The suspensory ligaments of the spleen,
including the sustentaculum lienis, are usually avascular except for the gastrocolic and lienorenal
ligaments on the medial side. The tail of the pancreas touches the spleen in 30% of cases and lies
within 1 cm of the spleen in 73%. Knowledge of these basic anatomic facts and the variations should
contribute to the safety of laparoscopic splenectomy.

L anatomie de la vascularisation de la rate est extremement variable. II existe deux principaux types
d’architecture vasculaire, le type distribue et le type magistral, qui incluent la majorite des variations.
Ces deux types different de par la longueur du tronc de l’artere splenique, de par le nombre des
branches arterielles et de par la proportion de la surface interne de la rate traversee par les vaisseaux.
Les ligaments suspenseurs de la rate, incluant le sustentaculum lienis, sont habituellement
avasculaires sauf pour les ligaments gastro-splenique et lieno-renal a la face interne. La queue du
pancreas touche la rate dans 30 % des cas et se situe en defa de 1 cm dans 73 %. La connaissance de ces
donnees anatomiques de base et de leur variations devrait contribuer a la realisation securitaire de la
splenectomie par voie laparoscopique.

surgery and video
L aparoscopic
imaging technology have al
lowed the observation of magnified
anatomic detail in the performance
of many surgical procedures. It has
also become increasingly clear that
minimal access surgery requires
maximal knowledge of anatomy to
ensure optimal hemostatic control
and preservation of anatomic integ
rity.
The knowledge of anatomy re
quired for safe performance of lapa
roscopic splenectomy is crucial be
cause the spleen is a fragile, highly
vascularized, solid viscus.1 Al
though most anatomy texts imply
that the splenic artery is constant in

its course and branches, Michels in
his classical essay in 19422 called
attention to the fact that each
spleen has its own peculiar pattern
of terminal splenic artery branches.
In this paper we summarize the
anatomic facts pertinent to the per
formance of laparoscopic splenecto
my with emphasis on the splenic
artery, its branches, the suspensory
ligaments of the spleen and the
pancreas.

History
Julius Caesar Arantius of Vienna
(1571) was the first to emphasize

the tortuous course of the splenic
artery. Lipshutz3 in a study of 83
cadavers described the terminal
branches of the splenic arteries out
side the parenchyma. Melnikoff4
(1923) dealt primarily with the divi
sions of the splenic artery within
the spleen, even claiming the exis
tence of a well-developed system of
collaterals. However, in the same
year (1923) Volkmann5 denied the
existence of any important collater
als in the spleen. Ssoson-Jaroschewitsch6 classified the highly
variable vascular anatomy of the
spleen in two main patterns: the
magistral type and the distributed
type. Henschen7 drew attention to
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the fact that the distributed type of
anatomy was more often encoun
tered in lobulated and unevenly
contoured spleens as opposed to
spleens that had a more even inner
surface.

surface of the spleen. They are
large and few (three to four). They
originate 3.5 cm on average from
the spleen and reach the centre of
the organ as a compact bundle
(Fig. 2).

T h e S p len ic Artery

B ranches o f th e S p len ic A rtery

The celiac axis is the largest and
the shortest branch (15 to 20 mm)
of the abdominal aorta. It arises
above the body of the pancreas and
in 82% of specimens divides into
three primary branches, the left
gastric artery being given off as the
first branch and the hepatic and
splenic arteries coming from a com
mon stem. Rarely, the splenic artery
takes its origin directly from the
aorta and even less often, a second
splenic artery is seen arising from
the celiac axis. Other variations
exist. They include origin from the
superior mesenteric artery, the mid
dle colic artery, the left gastric
artery, the left hepatic artery and
the accessory right hepatic artery.
As a rule, the splenic artery starts
from the celiac axis to the right of
the midline, thus necessitating a
crossing of the aorta to reach the
spleen. Its course can be very tortu
ous. Its tortuosity increases with
age and with a longer artery.
In his study of 100 cadaver
spleens, Michels2 reported that the
distributed type was found in 70%
of dissections. By definition, the
splenic trunk is then short, and
numerous long branches (6 to 12)
enter over 75% of the medial sur
face of the spleen. The branches
originate between 3 and 13 cm from
the hilus (Fig. 1). The magistral
type was present in the remaining
30% of the specimens. It is charac
terized by the presence of a long
main splenic artery dividing into
short terminal branches near the
hilus. The splenic branches enter
over only 25% to 33% of the medial

The splenic branches exhibit
such marked variations in length,
size and origin that no two spleens
have the same anatomy. Outside the
spleen, the arteries also present
frequent transverse anastomoses
with each other which, according to
Testut,8 arise at a 90° angle be
tween the involved arteries, as with
most collaterals (Fig. 1). Before it
divides, the splenic trunk usually
gives off a few slender branches to
the tail of the pancreas. Then, the
splenic artery divides into first and
second terminal branches (two to
six branches), after which there are
two other levels of division — the

penultimate and ultimate branches
(2 to 12 branches). The level of
segmental and subsegmental divi
sion is variable and can occur out
side or inside the spleen. The num
ber of arteries entering the spleen
varies from 6 to 36; the size of the
spleen does not determine the num
ber of entering arteries, but the
presence of notches and tubercules
usually correlates well with a great
er number of entering arteries.
The general scheme of splenic
artery branches may include up to
seven principal branches at various
division levels and in various ana
tomic arrangements. They include
the following: the superior terminal
artery, the inferior terminal artery,
the medial terminal artery, the su
perior polar artery, the inferior
polar artery, the left gastroepiploic
artery and the short gastric arteries
(Fig. 3). Veins are usually posterior
to the arteries except at the ulti
mate division level where they may
be anterior or posterior.

FIG. 1. Distributed type of vascularization. LG = left gastric artery, H = hepatic
artery, DP = dorsal pancreatic artery, SG = short gastric arteries, ANAS =
anastomosis, SP = superior polar artery, ST = superior terminal artery, IT =
inferior terminal artery, IP = inferior polar arteries, LGE = left gastroepiploic
artery, PU = penultimate branch, U = ultimate branch.
CJS, VOL. 36, NO. 5, OCTOBER 1993

485

POULIN AND THIBAULT

First Terminal Division
Branches

blood supply often coming from the
left gastroepiploic and polar vessels.

In Lipshutz’s study,3 72% of
specimens had three terminal
branches (superior polar, and supe
rior and inferior terminal), whereas
28% had two terminal branches.
The medial terminal artery was ob
served in only 20% of cases.3 When
the superior terminal branch is ex
cessively large, the inferior terminal
branch is rudimentary, an added

The Short Gastric Arteries
There may be up to six short
gastric arteries arising from the
fundus of the stomach, but usually
only the ones opening into the
superior polar artery of the spleen
need to be ligated during laparo
scopic splenectomy (Fig. 1).

The Left Gastroepiploic
Artery(ies)
This artery is the most varied of
the splenic branches and courses
along the left side of the greater
curvature in the anterior layer of
the greater omentum. In about 72%
of the cases, it arises from the
splenic trunk several centimetres
from its primary terminal division.
In 22% of cases, it originates from
the inferior terminal artery or its
branches. It may also originate
from the middle of the splenic trunk
or from the superior terminal ar
tery.
Characteristically this artery
gives off inferior polar branches,
which vary in number (from one to
five), size and length.

The Inferior Polar Artery

FIG. 2. Magistral type of vascularization. LG = left gastric artery, H = hepatic
artery, DP = dorsal pancreatic artery, SG = short gastric arteries, SP = superior
polar artery, ST = superior terminal artery, IT = inferior terminal artery, IP =
inferior polar artery, PU = penultimate branch, U = ultimate branch.

This artery is present in 82% of
cases. There may be up to five
collateral branches, which may arise
from the splenic trunk, the inferior
terminal artery or, as already men
tioned, from the left gastroepiploic
artery. Inferior polar branches may
have multiple origins and, usually,
the calibre of the artery is smaller
than that of the superior polar
branch.

The Superior Polar Artery
FIRST TERM IN AL
DIVISION

S u p e r io r

—►

SECOND TERMINAL II COLLATERALS
DIVISION

4.

S u p e rio r
p o la r

t e r m in a l
a rte ry

a rte ry

— ►

7.

S h o rt

! THIRD TERMINAL
1
DIVISION

—

FOURTH TERMINAL
DIVISION

— ►

g a s t r ic
a r t e r ie s
(1 -2 )

In f e r io r

— ►

5.

In fe rio r

------------------------------------------ ►

p o la r

t e r m in a l
a r te r y

a rte ry

P e n u lt im a te
b ra n c h e s
(2 t o 1 2 )

— ►

U ltim a te
b ra n c h e s
( w ith in s p le e n )
(2 t o 1 2)

6.

G a s tr o e p ip lo ic
a rte ry

M e d ia l’
t e r m in a l
a rte ry

FIG. 3. General scheme of splenic artery branches.* = Present in only 20% of cases.
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The superior polar artery is pres
ent 65% of the time and arises from
the main splenic trunk in 75% of
cases, from the superior terminal
artery in 20% of cases and occasion
ally from the inferior terminal ar
tery or separately from the celiac
axis, thus providing the spleen with
a double splenic artery. In the ma
jority of cases, it gives origin to one
or two short gastric branches and
rarely to the left inferior phrenic
artery and pancreatic rami. The

LAPAROSCOPIC SPLENECTOMY

incidence and calibre of this artery
appears to be correlated with tuber
cle formation, for it is more promi
nent in spleens having large tuber
cles. Frequently this artery is very
long and slender and may be torn
during splenectomy. This fact
prompted Henshen to suggest, in
1928, that ligation of splenic
branches should be started from the
inferior pole of the spleen.7

The Suspensory Ligaments of
the Spleen
Duplications of the peritoneum
form the suspensory ligaments of
the spleen. The phrenocolic liga
ment courses from the diaphragm
to the splenic flexure of the colon;
its superior end is referred to as the
phrenosplenic ligament.9 The at
tachment of the lower pole on the
internal side is called the splenocolic ligament. Between these two, a
horizontal shelf is formed on which
rests the inferior pole of the spleen.
It is often moulded into a sac that
opens cranially and is called the
sustentaculum lienis, acting as a
brassiere to the inferior pole of the
spleen. There are two ligaments on
the hilar side: anteriorly, the gastrosplenic ligament containing the
short gastric and the gastroepiploic
vessels and posteriorly, the lienorenal ligament with the splenic ves
sels and the tail of the pancreas
(Fig. 4).

Surgical Considerations
Precise knowledge of splenic
anatomy is required before its re
moval is attempted laparoscopically.
The surgeon should appreciate the
infinite variability of splenic vascu
lar anatomy. However, on seeing
the spleen and its hilus, the sur
geon can usually predict its type of
vascularization. A notched spleen
with a wide hilus will have a more
complicated type of vascularization.
The distributed type will have more
variations and more vessels, but
dissection will probably be easier
because of the greater space be
tween vascular structures. The
spleen with even borders and a
compact hilus (magistral type) will
have fewer variations and fewer
vessels. The dissection, however, is
more tedious and more risky be
cause of the narrow, compact na
ture of the hilus where vessels are
very close to one another and more
prone to injury.

In patients who undergo preoper
ative arteriography or splenic artery
embolization, the radiologist must
be familiar with the variability of
access to the splenic artery so as to
successfully cannulate the arterial
tree for proximal and distal emboli
zation.
Laparoscopic splenectomy is
started at the lower pole of the
spleen. When many branches of the
left gastroepiploic artery have to be
taken, it should be recognized that
the blood supply coming from the
left gastroepiploic artery through
its splenic branches may approxi
mate that reaching the spleen
through its primary lienal branches,
complicating the effectiveness of
preoperative embolization in some
cases.
Surgical control of the splenic
vessels is subsequently obtained dis
tal to the often-seen transverse col
laterals and proximal to the en
trance of vessels in the spleen,
resulting in 8 to 18 ligatures (arter-

The Pancreas
Michels2 stated that SsosonJaroschewitsch found the tail of the
pancreas in direct contact with the
spleen in 30% of cadavers. Baronofsky and associates10 confirmed
this finding and added that the
distance from the pancreas to the
splenic hilus was not more than 1
cm in 73% of their patients.

FIG. 4. Suspensory ligaments of spleen, lig. = ligament, a = artery.
CJS, VOL. 36, NO. 5, OCTOBER 1993
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ies and veins). The segmental distri
bution of arteries within the spleen
makes observation of parenchymal
colour changes very useful during
the procedure. Devascularized seg
ments (ligature or embolization) ap
pear charcoal gray, and viable seg
ments retain a pinkish hue. A char
acteristic phenomenon useful in la
paroscopic splenectomy is the ob
servation of selective distribution of
inferior polar arteries to notched
areas of the spleen, the arteries
being numerically proportional to
the notches.
When preoperative splenic artery
embolization is performed, place
ment of the proximal coils should
spare arterial branches of the sple
nic trunk to the tail of the pancreas
to avoid pancreatitis. During the
operation, pancreatic injury should
be avoided and the relationship of
the tail of the pancreas to the
splenic hilus borne in mind during
laparoscopic dissection. Therefore,
safe laparoscopic splenectomy re
quires careful dissection of the tail
of the pancreas from the splenic
hilus. Dissection should be very
close to the splenic hilus to avoid
pancreatic injury with instruments
like the cautery.
Knowledge of the structures
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found in the gastrosplenic and lienorenal ligaments of the spleen
should also prevent injury. One
should appreciate that the other
suspensory ligaments of the spleen
are avascular except in cases of
portal hypertension and myelo
proliferative disorders.11 The sus
tentaculum lienis, seldom noticed in
open surgery, is readily seen
through the laparoscope. It is avas
cular most of the time and is easily
sectioned with the cautery, close to
the spleen, with care taken of the
tail of the pancreas on the medial
side. Gentle downward traction on
the splenic flexure of the colon
helps the initial phase of the opera
tion when the phrenocolic, the splenocolic and the sustentaculum lie
nis ligaments are taken with the
cautery. After the gastroepiploic
vascular branches to the lower pole
have been ligated, the splenic flex
ure of the colon effectively drops
away from the operating field for
the remainder of the operation.
Care should also be taken to avoid
cautery burns to the splenic flexure
during lower-pole manipulations.
We believe that the appreciation
of these significant anatomical land
marks should contribute to the
safety of laparoscopic splenectomy.
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SPONSORS’ NEWS
NOUVELLES DES PARRAINS

The Canadian Association of General
Surgeons
1993 Annual Meeting
At the annual meeting of the Canadian Association of
General Surgeons (CAGS), held in Vancouver from
Sept. 9-13, 1993, a new executive was elected. The
new president is Dr. Fred Inglis. The president-elect
is Dr. Chris Heughan from St. John’s, Nfld. The
past-president is Dr. Marvin Wexler and the secretary
and treasurer remain Drs. Keith and Huntington
respectively.
At the annual meeting the postgraduate courses
on laparoscopic surgery and malignant diseases of
the large intestine were very successful; registrants
were delighted with the content of the two programs.
A new event was held this year. Dr. Wexler
initiated an annual dinner featuring presentations to
all of the past-presidents. The dinner was attended by
200 members and will become an annual event. The
presidential address was delivered before the annual
business meeting on Friday, Sept. 10. Dr. Wexler
reflected on the profile of general surgery in his
presentation entitled “The General Surgeon Through
the Looking Glass — Bright Reflections From a
Tarnished Image.”
The annual program featured guest lecturer by Dr.
Alfred Cuschieri from Dundee, Scotland, and Dr. E.
Moore from Denver, Colo., who delivered the W.R.
Ghent Lecture. The CAGS Lecture was presented by

Professor R.J. Heald from England, whose presenta
tion was entitled “Carcinoma of the Rectum —
Surgery, Radiotherapy and Chemotherapy: Are Cur
rent Priorities Correct?”
Annually, the CAGS honours two of its senior
members who have made major contributions to
general surgery in Canada. This year honorary
memberships were given to Dr. Tait McPhedran of
Calgary and Dr. Wally Chung of Vancouver.
During the annual business meeting, general sur
gical residents from the 16 Canadian departments of
surgery were presented with the CAGS/Merck
Frosst Resident Award for Teaching. This award is
sponsored by the association and Merck Frosst
Canada. Residents are recognized for the excellence
of their teaching contribution in their respective
medical schools during their senior year of residency.

Coat of Arms
The CAGS coat of arms was officially presented by
the Chief Herald of Canada to the Royal College of
Physicians and Surgeons of Canada on behalf of the
CAGS. This mounted and inscripted coat of arms will
be placed in the Royal College offices in Ottawa. The
presentation was conducted during the opening cere
monies of the Royal College annual meeting. The
association owes a debt of gratitude to Dr. Robert
Thorlakson for his major contribution in the develop
ment of this outstanding work of art.B
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ACTIONS
Ciprofloxacin, a synthetic fluoroquinolone, has a bactericidal mode of action. This action is achieved through inhibition of DNA
gyrase, an essential component of the bacterial DNA replication system. Inhibition of the alpha subunit of the DNA gyrase blocks
the resealing of the nicks on the DNA strands induced by this alpha subunit, leading to the degradation of the DNA by
exonucleases. This bactericidal activity persists not only during the multiplication phase, but also during the resting phase of the
bacterium.
Ciprofloxacin retained some of its bactericidal activity after inhibition of RNA and protein synthesis by rifampin and
chloramphenicol, respectively. These observations suggest ciprofloxacin may possess two bactericidal mechanisms, one
mechanism resulting from the inhibition of DNA gyrase and a second mechanism which may be independent of RNA and protein
synthesis.
INDICATIONS AND CLINICAL USES
A) Oral Administration
CIPRO (Ciprofloxacin hydrochloride tablets) may be indicated for the treatment of patients with the following infections caused
by susceptible strains of the indicated microorganisms:
Respiratory Tract Infections: Acute bronchitis and acute pneumonia caused by: £ cloacae, £ coli, H. influenzae, K. pneumoniae,
P. mirabilis, P. aeruginosa, S. aureus, S. pneumoniae
Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the respiratory
tract, bacterial eradications may not be achieved in patients who display clinical improvement despite evidence of in vitro
sensitivity. In patients requiring subsequent courses of therapy, CIPRO® should be used alternately with other antipseudomonal
agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing
should be performed periodically during therapy to detect the emergence of bacterial resistance.
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hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded.
Pseudomembranous colitis has been reported with virtually all antibacterial agents, including ciprofloxacin, and may range in
severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients with diarrhoea subsequent
to the administration of antibacterial agents.
Subsequent to diagnosis of pseudomembranous colitis, therapeutic measures should be initiated. Mild cases will usually respond
to discontinuation of drug alone. In moderate to severe cases, consideration should be given to the management with fluids,
electrolytes, protein supplementation and treatment with an antibacterial drug effective against C. difficile.
Prolonged use of CIPRO® and CIPRO® I.V. may result in the overgrowth of nonsusceptible organisms. Careful observation of the
patient is therefore essential, and if superinfection should occur during therapy, appropriate measures should be taken.
Pregnancy The safety of CIPRO® and CIPRO® I.V. in pregnancy has not yet been established. CIPRO® and CIPRO® I.V. should not
be used in pregnant women unless the likely benefits outweigh the possible risk to the fetus. CIPRO® and CIPRO® I.V. has been
shown to be non-embryotoxic and non-teratogenic in animal studies.
Nursing Mothers Ciprofloxacin is excreted in human milk. A decision should be made to discontinue nursing or to discontinue the
administration of CIPRO® and CIPRO® I.V., taking into account the importance of the drug to the mother and the possible risk to
the infant.
Drug Interactions Concurrent administration of ciprofloxacin with theophylline may lead to an elevated plasma concentration and
prolongation of elimination half-life of theophylline. This may result in increased risk of theophylline-related adverse reactions. If
concomitant use cannot be avoided, plasma concentrations of theophylline should be monitored and dosage adjustments made as
appropriate.
Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of caffeine. Excessive caffeine intake should
be avoided.

Urinary Tract Infections: Upper and lower urinary tract infections, such as complicated and uncomplicated cystitis, pyelonephritis,
and pyelitis, caused by: C. diversus, C. freundii, E. cloacae, E. coli, K. pneumoniae, K. oxytoca, M. morganii, P mirabilis,
P. aeruginosa, S. marcescens, S. aureus, S. epidermidis, S. faecalis

Some quinolones, including ciprofloxacin, have been associated with transient increases in serum creatinine levels in patients who
are concomitantly receiving cyclosporine.

Skin and Soft Tissue Infections: caused by: £. cloacae, E coli, K. pneumoniae, P vulgaris, P mirabilis, S. pyogenes, P aeruginosa,
S. aureus, S. epidermidis

Quinolones have been reported to increase the effects of the oral anticoagulant warfarin and its derivatives. During concomitant
administration of these drugs, the prothrombin time or other appropriate coagulation tests should be closely monitored.

Bone and Joint Infections: caused by: S. marcescens, P. aeruginosa, S. aureus, E cloacae

Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an increase in the level of ciprofloxacin
in the serum.

Infectious Diarrhea: (When antibacterial therapy is indicated) caused by: £ coli (enterotoxigenic strains), C. jejuni, S. flexneri,
S. sonnei

Concomitant administration of a nonsteroidal anti-inflammatory drug (fenbufen) with a quinolone (enoxacin) has been reported to
increase the risk of CNS stimulation and convulsive seizures.

B) Intravenous Administration
CIPRO® I.V. (Ciprofloxacin injection) may be indicated for the treatment of patients with the following infections caused by
susceptible strains of the indicated microorganisms:

Antacids containing aluminum or magnesium hydroxide have been shown to reduce the absorption of ciprofloxacin. Concurrent
administration with these agents should be avoided.

Respiratory Tract Infections: acute pneumonia caused by: £ coli, K. pneumoniae, £ cloacae, P mirabilis, P aeruginosa,
H. influenzae, H. parainfluenzae, S. pneumoniae

Administration of sucralfate prior to CIPRO® resulted in a 30% reduction in absorption of ciprofloxacin. Concurrent
administration with ciprofloxacin should be avoided.

Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the respiratory
tract, bacterial eradications may not be achieved in patients who display clinical improvement despite evidence of in vitro
sensitivity. In patients requiring subsequent courses of therapy, CIPRO® should be used alternately with other antipseudomonal
agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing
should be performed periodically during therapy to detect the emergence of bacterial resistance.

Oral ferrous sulfate at therapeutic doses decreases the bioavailability of oral ciprofloxacin, therefore concomitant therapy is not
advised.

Urinary Tract Infections: Upper and lower complicated urinary tract infections including pyelonephritis caused by: C. diversus,
£ coli, K. pneumoniae, P. mirabilis, P aeruginosa
Skin or Skin Structure Infections: caused by: £ cloacae, £ coli, K. pneumoniae, M. morganii, P vulgaris, P mirabilis,
P aeruginosa, S. aureus, S. pyogenes
Septicemia: caused by: £ coli, S. typhi
Bone: caused by: £ cloacae, P. aeruginosa
Appropriate culture and susceptibility tests should be performed prior to initiating treatment in order to isolate and identify
organisms causing the infection and to determine their susceptibilities to ciprofloxacin. Therapy with CIPRO® and CIPRO® I.V.
may be initiated before results of these tests are known. However, modification of this treatment may be required once results
become available or if there is no clinical improvement. Culture and susceptibility testing performed periodically during therapy
will provide information on the possible emergence of bacterial resistance. If anerobic organisms are suspected to be contibuting
to the infection, appropriate therapy should be administered.
CONTRAINDICATIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection] are contraindicated in patients who have
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.
WARNINGS
Children The safety of CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection) in children has not
yet been established. Damage to juvenile weight-bearing joints and lameness were observed both in rat and dog studies but not
in weaned piglets (see TOXICOLOGY in Product Monograph). Histopathological examination of the weight-bearing joints in
immature dogs revealed permanent lesions of the cartilage. Consequently, CIPRO® and CIPRO® I.V. should not be used in
prepubertal patients. Experience in pubertal patients below 18 years of age is limited.
Pregnancy The safety of CIPRO® and CIPRO® I.V. in the treatment of infections in pregnant women has not yet been established
(see PRECAUTIONS).
PRECAUTIONS
General Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients receiving therapy with CIPRO®
and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection). These reactions may occur within the first 30
minutes following the first dose and may require epinephrine and other emergency measures.
CIPRO® and CIPRO® I.V. may cause central nervous system (CNS) stimulation which may lead to tremor, restlessness, light
headedness, confusion, and very rarely to hallucinations or convulsive seizures. Therefore, CIPRO® and CIPRO® I.V. should be
used with caution in patients with CNS disorders, such as severe cerebral arteriosclerosis or epilepsy. Patients with known
convulsive seizure disorders should only be treated with CIPRO® and CIPRO® I.V. if anticonvulsant therapy has been initiated.
SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING CONCURRENT ADMINISTRATION OF
CIPRO® I.V. AND THEOPHYLLINE. These reactions include cardiac arrest, seizure, status epilepticus and respiratory failure.
Similar serious adverse events have been noted with administration of theophylline alone, however, the possibility that
ciprofloxacin may potentiate these reactions cannot be eliminated. If concomitant use cannot be avoided, the plasma levels of
theophylline should be monitored and appropriate dosage adjustments should be made.
Severe hypersensitivity reactions characterized by rash, fever, eosinophilia, jaundice, and hepatic necrosis with fatal outcome
have also been reported to occur very rarely in patients receiving ciprofloxacin in combination with other drugs. The possibility
that these reactions were related to ciprofloxacin cannot be excluded. Ciprofloxacin should be withdrawn at the first appearance
of a skin rash or other signs of hypersensitivity.
Crystalluria related to ciprofloxacin has been reported only rarely in man because human urine is usually acidic. Crystals have
been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well

The use of calcium supplement reduces the absorption of ciprofloxacin. Concurrent administration should be avoided. In particular
cases, concurrent administration of ciprofloxacin and glyburide can intensify the action of glyburide (hypoglycemia).
Renal Impairment Since ciprofloxacin is eliminated primarily by the kidney, CIPRO® and CIPRO® I.V. should be used with caution
and at a reduced dosage in patients with impaired renal function. (See DOSAGE AND ADMINISTRATION).
Hepatic Impairment In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin
pharmacokinetics were observed. The kinetics of ciprofloxacin in patients with acute hepatic insufficiency, however, have not been
fully elucidated. An increased incidence of nausea, vomiting, headache and diarrhea were observed in this patient population.
ADVERSE REACTIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are generally well tolerated. During
worldwide clinical investigation, 16,580 courses of ciprofloxacin treatment were evaluated for drug safety.
Adverse events, possibly, probably or highly probably related to ciprofloxacin occurred in 1395 (8.8%) of patients. The adverse
reactions according to treatment (oral, iv, and sequential therapy) show that the incidence of adverse reactions was 8.0% for the
group treated orally, 17% for the group treated with CIPRO® I.V. and 15.3% for the group treated sequentially. The difference
between the oral and iv group relates to adverse vascular reactions which are known to be associated with iv administration.
In orally treated patients enroled in clinical trials, the most frequently reported events, possibly,probably drug-related were:
nausea (1.3%) and diarrhea (1.0%).
In patients treated with CIPRO® I.V., the most frequently reported events, possibly, probably drug-related were: rash (1.8%),
diarrhea (1.0%), and injection site pain (1.0%).
Events possibly, probably drug-related occurring at a frequency of less than 1% with ciprofloxacin oral and i.v. treatment during
clinical trials and subsequent post-marketing surveillance are as follows:
Gastro-lntestinal: vomiting, dyspepsia, abdominal pain, flatulence, dysphagia, enlarged abdomen, dry mouth, stomatitis,
gastrointestinal moniliasis, anorexia, jaundice. The following have been reported very rarely: constipation, tooth discoloration,
ulcerative stomatitis, pseudomembranous colitis, intestinal perforation, esophagitis, increased appetite, gastro-intestinal
hemorrhage, melena, liver damage, tenesmus, ileus, toxic megacolon, hepatomegaly, glossitis.
Cardiovascular system: palpitation, tachycardia, phlebitis, The following have been reported very rarely: hypertension, hot flashes,
cerebrovascular disorder, syncope, kidney vasculitis, vasodilation, atrial fibrillation, cardiac arrest, angina pectoris,
electrocardiogram abnormality, myocardial infarct, substemal chest pain, pulmonary embolus, pericarditis, hypotension.
Nervous System: increased sweating, dizziness, agitation, tremor, somnolence, insomnia, confusion, hallucinations, convulsion,
headache. The following have been reported very rarely: anxiety, depression, nervousness, apathy, depersonalization, abnormal
dreams, hemiplegia, sleep disorder, neuritis, paresthesia, polyneuritis, diplopia, meningism, migraine, increase of intracranial
pressure. In some instances these reactions occurred after the first administration of CIPRO®. In these instances, CIPRO® has
to be discontinued and the doctor should be informed immediately.
Respiratory System: dyspnea. The following have been reported very rarely: hiccup, increased cough, stridor, larynx edema, voice
alteration, lung edema, pharyngitis, hyperventilation, lung hemorrhage.
Skin and Appendages: rash, pruritus. The following have been reported very rarely: urticaria, photosensitive dermatitis,
angioedema, alopecia.
Special Senses: tinnitus, abnormal vision, taste perversion. The following have been reported very rarely: conjunctivitis, comeal
opacity, eye pain, colour blindness, chromatopsia, diplopia, ear pain.
Urogenital System: albuminuria, hematuria. The following have been reported rarely: leukorrhea, dysuria, urinary retention, acute
kidney failure, abnormal kidney function, nephritis, vaginitis.
Hypersensitivity: rash. The following have been reported rarely: pruritus, drug fever, anaphylactic/ anaphylactoid reactions
including facial, vascular and laryngeal edema, serum sickness, petechiae, haemorrhagic bullae and small nodules (papules) with
crust formation showing vascular involvement (vasculitis), Stevens-Johnson-syndrome, interstitial nephritis, hepatitis; very rarely,
major liver disorders including hepatic necrosis, joint pain, Lyell Syndrome.

Blood and Blood constituents: eosinophilia, leukocytopenia, leukocytosis, anaemia, granulocytopenia. Very rarely: haemolytic
anaemia, thrombocytopenia, thrombocytosis, altered prothrombin levels.
Laboratory values: increased alkaline phosphatase, Gamma - GT, transaminases, cholestatic parameters, lactic dehydrogenase,
BUN, NPN, AST, ALT, decreased creatinine clearance, hypercholesteremia, albuminuria, bilirubinemia, hyperuricemia, increased
sedimentation rate. The following have been reported rarely: electrolyte abnormality, hypercalcemia, hypocalcemia, acidosis,
crystalluria and haematuria.
Other thrombophlebitis. Very rarely, asthenia, death.
Most of the adverse events reported were described as only mild or moderate in severity .There have been 54 reports of
arthropathies with CIPRO®. Ten of these reports involved children. Arthralgia was usually the first symptom which led to rapid
assessment and withdrawal of the drug. No irreversible arthropathies have been observed.

Sequential IV/PO Therapy
In patients receiving intravenous ciprofloxacin, oral ciprofloxacin may be substituted when clinically indicated at the discretion of
the physician. Clinical studies evaluating the use of sequential IV/PO therapy in septicemia have not yet been completed.
Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the
biliary system of the liver and through the intestine. This alternate pathway of drug elimination appears to compensate for the
reduced renal excretion of patients with renal impairment. Nonetheless, some modification of dosage is recommended,
particularly for patients with severe renal dysfunction. The following table provides a guideline for dosage adjustment. However,
monitoring of serum drug levels provides the most reliable basis for dosage adjustments. Only a small amount of ciprofloxacin
(<10%) is removed from the body after haemodialysis or peritoneal dialysis.____________________________________________

D0SA6E AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the
susceptibility of the causative organism, the integrity of the patient’s host-defense mechanisms, and the status of renal function.
Oral Administration
CIPRO® (Ciprofloxacin hydrochloride tablets) may be taken before or after meals. Absorption is faster on an empty stomach.
Patients should be advised to drink fluids liberally and not take antacids containing magnesium or aluminum.
Adult The recommended dosages of oral CIPRO® are:____________________________________________________________

Dose

Creatinine Clearance
m l/s (mL/min)

SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection).
In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be
carefully observed and given supportive treatment.

> 0 .5 (30)

No Dose adjustment

< 0.5 (30)
and patients on haemodialysis or
peritoneal dialysis

Use recommended dose once daily or
half usual dose twice daily

When only the serum creatinine concentration is available, the following formula (based on sex, weight and age of the patient)
may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal
function:
In traditional units mL/min

Creatinine Clearance mL/sec
Males:

Weight (kg) x (140 - age)
49 x serum creatinine (^mol/L)

Males:

Weight (kg) x (140 - age)
72 x serum creatinine mg/100 mL

0.85 x the above value

Females:

0.85 x the above value

location of Infection

Type/Severity

Unit Dose

Frequency

Daily Dose

Urinary Tract

Mild/Moderate
Severe/Complicated

250 mg
500 mg

q 12h
q 12h

500 mg
1000 mg

Females:

Lower Respiratory Tract
Bone £ Joint
Skin £ Soft Tissue

Mild/Moderate
Severe/Complicated'5

500 mg
750 mg

q 12h
q 12h

1000 mg
1500 mg

CIPRO® and CIPRO® I.V. should not be used in prepubertal patients (see WARNINGS).

Infectious Diarrhea

Mild/Moderate/Severe 500 mg

q 12h

1000 mg

Children
The safety and efficacy of CIPRO® and CIPRO® I.V. in children have not been established.

AVAILABILITY OF D0SA6E FORMS
Tablets:

1 e.g. hospital-acquired pneumonia, osteomyelitis

Cipro * 250

Depending on the severity of the infections, as well as the clinical and bacteriological responses, the average treatment period
should be approximately 7 to 14 days. Generally, treatment should last 3 days beyond the disappearance of clinical symptoms or
until cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6 to 8 weeks and up to 3 months.
With acute cystitis, a five-day treatment may be sufficient.
Intravenous Administration
Adult The recommended adult dosages of CIPRO® I.V. (ciprofloxacin injection) are:

equivalent to 250 mg ciprofloxacin. Bottles of 100.
Cipro * 500

Type/Severity

Unit Dose

Frequency

Daily Dose

Urinary Tract

Moderate/Severe/
Complicated

200 mg to
400 mg

q 12h

400 mg to
800 mg

Lower Respiratory Tract
Skin or Skin Structure
Blood
Bone

Moderate

400 mg

q 12h

800 mg

Each tablet is engraved MILES on one side and 513 on the other and contains ciprofloxacin hydrochloride
equivalent to 500 mg ciprofloxacin. Bottles of 100 and unit dose packages of 100.

Cipro '7 5 0

Location of Infection

Each tablet is engraved MILES on one side and 512 on the other and contains ciprofloxacin hydrochloride

Each tablet is engraved MILES on one side and 514 on the other and contains ciprofloxacin hydrochloride

Injection:
Ciprow I.V.

Each mL contains 10 mg of ciprofloxacin, in vials of 20 mL and 40 mL.

Product Monograph available upon request.

Definitive clinical studies have not been completed in severe respiratory tract and other infections.
The duration of treatment depends upon the severity of infection. Generally ciprofloxacin should be continued for a t least 3 days
after the signs and symptoms of infection have disappeared. The usual duration is 7 to 14 days. However, for severe and
complicated infections more prolonged therapy may be required. Bone and joint infections may require treatment for 4 to 6
weeks or longer.

© MILES CANADA INC., 1993
® Registered Trademark. MILES CANADA INC., is the Registered User of the Trademark CIPRO®, the original brand of
ciprofloxacin hydrochloride.
™ The trademark of the Cipro tablet, consisting of it's colour, shape and size, is a trademark of MILES CANADA INC.

CI042-0693E

References: 1. Cipro / Cipro I.V. Canadian Product Monograph, MILES CANADA INC., September 1991
2. Current manufacturers' prices as of Jan., 1993.

MILES CANADA INC.
Pharmaceutical Division
77 Belfield Road,
Etobicoke, Ontario M 9 W 1G6
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equivalent to 750 mg ciprofloxacin. Bottles of 50 and unit dose packages of 100.
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continued from page 430

INTRODUCTION TO VASCULAR
ULTRASONOGRAPHY. 3rd edition.
Edited by William J. Zwiebel. 423 pp.
Illust. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc., Philadel
phia, 1992. $95. ISBN 0-7216-3551-2
The nature of vascular imaging has
changed profoundly in the past 2 dec
ades, largely as a result of ultrasound
technology. During the last 5 years
colour-duplex sonography has emerged
as a common examination tool.
This book is a welcome update of a
standard reference text. Virtually any
radiologist, cardiovascular surgeon or
ultrasound technologist involved in vas
cular sonography will find this an indis
pensable and comprehensive guide.
The major addition to this third
edition is the discussion of colourduplex technology and imaging. The
book is divided into five sections. The
first section is devoted to the basic
principles of hemodynamics, Doppler
physics and instrumentation, spectrum
analysis and colour-duplex sonography.
These chapters are easily understand
able and well illustrated by both Dopp
ler and gray-scale images, as well as line
diagrams. In subsequent sections cere
brovascular disease, extremity arterial
and venous examinations and abdomi
nal vascular imaging are discussed. In
each of these sections there is a thor
ough discussion of normal anatomy,
technical considerations, pathologic fea
tures and pitfalls. Included in the ex
tremity arterial section is a chapter on
nonimaging physiologic tests for as
sessment of arterial disease, such as
plethysmography and arterial pressure
measurement. Echocardiography is not
dealt with in this text.
There are only two significant short
comings. First, most of the illustrations
are black and white. The relatively few
colour plates are grouped centrally
within the volume, making the reader
flip back and forth between text and
illustrations. However, as the author
points out, this results in a significant
cost saving — an important feature
when a substantial proportion of pur
chasers will be technologists. Second,
as a radiologist involved predominantly
in abdominal imaging, I would have
liked more detailed treatment of Dopp
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ler abnormalities associated with renal
and hepatic transplantation.
On the whole, the deficiencies of this
text are relatively minor. It is a compre
hensive and valuable book. It certainly
meets and surpasses its goal as an
introductory text of vascular ul
trasonography and should probably be
found in the library of every vascular
laboratory.
Joan P. Campbell, MD, FRCPC
Department of Diagnostic Imaging
St. Michael’s Hospital
30 Bond St.
Toronto, ON
M5B 1W8

ELECTRICAL TRAUMA: THE PA
THOPHYSIOLOGY, MANIFESTA
TION AND CLINICAL MANAGE
MENT. Edited by R.C. Lee, E.G. Cravalho and J.F. Burke. 440 pp. Illust.
Cambridge University Press, New
York. 1992. $120. (US). ISBN
0-521-38345-5
This is the first comprehensive text to
be published on electrical trauma. Elec
trical injury accounts for only 4% of
admissions to burn centres, but many of
these injuries can be devastating. There
has been no significant improvement in
survival following electrical injury dur
ing the past 20 years. This book was
motivated by a need to consolidate
information on the clinical and basic
science aspects of electrical injury so as
to facilitate understanding and integra
tion. Contributors to this multiauthored
book include world authorities in clini
cal practice, physics, engineering and
biology.
The book is well organized and well
illustrated. The bibliography is thor
ough, with current references. The text
is divided into four parts: the first two
deal with the clinical aspects of burn
injury and the last two present the basic
science aspects of electrical trauma.
Part I provides an introduction to elec
trical trauma, beginning with Edison’s
development of the electric lamp in
1879 and the design of the first legal

electrocution chair in New York in
1890. There are good descriptions of
electrical terminology. This is followed
by chapters on industrial accidents and
the pathophysiology of burn injury.
The latter is particularly strong.
Part II deals with the clinical mani
festations and management of electrical
injury. This section is excellent. There
are chapters on soft-tissue patterns of
injury, the spectrum of injuries, patho
physiology, neurologic sequelae, pediat
ric injuries and surgical salvage tech
niques.
Parts III and IV, the basic science
sections of the book, are comprehensive
and current. Many of the concepts are
quite technical and are probably more
helpful to basic scientists than to clini
cians. Part III describes the various
tissue responses to burn injury. There
are chapters on the role of arachidonic
acid metabolism, patterns of injury,
electrical impedance, impedance spec
troscopy and the presentation of an
upper extremity model. Part IV deals
with membrane rupture, cell membrane
permeability and the specific mecha
nisms involved in the injuries to various
tissues, including heart and skeletal
muscles.
This comprehensive text will be a
valuable library reference book for both
clinical practitioners and basic scientists
interested in electrical trauma.
Walter Peters, PhD, MD, FRCSC
Associate professor of surgery
University of Toronto.
Chief, Division of Plastic Surgery
The Wellesley Hospital
160 Wellesley St. E
Toronto, ON
M4Y 1J3

THE KNEE: FORM, FUNCTION, PA
THOLOGY & TREATMENT. Edited
by Robert L. Larson and William A.
Grana. 640 pp. Illust. W.B. Saunders
Co., Philadelphia. 1992. $125. (US).
ISBN 0-7216-3495-8
This text is intended to be a review of
all aspects of knee function, diagnosis

BOOK REVIEWS

and treatment. The editors are sports
medicine surgeons, and the book is
primarily directed to their own areas of
interest. The editors invited colleagues
to review their own areas of expertise
and have included virtually all aspects
of knee disorders, including not only
ligamentous and meniscal problems, but
also arthritis, tumours and fractures.
Because of the scope of the text’s
mandate, a number of subjects are
covered superficially. However, some
sections of the book are excellent, with
good references to complement the ma
terial.
This text is aimed at the general
orthopedist or resident in orthopedics
as a basic outline of diagnosis and
treatment, with references provided for
further in-depth reading.
The sections on rehabilitation and
biomechanics are excellent, with up-todate information on present methods of
physiotherapy.
The sections on diagnosis and man
agement of knee ligament instability
present the authors’ methods of assess
ment and surgical management. These
provide a reasonable grounding but do
not provide the detail needed for some
one with a subspecialty interest. The
difficulties regarding reproducible eval
uation of knee ligament instabilities are
noted, and references are given to an
international classification. Unfortu
nately, this classification is so compli
cated that it is not in widespread use.
The sections on tumour, fractures
and arthroplasty do not go into suffi
cient depth to be of great value to the
arthroplasty or fracture surgeon, but
they do provide a skeleton of manage
ment methods. These sections should
be regarded as a general overview only.
The sections on infections are also
primarily of interest for general assess
ment and management.
The chapter on arthroscopy provides
excellent information on the conditions
encountered and the present methods of
management of both meniscal and jointsurface problems. The chapter on allo
graft surgery provides some insight into
the methods now being used in some
centres for the treatment of certain
pathologic entities such as osteochon
dritis dissecans and localized posttraumatic arthritis.

No mention is made of an assessment
of underlying ligamentous problems as
sociated with osteoarthritis, nor of the
management of malalignment problems
with underlying osteochondritis.
At least three radiographs of knees
are upside down.
In summary, this text is of good
value for the general orthopedic sur
geon or orthopedic resident but in gen
eral does not provide sufficient depth
for the surgeon with a subspecialty
interest. However, there is a great deal
of basic information that is well pre
sented and provides a good overview of
knee problems for the orthopedic resi
dent who requires a summary of the
present methods of assessment and
treatment of knee disorders.

John C. Cameron, MD, FRCSC
Surgical Consultant,
Sports Medicine Programme
University of Toronto.
Staff surgeon
Orthopaedic & Arthritic Hospital
43 Wellesley St. E
Toronto, ON
M4Y 1H1

ADVANCES IN CARDIOVASCULAR
ENGINEERING, SERIES A: LIFE
SCIENCES, VOLUME 235. Edited by
Ned H.C. Hwang, Vincent T. Turitto
and Michael R.T. Yen. 443 pp. Illust.
Plenum Press, New York. 1992. $115.
(US). ISBN 0-306-44313-9

This text comprises the proceedings of
a meeting held in Malaga, Spain, from
Dec. 4 to 14, 1991. The purpose of the
meeting was to deal with advances in
cardiovascular engineering and how en
gineering principles might be adapted
to advances in clinical care. The topics
covered are well written and have great
depth in their respective areas. In par
ticular the chapters on microcirculation,
fluid dynamics and thrombosis are of
considerable interest and have a direct
application to advances in patient care.
Unfortunately, clinicians may find that
the mathematical concepts expressed by
the engineers and physicists involved in

this course are beyond the comprehen
sion of the non-mathematician.
Engineers, physicists and basic scien
tists involved in this field of medicine
will find this text of benefit. Physicians
may have trouble understanding some
of the mathematical concepts but may
find it useful as a reference text.
This book is an example of the
increasing number of meetings proceed
ings that are published some time after
the meeting and are designed primarily
for the benefit of those who could not
attend. As such, the material in the text
is usually topical but often not subject
to rigorous peer review before publica
tion. The role of education and the
advance of knowledge remains to be
seen; as reference texts for subsequent
work and publications their value re
mains uncertain.

Tomas A. Salerno, MD, FRCSC
Professor of surgery
University of Toronto.
Division of Cardiovascular
and Thoracic Surgery
St. Michael’s Hospital
30 Bond St.
Toronto, ON
M5B 1W8

SURGERY OF THE EAR AND TEM
PORAL BONE. Joseph B. Nadol, Jr.
and Harold F. Schuknecht. 494 pp.
Illust. Raven Press Ltd., New York.
1992. $165. (US). ISBN 0-88167803-1

Harold Schuknecht is a towering figure
in the field of clinical otology and
research related to the histopathology
of the temporal bone. This book, writ
ten with Joseph Nadol and their pupils,
is a clinical accompaniment to Schuknecht’s monumental Pathology o f the
Ear. It is lavishly illustrated, with nu
merous temporal bone sections that are
well produced in black and white, good
radiographic reproduction and superb
drawings relating to clinical examina
tion and surgical technique. Where col
our is needed, it is used. Robert J. Galla
has produced all the drawings, leading
CJS, VOL. 36. NO. 5. OCTOBER 1993
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to a wonderfully uniform appearance.
This book is much more than an atlas.
It has the style and content of older,
classical otologic texts. It deals at
length with otologic examination, softtissue and bony approaches to the ear,
and later, surgery of the external ear
and tympanic membrane, the middle
ear, mastoid and skull base. It contains
chapters on functional surgery after
conductive hearing loss, vertigo and
sensorineural hearing loss, and it ends
with surgery for trauma and tumours
and reconstruction of the auricle. A
chapter on photographic documentation
is unusual and contains excellent ad
vice. The section on imaging and the
section on evaluation of the vestibular
system, both from Chicago, are first
rate and give good clinical guidance.
The surgical sections are lucid, al
though some may quibble with the use
of large-diameter pistons for stapedecto

my. This exemplifies one of the prob
lems of the book — some of the
techniques and many of the references
are outdated — not a major problem in
the current era of easily accessible
computerized databases. The book’s
strengths are its excellent coverage of
the clinical aspects and abnormalities of
the temporal bone. Its weakness is a
lack of coverage of auditory physiology.
The book is expensive, although of
good value. A reviewer should attempt
to answer the question: Will I use it? As
a middle-aged otologist brought up in
the same school, I can answer affirma
tively. This text contains good practical
advice. It shows the reader how to do it
as no other text has done since the
earlier editions of Shambaugh’s stan
dard text, and its clear illustrations will
be used for teaching for years to come.
The text is generally of good quality,
well written and full of common sense.

There are some things the book does
not do: it does not deal with the
physiology of hearing or of the middle
ear; it is a book that tells how to rather
than why; and it does not tell the reader
what results to expect. It does, howev
er, describe what troubles may occur
and how to deal with them. The book is
true to its title. It is a text of surgery of
the ear and temporal bone and does not
pretend to be a text of otology. I
recommend it to both practitioners and
trainees. It has a prominent place on my
library shelf within easy reach because I
believe it will be consulted frequently.

Peter W. Alberti, MD
Otolaryngology Associates
The Toronto Hospital
EN7-229
200 Elizabeth St.
Toronto, ON
M5G 2C4

Like any other six-year-old.
Almost.
Hundreds of Canadian children are sick
with a disease that's turning their skin yellow,
and slowly but surely turning their bodies
against them.
Liver Disease. It’s now the fourth highest
killer disease in Canada —and it's on the rise.
Transplants have saved the lives of many
Canadians young and old, but we can't do
nearly enough of them.
We need your help to find cures. Please
give to the Canadian Liver Foundation. And
help us give little girls and boys back their lives.
CANADIAN
LIVER
FOUNDATION

1320 Yonge Street, Toronto, Ontario M4T 1X2
Charitable Registration No. 0367-151-13
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CLASSIFIED ADVERTISING
ANNONCES CLASSEES
The Canadian Journal o f Surgery is pleased to accept classified advertisements. T h e deadline is 1 month before issue date. Classified rates: $58
for the first 40 words or less, additional words 75c each (additional $23 for frame). Special Display under 100 words, 55 X 55 mm, $135. $17
charge (first insertion only) for CJS reply box numbers. Display rates available on request. V IS A , M AS TE R C AR D A N D A M E R IC A N
EXPRESS ACCEPTED.
Copy should be mailed to: Beverley Kirkpatrick, Manager, Classified Advertising, Canadian Jo u rn a l o f Surgery, PO Box 8650, Ottawa, O N
K1G 0G8. Tel: (613) 731-9331. Fax: (613) 523-0824.
Send all box number replies to: Box . . . , Canadian Journal o f Surgery, PO Box 8650, Ottawa, O N K1G 0G8.
Le Journal canadien de chirurgie accepte volontiers les annonces classees. Celles-ci doivent etre revues au Journal au plus tard 1 mois avant la
date de parution. Tarifs des annonces classees 58 $ jusqu’a 40 mots et 75 c par mot supplementaire (23 $ pour encadrement au trait). Encadre
special jusqu’a 100 mots, 55 X 55 mm, 135 $. L ’emploi d’une boite-reponse au Journal donne lieu a la perception d’ un supplement de 17 $
(pour la premiere insertion seulement). Tarifs des encadres grand format disponibles sur demande. V IS A, M ASTE R C AR D ET A M E R IC A N
EXPRESS ACCEPTES.
La texte des annonces doit etre adresse a : Beverley Kirkpatrick, Gestionnaire des annonces classees, Journal canadien de chirurgie, CP 8650,
Ottawa, ON K1G 0G8. T e l : (613) 731-9331. Fax : (613) 523-0824.
Veuillez faire parvenir les reponses aux numeros de boites a l’adresse suivante : Boite . . . , Jo u rn a l canadien de chirurgie, CP 8650, Ottawa,
O N K 1G O G 8.

General
Surgeon

M O UNT HOPF

ERIC WILLIAMS MEDICAL SCIENCES COMPLEX AUTHORITY

Republic of Trinidad & Tobago

Telephone: (809) 645-HOPE

CONSULTANT
ANAESTHETIST

northeastern

The Eric Williams Medical Sciences
Complex authority is a five hundred (500)
bed teaching Hospital to the University of
the West Indies. It is situated in the island
of Trinidad, West Indies, and is a major
referral centre for a population of
approximately 1.2 million. The Hospital is
in the process of being commissioned.
Applications are being invited for the
position of Consultant Anaesthetist.
Apply with Curriculum Vitae and
names of two referees to:

Chief Executive Officer
Eric Williams Medical Sciences
Complex Authority
Uriah Butler Highway
Trinidad
WEST INDIES

A full-time permanent General Surgeon
with F.R.C.P.C. qualification is required to
provide general surgical and m inor
orthopedicservices in our 64 bed accredited
acute care Hospital located in the City of
Fort St. John serving a population of
approximately 25,000. This is a private
practice position (fee for service). Gross
annual e a rnings are a p p ro xim a te ly
$200,000 to $250,000. There are two
qualified General Surgeons in Dawson
Creek, a community 50 miles away, which
would allow a call schedule for weekend
and vacation relief. There is an Obstetrician/
Gynecologist, Radiologist and Pathologist
on staff with excellent family physician
support. (Recruiting to replace the Medical
Internist is underway.)

British
Columbia
offering a
variety of
cultural
and
sporting
activities
and daily
air service

P le ase co n ta c t:

to

Administrator.

M rs. M. A s lin g ,
S93-167

Vancouver
and
Edmonton.
S93-168

Fort St. John General Hospital

9636 - 100th Ave., Fort St. John, B.C. V1J 1Y3
Tel: (604) 785-6611 Local 260 Fax: (604) 785-4060

CLASSIFIED ADVERTISING Unlike a tabloid or newspaper that is read today and discarded tomorrow, an adver
tisement in the Classified Advertising section of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons. No other Canadian surgical publication reaches over 6000
subscribers every 2 months, giving wide coverage for your advertising dollar.
Average issue readership of CJS (81%) is among the highest of any medical journal in Canada, the latest readership studies confirm the best and most cost efficient way to reach Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU
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CARDIOVASCULAR AND THORACIC
SURGEON: AB - Required to join a wellestablished private practice group in midwestern Canada. FRCSC required. Respond
with CV to: Cardiovascular and Thoracic
Surgical Associates, PO Box 7 5 0 3 0 , Cam 
brian Post O ffice, Calgary, AB, Canada
T 2K 6J8.
-S93-165
SURGEON: BC — Required for 44-bed hospi
tal with cooperative medical community serv
ing a large retirement population in scenic
mountain valley in British Columbia close to
the Idaho border. Hospital equipped for Gl
endoscopy and laparoscopic surgery. Moder
ate workload would permit enjoyment of the
area recreational facilities which include golf,
fishing, hiking, skiing, etc. Contact: Dr. H.G.
Harding, PO Box 130, Creston. BC VOB
1G0; tel (604) 4 2 8 -7 0 2 1 , fax (604)
4 2 8 -3 5 8 1 .
-S93-154
DIRECTOR, BURN UNIT: ON - Ross Tilley
Burn Centre, University of Toronto invites
applications from qualified academic plastic
surgeons for the position of Director of the
Ross Tilley Burn Centre. This appointment will
be at the rank of assistant or associate
professor, depending upon qualifications and
experience. The centre is currently a six-bed
fully contained surgical and nursing unit with
complete facilities for the management of
every aspect of burn patient care. The suc
cessful candidate will have a strong academic
background, demonstrated research ability
and administrative experience. A Royal Col

lege of Physicians and Surgeons of Canada
fellowship or equivalent is also required. The
University of Toronto encourages applica
tions from qualified men and women, mem
bers of visible minorities, aboriginal peoples
and persons with disabilities. In accordance
with Canadian Immigration requirements, this
advertisement is directed firstly to Canadian
citizens and permanent residents. Please sub
mit by Oct. 31, 1993 a letter of application, a
complete curriculum vitae and the names of
three referees, to: Dr. R.T. M anktelow,
Chair, Division of Plastic Surgery, Univer
sity o f Toronto, c/o EN10-236, The Toron
to Hospital - General Division, 200 Eliza
beth St., Toronto, ON M5G 2C4.
-S93-164

GENERAL SURGEON: ON - Well-estab
lished group practice is looking to replace a
retiring partner/surgeon to serve a communi
ty of 30 000 + located 25 minutes west of
London. Town population 10 0 0 0 + . Fully
computerized, modern clinic adjacent to a
fully accredited, well-equipped hospital using
116 acute care beds. Busy emergency de
partment. Preference will be given to orthopedics/gynecology. Essentials include la
paroscopy skills and fellowship status. Onein-three on-call schedule for this pleasant
community. Large referral base guaranteed.
Associate to full partnership attainable.
Please contact or send CV to: Steven W ong,
c/o Strathroy Medical Clinic, 376 Carrie
St., Strathroy, ON N7G 3E3: tel (519)
2 4 5 -0 4 3 0 .
-S92-128

ORTHOPEDIC SURGEON
Cambridge Memorial Hospital is seeking a
C a n a d ia n c e rtifie d , O n ta rio lice n se d ,
recent graduate in orthopedic surgery to
join the existing complement of two other
orthopedic surgeons. The candidate must
have a broad interest in orthopedics (no
subspecialty needed) and a willingness
to assum e re g u la r o n -call d u tie s in a
353-bed accreditated hospital.

This 1-year postgraduate fellowship offers a
wide range of clinical experience in en~
dourology including percutaneous surgery,
ureteroscopy, ESWL and laparoscopic sur
gery in urology. Approximately 50% of the
fellow's time will be spent in the laboratory
participating in projects related to endourologic and shock wave lithotripsy re
search. Salary will commensurate with the
level of training.
Please reply with curriculum vitae to:
Dr. John Denstedt
Chief of Urology
St. Joseph's Health Centre
2 68 Grosvenor St.
London, ON N6A 4V2
-S93-163

GENERAL SURGEON: SK - Associate re
quired in a busy referral private practice.
Laparoscopic surgery forms a significant and
increasing portion of the practice. Moving to
new facility within 12 months. University city
of 180 000+ with many amenities. FRCS
required. Contact and send CV to: Dr. Len F.
Rivers, 4 0 6 -7 5 0 Spadina Cres. E, Saska
toon, SK S7K 3H3: tel (306) 6 5 2 -4 7 5 4 ,
fax (306) 2 4 4-6001.
-S93-157

ADVERTISERS’ INDEX
INDEX DES ANN0NCEURS
Canadian Medical Association
Inside Back Cover

Davis & Geek

Valtrac

Outside Back Cover

Frosst

Vasotec IV 466, 467, Inside Front
Cover

Cambridge is in the heart of southwestern
Ontario and provides a high standard of
living, including excellent social, recre
ational and educational facilities.

Miles Canada Inc.

For more inform ation, contact: Dr. J.K.
Stapleton, Chief, Department of Surgery,
tel (519) 623-7200; or send a resume to:

Anusol-HC 460

Secretary, Orthopaedic
Surgeon Search Committee
Cambridge Memorial Hospital
700 Coronation Blvd.
Cambridge, ON
N1R3G2
S93-166
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T h e Illustrated History
of Medicine
J rom paleomedicine to contempo
rary laboratory medicine, from
Mesopotamia to Greece and Europe,
through China, India and the Ameri
cas, this history of medicine, or rather
the history of different kinds of
medicine, is found here in illustrated
form — a rigorous and elegant syn
thesis and chronology in 13 chapters.
Professor Jean-Charles Sournia
explores medicine’s theories, diag
noses and therapies, public health
and hygiene. But he also contrasts
themes such as the continuity and
breakdown of medical practices, or
different forms of medicine based in
belief and reason.

that truly bring this new study to life;
The Illustrated History of Medicine
gives pride of place to pictures and
their commentaries. More than 700
paintings and photographs from
around the world enrich the history;
300 of these fascinating images are in
colour.
T he Canadian Medical Associa
tion is proud to be the exclusive
agent in Canada for Harold Starke
by Jean-Charles Sournia
Publishers’ 'The Illustrated History of
Medicine. Distinctively different
medical masters, from ethnomed- from other published histories, this
icine to technomedicine, from Sum beautiful volume will be a treasured
erian concepts linking illness with addition to your library.
sin to today’s Hippocratic tradition.
T he volume charts the distances and
differences in more than 50 chrono
The Illustrated History o fMedicine
logical tables, a glossary of terms, an
Professor Jean-Charles Sournia
index of names and a bibliography.
ISBN 1-872457-05-3

This history of medicine is also
the history of physicians through the
ages, of their philosophies, living
conditions, social status, tensions
But it is the beautifully repro
and differences, from the unknown
duced
paintings and photographs
healers of prehistory to modern
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The benefits continue
long after Valtrac
has disappeared.
Introducing the Valtrac*
biofragmentable anastomosis ring,
a major breakthrough in bowel
anastomosis technology that’s both
surgeon friendly and patient friendly.
Already surgeons have proved Valtrac’s
procedural superiority over sutures and
staples in thousands of patients. Valtrac
provides uniform application
regardless of location and
disparate bowel end sizes. It
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VALTRAC side-to-side procedures.

And, finally, Valtrac closes under direct
visualization. So you know it’s closed.
Valtrac is patient friendly because it
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or obstruction1.
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Valtrac story, please call: (416)470-3600
and ask for the Valtrac line.
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